Ruthenium arene azo anticancer complexes by Dougan, Sarah J.
Ruthenium Arene Azo Anticancer 
Complexes 
A Thesis Submitted for the Degree of Doctor of Philosophy 
by 
Sarah J. Dougan, MChem 
I V 
IN 
School of Chemistry 
Faculty of Science and Engineering 




Ruthenium(II) arene complexes of the type [(
71
6-arene)Ru(en)Cl]PF6 (en = 
ethylenediamine) exhibit promising anticancer activity in vitro and in vivo. The 
complexes are thought to be activated by hydrolysis of Ru-Cl to allow for 
interactions with biomolecules such as DNA. Structure-activity relationships have 
revealed that changes to the chelating ligand and the arene can have dramatic effects 
on the cytotoxicity, whilst the 'leaving group' typically plays a more minor role. 
This thesis is concerned with the design of ruthenium(II) arene anticancer complexes 
where the chelating ligand contains an azo-imine group (N=N-C=N) which binds to 
the ruthenium to form a five-membered chelate ring. 
Several mononuclear complexes containing the chelating 2-phenylazopyridine ligand 
or derivatives thereof were found to be moderately cytotoxic towards A2780 human 
ovarian and A549 human lung cancer cells (IC 50 18-88 MM). These complexes were 
found to hydrolyse (Ru-C1 -+ Ru-OH 2 ) slowly in aqueous solution and arene loss 
was a competing reaction. X-ray crystal structures revealed that the arene ligand is 
not as tightly bound to the ruthenium as in the case when the chelating ligand is en. 
Synthesis of the corresponding dinuclear analogues, where two 2-phenyl azopyri dine 
ligands were joined together via a linker, did not improve the cytotoxicity. Unlike 
their mononuclear analogues, the complexes appeared to undergo electrochemical 
reduction with radical formation in aqueous solution. An EPR spectrum of the mono-
reduced anion revealed an entirely ligand based radical. 
Surprisingly, replacement of Cl - by 1 in the mononuclear complexes led to 
compounds that were highly cytotoxic towards both A2780 and A549 cancer cells 
(IC50 1-5 MM). Interestingly these complexes were resistant to hydrolysis in aqueous 
solution suggesting that this class of compounds had a novel mechanism of cytotoxic 
action not involving activation by hydrolysis. 
The redox chemistry of these complexes proved to be central to their observed 
cytotoxicity. The complexes were rapidly reduced by the biological reductant 
ascorbate, catalytically oxidised the tripeptide glutathione and generated reactive 
oxygen species (radicals) inside A549 cancer cells. These reactive oxygen species 
were shown to be involved in cell death. 
11 
These iodide complexes were also found to be cytotoxic towards non-cancerous 
W138 human lung cells (IC 50  1-6 MM) and attempts were made to target one complex 
specifically to cancer cells, through conjugation to transferrin. 
Overall this thesis demonstrates that ruthenium(II) arene anticancer complexes can 
be cytotoxic through mechanisms of action different from the classical mechanism 
involving hydrolysis and binding to biomolecules. 
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This thesis is concerned with the synthesis and characterisation of ruthenium 
complexes and their use as anticancer agents. In this Chapter an introduction to 
inorganic biochemistry and inorganic drugs is given, followed by an introduction to 
cancer and the inorganic anticancer drugs that are used for its treatment. Then 
previous work on the potential use of ruthenium(II) arene complexes as anticancer 
agents will be reported followed by cytotoxic ruthenium complexes containing 
chelating azo ligands. The aims of this thesis are also described in this Chapter. 
1.1 The Elements of Life 
The elements carbon, hydrogen, nitrogen, oxygen, phosphorus and sulfur provide the 
building blocks for major cellular components including proteins, nucleic acids, 
lipids-menibranes, polysaccharides and metabolites. However, life cannot survive 
with these elements alone and it is now clear that >20 elements are thought to be 
essential for most species to function. Inorganic elements are involved in all of life's 
processes e.g. charge balance and electrolytic conductivity (Na, K), signalling (Ca), 
Lewis acid-base catalysis (Zn, Fe, Ni, Mn), redox catalysis (V, Mn, Fe, Co, Ni, Cu, 
W) and electron transfer (Fe, Cu, Mo).W  For example, catalytic activities for Ca. 
12% of all enzymes can be attributed to metal centres. 121 
1.2 Therapeutic uses of inorganic compounds 
Metal compounds have been used in medicine since the 16 "  century. Currently a 
range of metal containing drugs are used therapeutically to treat a wide range of 
diseases including silver 13) (antibacterial), gold 14J  (antiarthritic), bismuth 15J  (antiulcer), 
vanadium 16J  (antidiabetic), iron 171  (antimalarial) and platinum t 8 ' 9' (anticancer). 
Metal ions are electron deficient whereas most biological targets e.g. proteins, DNA, 
are electron rich so consequently there is a general tendency for metal ions to bind to 
and interact with many important biological molecules. 12J Furthermore metal ions 
have a high affinity for many small molecules e.g. 02 that are crucial for life. [2j 
Whilst metal-based drugs are often more active in vitro at lower concentrations than 
organic drugs, several problems need to be overcome in order for an inorganic 
2 
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compound to be successful: [21 metals are often toxic at higher concentrations and so a 
balance between therapeutic and toxic effect needs to be reached. Often metal 
complexes have poor aqueous solubility, hydrolytic instability and the tendency to 
rapidly decompose when exposed to solvents, humidity, light or air. Interestingly, 
however, the statistical success of metal-based compounds reaching the clinic 
through the NIH anticancer screening program is about the same as for carbon-based 
compounds (1 in 6000 tested). 1101 
1.3 Cancer 
This thesis is concerned with the design of anticancer drugs and so an introduction to 
cancer is first given. 
1.3.1 What is cancer? 
Cancer is the name given to any illness resulting from one of our body's own cells 
growing out of control. It is caused in almost all instances by mutation or abnormal 
activation of cellular genes that control cell growth and cell mitosis."', 121 Only a 
fraction of the cells that mutate in the body ever lead to cancer since (a) most 
mutated cells have less survival capacity than normal cells and simply die, (b) only a 
few of the mutated cells that do survive lose the normal feedback controls that 
prevent excessive growth, and (c) those cells that are potentially cancerous are 
usually destroyed by the body's immune system before they grow into a cancerJ' !J 
The three main differences between cancerous and normal cells are as follows: [ ' 11 
• The cancer cell does not respect normal cellular growth limits. The reason 
for this is that the cells presumably do not require the growth factors that are 
necessary to cause growth of normal cells. 
• Cancer cells are much less adhesive to each other than are normal cells. They 
can thus enter the bloodstream and be transported all throughout the body and 
form new cancerous growths. 
• Some cancers produce angiogenic factors that cause new blood vessels to 
grow into the cancer, thus supplying the nutrients required for cancer growth. 	- 
3 
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Cancer kills because cancer tissue competes with normal tissue for nutrients. 
Because cancer cells continue to proliferate indefinitely, they eventually demand 
all the nutrients available to the body and as a result normal tissue gradually 
develops nutritive death. 
1.3.2 Strategies to combat cancer 
There are several treatments available to try to combat cancer t 13 and two of the most 
common are as follows; chemotherapy which involves treating the patient with 
cytotoxic (cell killing) drugs whereas radiotherapy involves the use of radiation to 
destroy the cells in the treated area. This can be achieved by using X-rays (external 
radiotherapy) or b' a radioactive material (internal radiotherapy). In both these 
treatments healthy cells are affected but normal cells tend to be better at repairing 
themselves than the cancer cells. 
1.3.3 Inorganic drugs used in cancer therapy 
1.3.3.1 Platinum 
The anti-tumour activity of platinum was discovered in 1969 by accident in the study 
of the inhibition of cell division in Escherichia co/i by electrolysis. 1141 It was found 
that trace amounts of platinum from the electrode caused inhibition of cell division 
and filamentous growth. Several platinum complexes were subsequently tested for 
anti-tumour activity [151  and it was found that cisplatin, cis-[PtC12(NH3)2], was a 
potent anticancer agent. Cisplatin is currently used clinically to treat a wide range of 
cancers including testicular tumours (where there is ca 90% cure rate), ovarian 
carcinomas, as well as head and neck cancers. ' 61  The mode of.action of cisplatin is 
well understood and its anticancer activity is thought to be due to its interaction with 
cellular DNA. 1171  When administered to the blood stream the cisplatin encounters 
relatively high chloride ion concentrations (-100 mM), which suppresses its 
hydrolysis. Upon entering the cells, the reduced chloride concentration (-20 mM) 
facilitates hydrolysis. The aquated form, [PtC1(NH 3 )2(OH2)] can react more readily 
with cellular targets. This aquated cisplatin binds preferentially to the N 7 atom of a 
guanine base of DNA since this is the most electron rich site of DNA, with 
displacement of the water molecule, to form a mono-functional adduct. The bi- 
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functional adduct is then formed by hydrolysis of the second Cl - ligand. The major 
product is a 1,2-intrastrand adduct with binding at two neighbouring 0-N 7 bases. 
By binding to DNA, cisplatin is thought to inhibit replication or transcription (and 
hence inhibit unregulated cell division). The ultimate result is apoptosis 
(programmed death) of the cancer cell. 
This drug, however, has several major drawbacks including toxicity and tumour 
resistance. ' 71  These drawbacks, and the fact that the drug is ineffective to some 
cancers, have led to the development of several other potential platinum containing 
drugs. In general, however, the spectrum of activity for the active analogues is 
similar to and not broader than that of cisplatin itself. Thus whilst to date there have 
been thousands of platinum analogues synthesised and tested for anti-cancer 
acti vity, t 18 1 only five other platinum drugs have been approved for clinical use (in at 
least one country).' 19J  
1.3.3.2 Ruthenium 
	
1.3.3.2.1 	Properties of Ruthenium 
Ruthenium is a group 8 transition metal and displays many characteristic properties 
of the platinum group metals. It has the ability to exist in a wide range of oxidation 
states (Ru° to Ru") 12o1  with the most common oxidation states in aqueous solution 
being Ru" and Ru". Perhaps the most interesting feature of substitution at 
ruthenium(II) and ruthenium(III) is that both oxidation states are inert, thought the 
former much less so. This double inertness is an enormous advantage for studies of 
electron transfer and ruthenium is the only element in the periodic table with two 
substitution inert oxidation states. 12  The inertness is an advantage that is exploited 
in the design of ruthenium complexes as anticancer agents since the success of 
platinum compounds is mainly due to their lack of reactivity. 
1.3.3.2.2 	Early Work 
Due to both the success and drawbacks of cisplatin and related platinum drugs the 
search of inorganic anticancer agents has been extended to other metals. In 1978 
Clarke postulated that by using other metal ions and paying a careful attention to 
5 
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their chemical properties, more selective and less toxic drugs could be developed .22 
Around this time the anticancer properties of ruthenium was reported when the Ru" 
compound fac-[RuC13(NH3)3]  was found to induce filamentous growth of E. Coli at a 
concentration comparable to the concentration required for cisplatin to produce 
similar effects. 1231  This compound, and analogues such as cis-[RüC 12(NH3)4] 
demonstrated the potential anticancer activity of ruthenium complexes. However, 
they were too insoluble for pharmacological use. [24] 
1.3.3.2.3 	Ruthenium(HI) Complexes 
Since this discovery, there have several other reports of ruthenium complexes which 
exhibit anticancer activity, most of which contain Ru". Perhaps two of the most 
exciting 	Ru" 	anticancer 	compounds 	are 	imidazolium 	trans- 
tetrachlorodimethylsulfoxideimidazoleruthenate(III) complex or NAMI-A and 
indazolium trans -tetrachlorobis( 1 H- i ndazole)ruthenate(III) complex or KP- 1019 
since both compounds have entered clinical trials t 25 ' 261 as anticancer drugs. 
It has been suggested that Ru" complexes are "activated by reduction" in vivo to Ru" 
to coordinate more rapidly to biomolecules t101 due to the increased lability of 
bonds. 1251 There is a lower oxygen content and more acidic pH in tumours than in 
normal tissue and so the production of Ru" relative to Ru' 1 ' should be favoured in 
tumours .LI 
1.3.3.2.4 	Ruthenium(II) Complexes 
Because Ru" may be an active form of ruthenium, there is now an increased effort 
into research on the anticancer activity of Ru" complexes. Early work on 
ruthenium(II) complexes, for example cis-[RuC12(DMSO)4]  and trans-
[RuC12(DMSO)4] 127291  showed that Ru" complexes are potentially interesting in the 
design of new drugs. 
1.4 Ruthenium(H) arenes as anticancer agents 
This thesis is concerned-with the use of Ru" arene complexes as anticancer agents. 
Their general structure is shown in Figure 1.1. All complexes contain an r- 6 arene 
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dentate ligand occupying the final site. The fl 6-arene stabilizes the ruthenium in the 
+2 oxidation state so that oxidation to ruthenium(III) becomes unfavourable. [301 
Depending on the nature of the chelated ligand, these complexes are either neutral or 
positively charged (and isolated as salts). Variations to all three ligand types can be 
achieved, so there is a great scope for the synthesis of a vast library of potential 
anticancer complexes. There are several synthetic routes to the complexes and these 
have recently been summarized. t311 
Figure 1.1. General structure of Ru" arene anticancer complexes containing an 
arene, a chelating ligand YZ and a monodentate labile ligand X that provides a 
reactive site for the molecule. In water, the Ru-X bond is subject to hydrolysis to 
generate the corresponding aqua adduct which can be deprotonated (depending on 
the pH) to give the hydroxo form. 
The mechanism of cytotoxic action of Ru" arenes is generally thought to involve 
initial activation of the Ru-X bond by hydrolysis generating an active Ru-OH2 
species. This species will exist over a range of pH values, but above pH = pKa value 
(the pH at which 50% of the species exists as Ru-OH2 and Ru-OH through 
deprotonation of the H20 ligand), the hydroxo Ru-OH species will predominate, and 
this complex is usually considered to be a less reactive species (Figure 1.1). 
Hydroxide is a less labile ligand than water and hence will not be as easily displaced 
by biomolecule targets. Thus ideally pKa values of Ca. pH >7 for aqua adducts 
should ensure that the active species predominates at physiological pH (7.2-7.4). 
Furthermore the rate of hydrolysis is important; if the complexes hydrolyse too fast 
they may not reach the target site. 
Hydrolysis can be suppressed extracellularly due to high [Cl] (ca. 0.1 M) but 
becomes possible after the complex enters the cells due a lower [CI - ] (ca. 4-25 mM) 
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found intracellularly. We thus obtain selective activation inside the cell. The 
primary cellular target for Ru" arenes, as for many metal-based drugs is thought to be 
DNA 132J  and so factors affecting DNA binding such as rate and extent of binding and 
non-covalent interactions such as hydrogen bonding and DNA intercalation become 
important. 
1.4.1 Structure-Activity Relationships 
Structure—activity relationships between the molecular structure and the cytotoxicity 
displayed reveal that the choice of arene, chelating ligand and even leaving group 
can all have an effect on the cytotoxicity. 
1.4.1.1 Role of the 1q 6-arene 
The arene is considered as a it-acid I it-acceptor ligand towards ruthenium. Evidence 
for this comes from (a) arene 'H proton resonances which, upon coordination to Ru" 
shift to a lower frequency due to increased electron density [331  and (b) from UV-Vis 
spectroscopic observations. [341 Ru-arene bonds are generally stable towards 
hydrolysis, although it has recently been reported that the photochemical 
displacement of the arene can occur in aqueous solution for dinuclear complexes 
such as [{( 6-indan)RuC1}2(u-2,3-dpp)](PF6)2 , (2,3-dpp = 2,3-bis(2-
pyridyl)pyrazine)J 35' The structural and electronic features (especially with respect 
to Molecular Orbital Diagrams) of metal-arene bonding have been thoroughly 
reviewed. [36] 
Initial results demonstrated that complexes containing more hydrophobic extended 
arenes were more cytotoxic.137' 381  Table 1.1 shows the IC 50 values against the 
A2780 human ovarian cancer cell line for Ru" arene complexes containing 
ethylenediamine (en) as the chelating ligand, chloride as the leaving group and a 
variety of 16-arenes  (Figure 1.2). Thus derivatives such as [( 6-p-cym)Ru(en)C1] 
and [(ij  (p-cym = p-cymene, bip = biphenyl) inhibited the growth of 
the A2780 cancer cells with IC 5 0 values of between 6-10 pM, comparable to the 
clinically-used anticancer drug carboplatin (6 pM). When the arene is benzene (bz) 
the cytotoxicity decreased approximately two-fold. However, the complex [(71 6_  
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tetrahydronaptha1ene)Ru(en)C1] containing a fused three ring tetrahydroanthracene 
(tha) arene was equipotent with cisplatin (0.6 pM). 
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Table 1.1. IC50 values against the A2780 cancer cell line for Ru" arene complexes 
containing different arenes. The results for the platinum controls are also included. 
Data from references [37, 38]. 
Arene / Pt control IC50  (PM) 
bz 	 17 
	
p-cym 	 10 
bip 	 5 






CI U NH, 
H2N) 	 bz p-cym 
OrIIIircIIJ 
bip 	 tha 
Figure 1.2. Molecular structure of [(i6-arene)Ru(en)Cl]PF6  complexes containing 
different arenes. 
Further studies showed that introduction of polar substituents into the coordinated 
benzene ring in [(i6-arene)Ru(en)C1]PF6  complexes lowers their cytotoxicity towards 
A2780 human ovarian cancer cells. 311 On the other hand, benzene arenes substituted 
with relatively non-polar sterically-demanding alkyl, phenyl or benzyl groups are 
much more potent with IC50 values as low as 3 riM. The activity against the A2780 
cancer cell line for analogous complexes in which the arene is a fused system has 
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also been evaluated. 1311 In general the trend is that cytotoxicity increases with arene 
ring size in these cases, as described earlier. 
1.4.1.1.1 	Influencing Cellular Uptake 
A major role of the arene is thought to be to provide a hydrophobic face to the 
molecule and this may help in crossing cell membranes and allow for greater 
accumulation inside cells. More hydrophobic arenes can thus allow for a greater 
uptake into the cell. For example, analysis of total ruthenium taken up into A2780 
cancer cells after 24 h exposure to 2.7 iM Ru was measured for [(1 6 
tha)Ru(en)C1JPF6 and [(Tl  The former compound, containing 
the more hydrophobic anthracene type arene was taken up into cells at a 
concentration of Ca. 37 pm01/106 cells, whereas the latter, containing the less 
hydrophobic biphenyl arene was taken up at a concentration of Ca. 5 pmol/106 cells. 
1.4.1.1.2 	Arene-Nucleobase Stacking and Intercalation 
The choice of arene can dramatically influence the interactions of the complex with 
DNA. The interaction of [(il  complexes (arene = 
tetrahydronapthalene (tha), dihydronapthalene (dha)) and guanine DNA derivatives 
9-ethylguanine (9EtG) has been studied extensively, in both the solid (X-ray crystal 
structures) and solution (NMR) state. t40' Although there is strong bonding between 
the DNA nucleobase and Ru", other non-covalent interactions including intercalation 
and hydrogen-bonding become important for DNA recognition. The X-ray crystal 
structures of [(i 6-tha)Ru(en)9Et-G (N7)] and [(i 6-dha)Ru(en)9Et-G (N7)] show the 
presence of strong intramolecular it-it arene-nucleobase stacking. The outer ring of 
thaldha lies directly over the purine base and the centroid-centroid separation 
between the outer ring of the arene and the purine ring is 3.45 A for [(16 
tha)Ru(en)9Et-G (N7)], and 3.31 A for [(i6-dha)Ru(en)9Et-G(N7)], with dihedral 
angles of 3.3° and 3.1° respectively. This strong stacking is essentially optimum; the 









Figure 1.3. X-ray structures (at 30% probability thermal ellipsoids) and atom 
numbering schemes for (A) [(r16-C 14H 14)Ru(en)(9EtG-N7)] 2 , and (B) [(rj-
C Hi 2)Ru(en)(9EtG-N7)1 2 . The space-filling models show the intramolecular 
arene-guanine base stacking and H-bonding interactions between en NH and G 06. 
Color code: C of C 141-114 and C 14H 1 2 yellow, C of 9EtG and en gray, Ru purple, 0 
red, N blue, and H white. Reproduced from reference [ 401. 
The intercalation of the arene ligands into double helical DNA has been confirmed 
by ethidium bromide (EtBr) fluorescence experiments. 
141 EtBr is a probe which is 
fluorescent when bound to DNA and can be used to distinguish intercalating and 
non-intercalating ligands on DNA by competition. 
[421 Complexes (rl6 
bip)Ru(en )Cl]), ([(1 6-tha)Ru(en)Cll ) and ([(r1 6-dha)Ru(en)Cl f' can intercalate into 
the double helix of DNA, whereas (q-p-cym)Ru(en)Cl1) does not. 
Further evidence for intercalation comes from DNA unwinding experiments. 
Complexes (TI 6-bip)Ru(en)Cl1), ([01 6-tha)Ru(en)Cl1) and ([(1 6-dha)Ru(en)Cl] 
unwind negatively supercoiled pSP73KB plasmid DNA by 14 ± 1 0  per bound 
ruthenium and (16-p-cym)Ru(en)Clf 4 ) by only 7 ± 
0. 5 0 . 1411  These results suggest 
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that the extra unwinding is a result of the intercalation of the extended arene or 
another non-covalent interaction of these complexes with DNA upon mono-
functional binding. Large unwinding angles of 15 or 19 produced for the platinum 
compounds cis-[Pt-(NH3)2(N8-ethidium)Cl]2 and cis- [Pt - (NH3)2(N3 -ethidium)Cl] 2 
which contain the known intercalator ethidium and can form only mono-functional 
adducts of DNA, have also been explained this way. [431 
1.4.1.1.3 	Rates of Hydrolysis 
The rates of hydrolysis of [(i6-bip)Ru(en)C1],  [( 6-tha)Ru(en)Cl] and 
[(116_ 
dha)Ru(en)Cl] (bip = biphenyl, tha = tetrahydroanthracene, dha = 
dihydroanthracene) are essentially independent of ionic strength and increase with 
the size of the arene: 3.95 x 10 s, t 112= 2.92 min for arene = bip, 6.84 x 10-3S- I , t112 
= 1.69 mm n for arene = tha and 6.49 x 10 3 s' t112= 1.78 min for arene = dha (310 K, 
0. 1M NaC104, 0.3 mM bip, 0.5 mM tha and dha complexes)) .144]  The rates of the 
corresponding anation reactions (replacement of H20 by Cl) were also studied and 
decrease by about two-fold on increing the ionic strength from 0.015 to 0.5 M 
NaC104 . This decrease is expected on the basis of the Brønsted equation, i.e. that the 
rate constant is expected to be independent of the ionic strength when one of the 
reactants remains uncharged, whereas the rate constant decreases with ionic strength 
if the charges on the two ions are of opposite sign. The anation reactions were rapid, 
reaching equilibrium within ca. 100-1600 s. Generally the anation reactions of the 
[(ri6-tha)Ru(en)C1] and [( 6-dha)Ru(en)Cl] complexes were about 2.5-fold faster 
than [( 6-bip)Ru(en)Cl]. These results demonstrate that the arene influence the rates 
of hydrolysis, and this is obviously important in the design of Ru" arene anticancer 
complexes. 
1.4.1.1.4 	Rates of Reaction with cGMP 
The half-lives for reaction of five ruthenium(II) arene en chloride complexes (arene 
= bip, tha, dha, bz and cym) and the corresponding aqua adducts with cLGMP are 
summarized in Table 1.2.' °' The rates of reaction of c-GMP with [(TI 6 _  
tha)Ru(en)OH2} 2 [(116-dha)Ru(en)OH21 2 and [(6-bip)Ru(en)OH2] 
2+  complexes are 
more than three times faster than those for the [(r 6-p-cym)Ru(en)OH2] 2  and [(16 
13 
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bz)Ru(en)OH2] 2' complexes. The rates of reaction of the chloride complexes are 
slower due to the two-step process of reaction: hydrolysis followed by Ru-N7 
binding. The same trend in reactivity was observed for the chlorido and aqua 
complexes. For the complexes [(i 6-tha)Ru(en)Cl], [(716-dha)Ru(en)Cl] and E(1 6 
bip)Ru(en)Cl], 100% of the N7-bound product was observed after 2 d whereas only 
Ca. 80% of the N7 bound product formed for the p-cym and bz complexes after 4 d. 
Thus the rate of reaction of the Ru aqua complexes (and chloro complexes) with c-
GMP depends markedly on the nature of the arene decreasing by over an order of 
magnitude as the arene is changed from tha> bip > dha >> p-cym > bz. 
Table 1.2. 	Half lives 4112) for reactions of Ru 1 ' arene complexes [(TI 6 
arene)Ru(en)Cl] 	and the corresponding aqua complexes [(i 6-arene)Ru(en)OH2] 2 
with cGMpa. 
L(q 6-arene)Ru(en)CI] 	t(1/2) I h 	 [(11 6-arene)Ru(en)OH2] 2 	t(1/2) / h 
tha 	 1.1 	 tha 	 0.38 
bip 	 2.0 	 bip 	 0.69 
dha 	 3.6 	 dha 	 0.78 
p-cym 	 7.1 	 p-cym 	 2.23 
bz 	 13 	 bz 	 4.94 
aconditions  Ru:G 1:1, 100 mM NaC10 4, 298 K, 5 mM for [(i °-arene)Ru(en)OH2Y', 2 
mM for [(ri 6-arene)Ru(en)ClJ. 
Because the 'fastest rates are for the complexes containing the larger arene ligands, 
this implies lower activation energies (AG) for formation of seven-coordinate 
transition states (assuming an associative mechanism). A significant contribution to 
may arise from m - it stacking of the arene and the punne ring in the transition 
state (negative z\H).  Such an interaction is not possible for the p-cymene and 
benzene complexes. Thus these hydrophobic interactions could produce a driving 
force for DNA binding. 
- 	14 
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1.4.1.2 Role of the Leaving Group 
Hydrolysis of the Ru-X bond is thought to be central to the cytotoxicity of Ru" arene 
complexes since it is this step that activates the complex for potential binding to 
DNA or other possible cellular targets. 
Good correlations between hydrolysis rates, hydrolysis equilibrium and cytotoxicity 




X: NJ 	 Nc.CN N 
 
H2N 	X 	 Cl 	 F 












X= Cl Br I N3 pcpdcp pi. 	SPh 
Complex 	1 	5 	9 14 ' 	 21 
Figure 1.4. Correlation of hydrolysis with cytotoxicity. (Upper) Structures of the 
complexes and leaving groups. (Lower) Hydrolysis rates, equilibrium percentage of 
total Ru as ftrjôhmb)Ru(efl)(H2O)12+  ([Ru(H20 )]e %) and A2780 cancer cell 
cytotoxicity IC 50 values for [(1 ('-hmb)Ru(efl)X1 complexes with different 'leaving 
groups'. Reproduced from reference [451. 
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In general, a faster hydrolysis rate and a high percentage of aqua species at 
equilibrium correlated with good cytotoxicity towards the A2780 human ovarian 
cancer cell line. An exception is for the complex ([(1 6-hmb)Ru(en)SPh] which 
hydrolyses very slowly and to a low extent. This complex may be activated by 
oxidation of bound SPh to the sulfenate or sulfinate by oxygen and subsequent 
labilisation, since reactions of Ru" arenes with GSH show similar behavior. t461 
Density functional theory calculations t451  for aquation of [(1 6-benzene)Ru(en)X], X 
= Cr, Bf, F, N 3 suggest that the aquation proceeds via a concerted interchange 
pathway and does not appear to be strongly associatively- or dissociatively-
activated. The reaction barriers and overall reaction energies for aquation follow the 
order Br < Cl < I < N3 . The reactions appear to occur nearer the 'a  (interchange-
associative) mechanistic continuum rather than the Li (interchange-dissociative 
mechanism). On the basis of electronegativity, the N 3 complex would be expected to 
hydrolyze at a rate between the Cl - and Br-, analogues but a much slower rate is 
observed. The lower rate is ascribed to the increased steric bulk of this polyatomic 
pseudohalide; an 'a  substitution is more influenced by steric factors than an Li 
pathway. Furthermore, the electron-accepting effect of the strong it-acid arene 
ligands is thought to be responsible for the shift towards a more associative Ia 
pathway. Ru" complexes usually react via associative pathways 
1471 whereas Ru" 
complexes are more suited to dissociative mechanisms. 
1481  The it-acid arene accepts 
electron density from ruthenium to produce a higher charge on the metal. Thus Ru" 
in {(116-arene)Ru} 2  may behave more like a Ru" centre. 
1.4.1.3 Role of the Chelating Ligand 
Increased cytotoxicity is associated with a chelating ligand and a single reactive site. 
Ruthenium complexes containing mono-dentate ligands such as [(r 6-p-
cymene)Ru(CH3CN)2Cl1 and [(1 6-p-cym)Ru(isonicotinamide)2CIIF' were found to 
be inactive towards A2780 cancer cells (10 50 > 150 tiM). Monodentate ligands on 
Ru'1  arenes are more labile than bidentate ligands' 49' and can readily exchange with 
solvent whereas the chelating ligand is more resistant to hydrolysis/solvent exchange. 
Most of the work to date on Ru" arene anticancer complexes involves the chelating 
ligand ethylenediamine (en). 
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1.4.1.3.1 	Specific Hydrogen Bonding 
In all three crystal structures of [(ij 	
{(6 
tha)Ru(en)9Et-G(N7)] + and [(1 6-dha)Ru(en)9Et-G(N7)] , strong stereospecific 
hydrogen-bonding occurs between an en NH proton oriented away from the arene, 
pointing towards the DNA base (so called NHdo,n  protons) and the C6 cabonyl 
oxygen of the guanine (average distances 2.8 A N ... O, N-H ... O 163 0) (see Figure 
1.3) .140J  Such stereospecific hydrogen-bonding between the en ligand and the 
exocyclic oxygen atom of guanine, may play an important role in both the stability 
and conformation of this adduct. 
Structure-activity relationships have revealed that replacement of the 
ethylenediamine chelating ligand with the N,N-dimethyl-ethylenediamine derivative 
results in a dramatic loss of cytotoxicity (e.g. [(ij  1050 = 10 PM, 
[(16-bip)Ru(N,N-dimethy1-en)Cl], IC 50 >100 jiM). 31 ' This may be related to the 
inability of the complex to form strong stereospecific C60 HN hydrogen bonds 
with guanine bases, an interaction thought to stabilize and enhance the. 
recognition. 140J The reaction of [(16-bip)Ru(N,N-dimethyl-en)C1j with 9-EtG was 
followed by 'H NMR spectroscopy and no binding was observed. Thus steric effects 
of the methyl groups (preventing approach by 9-EtG) as well as a lack of potential 
hydrogen bonding towards DNA bases may contribute to the loss of activity. 
1.4.1.3.2 	pKa of coordinated water 
The pKa values of the aqua, complexes [(6-bip)Ru(en)H20]2, [(16 
dha)Ru(en)H20J 2  and [(1 6-tha)Ru(en)H2O] 2  are 7.71, 7.89 and 8.01, 
respectively. 441  Thus in the blood plasma, where the chloride concentration is high 
(ca. 0.14 M) all three complexes exist largely (>89%) in this inactive chiorido form. 
Upon entering the cytoplasm and nucleus, the chloride concentrations drop to ca. 23 
and 4 mM, respectively. Hence the extent of aquation is predicted to increase from 
about 30% in the cytoplasm to about 70% in the nucleus. This would represent an 
activation mechanism for these chioro complexes inside the cytoplasm/nucleus. 
Interestingly, only a small amount of Ru-OH hydroxo adducts (average <10% of 
total ruthenium) is predicted to exist inside cells due to the high pK a . value of the 
aqua adducts This becomes important for DNA binding, since the Ru-OH bond is 
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found to be less reactive towards DNA nucleobases compared to Ru-OH2 (vide 
supra). 
1.4.1.3.3 	Other N,N-chelating ligands 
Changing the chelating ligand from ethylenediamine to propylene-diamine (prop) 
(i.e. changing the chelate ring size from five to six membered) did not affect the 
cancer cell cytotoxicity [(i 6-p-cym)Ru(en)Cl] IC 50 = 10 tiM, [(r 6-p-
cym)Ru(prop)C1] IC 50 = 10 iM. 1311 However, addition of a polar OH substituent on 
the propylenediamine backbone decreased the activity. Further derivativisation of en 
ligands has varying effects on the cytotoxicity; 1311 mono-methylation of en does not 
affect IC 5 0 values, whereas dialkylation via ring formation lowers the activity three 
fold and cyclisation of en to give homopiperazine results in an inactive compound 
(1050 >50 1iM). 
Good cytotoxicity is retained when ethylenediamine ligands are replaced with 
chelating 1,2-diaminobenzene ligands. t31 ' A slightly different trend was observed 
with cytotoxicity on changing the arene in 1,2-diaminobenzene complexes; the IC 50 
value increased in the order biphenyl (5 IJM), dha (7 riM) < p-cymene (11 1iM), 
tetralin (13 tiM) <tha (23 pM). Interestingly these complexes are able to overcome 
cross-resistance to the 2780 AD cell line, in contrast to en complexes. 
[381 
1.4.1.3.4 	0,0 Chelating Ligands 
A a-donor 7c-donor oxygen -chel ating ligand dramatically changes the reactivity of 
the ruthenium arene with respect to hydrolysis, cytotoxicity and DNA base 
specificity. The chemistry of ruthenium(II) arenes containing the anionic 0,0-
chelating ligand acetylacetonate (acac) has been reported. 150j Complexes such as 
[( 6-p-cym)Ru(acac)CI] hydrolyze rapidly in water and equilibrium is reached in less 
than 5 minutes (298 K). The pK a of the coordinated water molecule in the aqua 
adduct [( 6-p-cym)Ru(acac)OH 2F is 9.41, which means that at physiological pH (pH 
7.4) the complex exists almost exclusively in the reactive aqua form. The increased 
pKa value is due to the acac ligands being strong cr-donor and it-donors towards the 
Ru" centre, increasing the electron density and hence decreasing the acidity of the 
ruthenium centre. 15 ' 1 In the reaction of [( ,q 
6_p-cym)Ru(acac)CI] with guanosine (2 
EI 
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mM 1:1) at equilibrium Ca. 80% of the guanosine is bound. A similar result is 
obtained for adenosine (ca. 80% is bound ratio of adoN7:adoNl 4:1). This 
selectivity is in stark contrast to the corresponding ethylenediamine analogues for 
which negligible binding to adenosine is observed and a strong preference for 
guanosine is observed.t521 
The complexes [(16-arene)Ru(acac)Cl] (arene = p-cym, bip, bz, indan and dha) 
exhibit moderate activity towards A2780 ovarian cancer cells (IC 5 0 19-70 MM).' 31 ' In 
general the acac complexes hydrolyze rapidly and have poor aqueous solubility. The 
reason for the reduced cytotoxicity compared to the en analogues may in part be due 
to the protonation and irreversible displacement of the chelated acac derivative under 
some conditions; the aqueous solution chemistry of the osmium analogue ftq 6-p-
cym)Os(acac)Cl] was studied using conditions mimicking the cytotoxicity testing 
[531 
and this revealed that only one species was present, assignable to the hydroxo-
bridged dimer [(16-pcym)Os(g2-OD)3Os(r 6-p-cym)V, i.e. acac is readily lost from 
the complex. This complex is inactive towards the A2780 cancer cell line (IC 50 > 50 
1.4.2 Comparison with Cisplatin and other Platinum Complexes 
Because Ru' 1  arene complexes are mono-functional (as opposed to cisplatin which is 
bifunctional) they are expected to differ in their mechanism of action. This is 
desirable since most platinum analogues of cisplatin are cross resistant with cisplatin 
and this severely limits their therapeutic application) ' 8 ' 
1.4.2.1 Activity towards A2780cis (Cisplatin Resistant) Cell Line 
Firstly Ru 1' arene complexes are completely non-cross resistant with cisplatin 
towards the A2780cis cell li ne. t 381 This is interesting as it suggests that the 
mechanism of action differs from that of cisplatin. Furthermore the in vivo 
antitumour activity in human ovarian A2780, and A2780cis xenografts for the 
complex [( 6-bip)Ru(en)Cl1 showed that it produced a significant growth delay in 
A2780 cells and maintained the growth inhibitory activity in the A2780cis xenograft. 




1.4.2.2 Reactions with DNA 
The interaction of several ruthenium arene complexes with DNA in a cell-free 
medium have been compared to cispiatinJ 411 The extent of ruthenation of double 
helical CT-DNA (0.1 mg/mL) (CT = Calf Thymus) by the arene complexes at an r 1 
value of 0.1 (molar ratio of free ruthenium complex to nucleotide phosphates at the 
onset of incubation with DNA) in 10 mM NaC10 4 at 310 K was followed. The 
amount of ruthenium bound per DNA nucleotide phosphate increased with time and 
the time at which binding reaches 50% (t50%) was markedly dependent on the arene: 
10 mm (ftq6-bip)Ru(en)Cl]) and ([( 6-tha)Ru(en)Cl]), 15 mm ([(1 6 
dha)Ru(en)Cl]) and 3.5 h ([(ij  Under the same conditions t50% 
for cisplatin binding is ca. 2 h. Thus for ([( 6-bip)Ru(en)Cl]), ([(1 6-tha)Ru(en)C 11) 
and ([(16-tha)Ru(en)Cl]), reactions are an order of magnitude faster than for 
cisplatin. 
1.4.2.3 RNA synthesis 
The in-vitro RNA synthesis by RNA polymerases on DNA templates has been 
studied using a linear DNA fragment modified by these ruthenium arene complexes, 
cisplatin and monofunctional [PtCI(dien)]C1. 1411  RNA synthesis on these modified 
plasmid fragments yielded fragments of defined size, which indicates that RNA 
synthesis on these templates was prematurely terminated. For cisplatin, the 
termination sites are similar as for the Ru" arenes (i.e. mainly at G) but the efficiency 
of the ruthenium-adducts to terminate RNA synthesis in vitro is reduced relative to 
that of cisplatin. Furthermore the efficiency of the ([( 6-p-cym)Ru(en)Cl) adducts 
was noticeably lower than for the other three Ru" arenes. Interestingly, no 
termination of RNA synthesis by the mono-functional [Pt(dien)Cl]Cl was observed, 
and this inability has been observed for several mono-functional platinum adducts. [54-  
561 This suggests that the ruthenium complexes bind and distort DNA in a somewhat 
different fashion to the mononuclear Pt complex [Pt(dien)Cl]C1. 
1.4.2.4 DNA Repair Synthesis 
Considerably different levels of damage-induced DNA repair synthesis were detected 
in plasmids modified by [(1 6-tha)Ru(en)Cl], [(ij 	and c i splati n. L 571 
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DNA repair synthesis can occur by various repair mechanisms including the 
nucleotide excision repair (NER) mechanism (which is the usual repair mechanism 
for cisplatin). Compared to cisplatin the monofunctional adducts of [(71 6_  
tha)Ru(en)Cl] and [( 6-p-cym)Ru(en)C1] are excised with a significantly lower 
efficiency than the major intrastrand crosslink of cisplatin, and [(1 6-p-
cym)Ru(en)Cfl adducts are excised slightly more than those of [(71 6-tha)Ru(en)Cl]. 
The HMG (High Mobility Group) protein plays a role in sensitizing the cells to 
cisplatin. For example it has been shown that the HMG domain proteins recognize 
and bind to DNA adducts formed by cisplatin. 117 ' An important structural motif 
recognized by HMG domain proteins on DNA modified by cisplatin is a directional 
bend of the helix axis towards the major groove. No recognition of the DNA 
monofunctional adducts of [(11 6-tha)Ru(en)C1] or [( 6-p-cym)Ru(en)ClV by HMGB 1 
has been observed, suggesting that these adducts do not afford structural motifs 
recognized by HMG domain proteins. Thus the mechanism of antitumour activity .  of 
Ru" arenes does not involve recognition of its DNA adducts by HMG domain 
proteins as a crucial step, in direct contrast to cisplatin. 
1.5 2-Phenylazopyridine (azpy) Chelating Ligands 
Ruthenium(II) is well recognized as a metal ion capable of entering into dir-pit back 
bonding with it-acceptor ligands 1581 and to date the most common it-acceptor ligand 
studied with ruthenium is bipyridine. 591 The chelation of less common it-acceptor 
ligands such as 2-phenylazopyridine to ruthenium was first investigated in 19801601 
with the view that these complexes may exhibit interesting chemical properties 
similar to bipy, since most of the novelty of Ru-bipy complexes arises from the it-
interactions between the metal and ligand. 	2-Phenylazopyridine (azpy), in 
complexes such as [RuC12(azpy)2] was found to be a much better ligand for 
stabilization of Ru" than bipy (E112 Ru" —*Ru" 1.00-1.21 V (azpy), 0.30 V (bipy)) 
showing greater difficulty in oxidation of Ru-azpy complexes to Ru". 1601 
The pKa values of the corresponding aquo complexes [Ru(azpy) 2 (H20)2] 2  (pKai = 
6.80 ± 0.05) and pKa2 = 8.66 ± 0.05) and [Ru(azpy)2(py)(OH2)] 2 (pKa = 6.80 ± 0.05) 
are much lower than the corresponding bipy complexes (for example 
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[Ru(bipy)2(py)(OH2)] 2 (pKa = 10.26 ± 0.05),161 1 again attributed to the much 
stronger it-acceptor character of azpy compared with bipy; the Ru-OH2(7-bond is 
correspondingly stronger in the azpy case resulting in easier deprotonation. 
The azo N=N infrared stretch for ruthenium-2phenylazopyridine complexes of the 
type [Ru(azpy) 2(AB) 	is sensitive to the it-accepting nature of the coligand (AB) 
with a better it-acceptor ligand giving a higher u(N=N), and can thus be used as a it-
bonding probe. t621  Other applications of Ru-phenylazopyridine complexes include as 
catalysts for the oxidation of alcohols to acids by NaBr0 3 1631 and of glucose. [641 
1.5.1 The anticancer activity of ruthenium(II) azpy complexes 
Previous work has shown that the ruthenium(II) complexes containing the chelating 
azo ligand azpy display interesting anticancer activity. 
1.5.1.1 Mononuclear complexes 
Because the chelating ligand azpy lacks a two-fold symmetry axis, ruthenium 
complexes of the type [Ru(azpy) 2Cl2] can theoretically exist as 5 isomers, but early 
work reported only three ct- [Ru(azpy) 2C12], 3- [Ru(azpy) 2C1 2] and y-  [Ru(azpy) 2C12] 






Figure 1.5. Structural representations of a- [Ru(azpy)2C1 2] (a-Cl), 3- [Ru(azpy) 2 C12 ] 
(n-Cl) and 7-[Ru(azpy)2C12]  (y-Cl). Reproduced from Reference [65]. 
More recently the structure of a fourth isomer (6-[Ru(azpy) 2C12]) has been 
reported. 166 J The cytotoxicity of these three isomers against a series of human 
tumour cell lines was determined [65J  and whilst n-Cl and 7-C1 showed low to 
moderate cytotoxicity 1671 , the a-C1 isomer was roughly an order of magnitude more 
cytotoxic with IC50 values comparable to cisplatin in some cell lines, and even more 
active than cisplatin in some of the faster growing cell lines. Furthermore, no cross-
resistance was observed in the A2780cis resistant cell line suggesting that this 
compound may be able to avoid the DNA repair mechanisms that are present in 
cisplatin-resistant cells, or be unaffected by the elevated GSH levels. 1611  Cellular 
uptake studies showed that after one hour exposure to TS/A murine adenocarcinoma 
cells, the ruthenium concentration for the a-Cl isomer was approximately six fold 
higher than the n-Cl isomer (0.0 160 j.tg VS 0.0028 p  / 1 x 106  cells). 
Several azpy derivatives have subsequently been synthesized including methylated 
phenylazopyridine derivatives (o-tolylazopyridine (tazpy) and 4-methyl-2-
phenylazopyridine (mazpy)) where a-[Ru(tazpy) 2Cl2] was found to be more 
cytotoxic than a-Cl whereas u-[Ru(mazpy)2Cl2] slightly less active. 169' The a-Cl 
analogue was poorly soluble in water and so the nitrate analogue a-
{Ru(azpy)2(NO3)2] was developed [701  in order to study the interaction of this 
compound with DNA bases, since DNA is considered the target for this type of 
complexes. 71 ' In the reactions of this complex with DNA model bases (9-EtG, Guo) 
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no bifunctional adducts were obtained and the orientation of the 9-EtG in the 
monofunctional adduct a-[Ru(azpy) 2(9-EtG)XJ varied depending on X (X = Cl, 
H20), with two rotamers being observed in solution. 170J This was in contrast to the 
structurally similar yet non-cytotoxic cis-[Ru(bipy)2C12]  which, upon reaction with 9-
EtG, gave only one 9-EtG orientation. 172J Thus the larger, more flexible azpy ligand 
allowed for more orientations with guanine derivatives. Interestingly, upon reaction 
of a-[Ru(azpy) 2 (NO3 )2] with 9-MeA, a rare neutral imine tautomer of 9-MeA is 
observed whereby one nucleobase mimic coordinated to the ruthenium in a bidentate 
fashion via its N7 and exocyclic N6 atoms to form a-[Ru(azpy) 29-MeA] 2 . 173 ' The 
nitrate derivatives, although showing an increased aqueous solubility, were about a 
factor of ten less cytotoxic then the less soluble chloride analogues. [68 
It was thus hypothesized that Structure-Activity Relationships must specify two 
labile cis chloride ligands (which can hydrolyse enabling DNA binding). In order to 
test this hypothesis a series of tris-chelating ligand complexes [RuL 3 ](PF6)2 (mer-
[Ru(azpy) 3 1 (PF6) 2 , a- [Ru(azpy) 2(bipy)] (PF6)2 and 13- [Ru(azpy) 2(bipy)] (PF6)2, and 
[Ru(azpy)(bipy)21(PF6)2) all incapable of hydrolysis were tested for cytotoxicityJ 741 
These complexes were predicted not to display cytotoxicity but surprisingly, when 
evaluated against a series of human tumour cell lines significant cytotoxicity was 
demonstrated in one or more line. This result may mean that the cytotoxicity of 
these complexes is by a different mechanism of action to a-[Ru(azpy)2C12] and may 
be caused by an intercalative interaction with DNA as opposed to direct coordination 
by Ru.. 
1.5.1.2 Dinuclear Complexes 
There is a growing interest in the design of anticancer complexes which impart 
cytotoxicity in a different way to cisplatin (i.e. not through coordinative DNA 
binding),"', 761  and the cytotoxicity of two isomeric dinuclear unsaturated 
ruthenium(II) complexes linked via the dinuclear chelating ligand 2,2'-
[methylenebis(4, 1 -phenyleneazo)]bis-pyridine  (L) to form [Ru 204L2] has recently 
been reported. 1771  The complexes exist as three different double-stranded 
architectures: the trans-trans (yy) isomer (in which the chlorine ligands at both 
ruthenium centres are in a trans configuration), the trans-cis isomer (ycL) and the cis- 
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cis (cia) isomer. The trans-trans isomer and the trans-cis isomer were tested for 
cytotoxicity towards two human breast tumors cell lines HBL100 and T47D. Both 
complexes were very active in these cell lines with the trans-cis having similar 
activity to cisplatin in the HBLIOO cell line (5.1 vs. 4.9 MM) and better activity in the 
TD47D cell line (1050 6.7 vs. 28.3 MM) whereas the trans-trans isomer was 
approximately 30 times more potent than cisplatin in the HBLIOO cell line (0.16 MM) 
and 100 times more in the T47D line (0.16 MM). Interestingly thus the same trend in 
cytotoxicity was observed as seen for the mononuclear species in that the highest 
activity is observed for the -y-isomer than the u-isomer. 66 ' 69 ' 
1.6 Aims 
The overall aim of this thesis is to investigate the anticancer activity of ruthenium(II) 
arene complexes containing a 2-phenylazopyridine as the N,N-chelating ligand. 
Much of the work to date had focused on the use of N,N-chelating ligands that bind 
to ruthenium in a cs-donor-only fashion and so the effect of changing the type of 
bonding of the ligand to ruthenium (i.e. the incorporation of a it-acceptor ligand) can 
be investigated. More specific aims are as follows. 
To synthesise and characterise ruthenium arene complexes containing 2-
phenylazopyridine ligands with variations to the arene, leaving group and the azo 
ligand. 
To study the aqueous solution chemistry of these complexes and compare the 
behaviour to that reported for en and acac derivatives. 
To investigate the reactivity of the complexes towards nucleobases, potential 
cellular targets. 
To investigate the cancer cell cytotoxicity of the complexes. 
To elucidate the mechanism of cancer cell cytotoxicity 
Thus essentially the overall aim of the work is to assess the potential of using 
ruthenium(II) arene complexes containing chelating azo ligands as anticancer agents 
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Chapter 2: Experimental Section 
This Chapter details the major experimental techniques used in this work. An 
overview of the technique is given, followed by the methods used. Some more 
specific techniques are outlined in individual chapters. The synthesis of the starting 
materials that are used in subsequent chapters for the synthesis of the ruthenium 
complexes is also described here. 
2.1 Nuclear Magnetic Resonance (NMR) Spectroscopy' 5 ' 
Nuclear magnetic resonance spectroscopy is one of the most powerful tools available 
to chemists for elucidating the structure of both organic and inorganic species. In 
this thesis the main nucleus studied is 'H, although a small number of experiments 
was performed on 31 P. 'H NMR spectroscopy was used to characterise synthesised 
complexes as well as to follow the reaction of complexes in aqueous solutions. 
2.1.1 Experimental Technique Overview 
Nuclear magnetic resonance spectroscopy involves the study of transitions that are 
induced between nuclear spin energy levels, whose degeneracy has been lifted by the 
presence of a magnetic field. 
For every nucleus, the spin properties of the protons and neutrons present combine to 
define the overall spin of the nucleus, termed the nuclear spin quantum number (I). 
When both the number of protons and neutrons are even and paired there is a net spin 
angular momentum of zero (1=0). When both the number of protons and neutrons are 
odd generally the nucleus has an integral non-zero quantum number because the total 
number of unpaired nucleons is even and each contributes ½ to the quantum number. 
When there is either an odd number of protons or an odd number of neutrons, the 
nuclear spin quantum number adopts a ½ integral quantum number. Some properties 
of common nuclides are listed in Table 2.1. 
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Table 2.1 NMR properties of some common nuclides 
Nucleus Natural Abundance (%) y / (1O7 Ts') v at 9.4 T I 
1 H 99.985 26.75 400.0 ½ 
0.02 4.11 61.4 1 
1.108 6.73 100.6 ½ 
14 N 99.63. 1.93 28.9 1 
' 5N 0.37 -2.71 40.5 ½ 
100 10.84 162.1 ½ 
For a spinning nucleus, the magnitude of the magnetic moment (j.t) produced by a 
nucleus varies from atom to atom as defined by the equation: 
t=yh I 
where y  is the gyromagnetic ratio, which is a characteristic of each nucleus and h is 
Planks constant h divided by 27t. In the absence of a magnetic field the spin angular 
momentum has no preferred direction. In the presence of a magnetic field the 
orientation of the magnetic moment j.i to the field direction (z-axis) is quantised and 
depends on I: 
j.t=yh m1 
where m1 is the magnetic quantum number which has 21 +1 values in integral steps 
between +1 and —I. 
Thus to study nuclear magnetic properties, nuclei are subjected to a strong magnetic 
field (130 / Tesla) along the z-axis and this affects the energies of the nuclei. There is 
a slight preference for alignment in the general direction of B0 (+z) over the opposite 
direction (-z). The nuclear magnetic moments are not lined up fully in the +z/-z 
direction; instead the force of B0 causes the magnetic moment to move in a circular 
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fashion about the +z / -z direction, see Figure 2.1. This rotating particle moves in a 
circular path (precesses) around the magnetic field and the frequency of precession 
(VO), called the Larmor Frequency is defined as V = yBo / 2ir. 
z 
B0 = +1/2 
I XSpinningNucleus 
= -½ 
Figure 2.1. The alignment of nuclear magnetic moments in the presence of the 
magnetic field B0 for a nucleus with I = ½. The population difference between +z/-z 
is given by Boltzmann's Law: n(+ ½ )/n(- ½) = exp (iEfkT) 
In NMR experiments these two states (+z/-z) are made to interconvert by applying a 
second magnetic frequency, B 1 , whose frequency corresponds to the Larmor 
Frequency. Because there is an excess of alignment at +z, there is a net absorption of 
energy. This process is called resonance and the absorption may be detected 
electronically and displayed as a plot of frequency vs. amount of energy absorbed. 
Modern NMR experiments used a pulsed (Fourier transform) technique where the 
nuclei in a magnetic field are subjected periodically to brief pulses of intense 
radiofrequency radiation (length - < 10 jis) and in the interval between pulses (T, 
several seconds) a time domain radio-frequency signal is emitted as nuclei return to 
their original state. 
2.1.2 Chemical Shift, Resonance Intensities and Spin-Spin Coupling 
2.1.2.1 Chemical Shift 
NMR is such a powerful structural tool because the observed resonance frequency 
(u0) depends on the molecular environment as well as on y  and B 0, since the electron 
cloud that surrounds the nucleus also has a charge, motion and hence a magnetic 
moment. This electronic modulation of B0 is termed (de)shielding and variation of 
the resonance frequency with (de)shielding is termed the chemical shift. As an 
-1 
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example, an electron-withdrawing group attached to a proton will reduce the electron 
density around the proton resulting in less shielding and a higher resonance 
frequency than in the case of a molecule that lacks the electron-withdrawing group. 
Similarly an electron donating group attached to a proton will increase the electron 
density around the proton resulting in more shielding and a lower resonance 
frequency. Several effects including inductive effects, resonance effects and 
hydrogen bonding will all modify the magnetic environment of the proton. 
2.1.2.2 Resonance Intensities 
The intensity of a resonance (the area under the peak; the integral) is proportional to 
the number of nuclei giving rise to it. However, it is important to remember that the 
values obtained may be in error by as much as Ca. 10% lower than their true values. 
For integration to be reliable, it is essential that all the nuclei relax to their 
equilibrium values between successive pulses and this is governed by the 
longitudinal relaxation time T 1 . 
In order to determine if the resonance is equivalent to e.g. one, two or three protons, 
the level of accuracy is usually enough to determine this unambiguously. 
2.1.2.3 Spin-Spin Coupling 
If a nearby nucleus has a spin, then that spin affects the magnetic environment of the 
nucleus and the signal detected is not a singlet but a multiplet, the complexity of 
which is dependent upon the nature and number of nearby atoms. This phenomenon 
is called spin-spin coupling. This spin-spin coupling is measured by the coupling 
constant, J (Hz). For first order proton spectra, in which the chemical shift is large 
compared to the coupling constant, the following characteristics are exhibited. 
Firstly, multiplicities resulting from coupling reflect the 2n1+1 rule. Thus, as an 
example, two neighbouring nuclei of I = ½ will split the resonating nucleus into three 
peaks. Secondly, the intensities of the spin-spin multiplets correspond to the 
coefficients of the binomial expansion given by Pascal's triangle for spin ½ nuclei. 
Thirdly, spacings between adjacent components of a spin-spin multiplet are equal to 
J. Furthermore, protons that are equivalent show no coupling towards each other. 
Thus splitting patterns can be used to aid the assignment of proton peaks. 
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2.1.3 Two Dimensional Techniques: COSY (COrrelation SpectroscopY) and 
TOCSY (TOtal Correlation Spectroscopy) 
In these 2D-NMR techniques a second frequency dimension is introduced into the 
experiment in which the magnetic interactions between nuclei through structural 
connectivity are further considered. In both cases two identical chemical shift axes 
are plotted orthogonally, with the one-dimensional spectrum appearing on the 
diagonal of the plot. In COSY experiments, the peaks that are mutually spin-spin 
coupled are shown by cross-peaks which are symmetrically placed about this 
diagonal. The cross-peaks usually include geminally (two-bond) or vicinally (three-
bond) coupled protons but longer range coupling is not usually observed. In 
TOCSY experiments the connectivity within an entire spin system is mapped out by 
bringing all protons in the same spin system into equivalence. 
2.1.4 Water Suppression 
Proton NMR experiments performed in aqueous medium (100% D 20 or 90% H 20 / 
10% D20) have a large residual solvent peak (H20, HOD) which can be suppressed 
using 1D Double Pulse Field Gradient Spin Echo (DPFGSE) experiments or by pre-
saturation methods. Pre-saturation involves saturating the water signal by irradiating 
the frequency of the water signal in between pulse sequences whereas in DPFGSE 
experiments pulsed field gradient spin echoes are used in which the refocusing pulse 
is the sequence soft 7r(x)-hard 7r(x). 161 
2.1.5 Experimental Methods 
NMR spectra were recorded on either a Bruker Avance 600 MHz equipped with a 
TX! [1fl,  ' 3C, 15N] x,y,z-gradient probe or a TX! ['I-I, 13C, ' 5N] z-gradient cryoprobe, 
a Bruker Avance 800 MHz equipped with a IC! ['H, ' 3C, ' 5N] z-gradient cryoprobe 
or a TX! ['H, 13C, ' 5N] x,y,z-gradient probe, a Bruker DMX 500 MHz equipped with 
a TB! ['H, ' 3C, ' 5N] z-gradient probe, or a Bruker DPX 360 MHz spectrometer 
equipped with a QNP ['H, 13C, ' 5N] probe. 'H NMR signals were referenced against 
the residual solvent peak, 5 7.27 (chloroform), 2.52 (DMSO), 2.07 (acetone) 3.32 
(methanol) and for aqueous solutions (containing D 20) dioxan was added as an 
internal reference (6 3.75). All spectra were recorded in 5 mm quartz N1vIR tubes at 
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298 K unless otherwise stated using standard pulse sequences modified by Mr Juraj 
Bella or Dr Dusan Uhrin (The University of Edinburgh) and data were processed 
using Xwin-NMR (Version 2.0 or 3.6 Bruker UK Ltd). 
2.2 Ultraviolet-visible (UV-VIS) Spectroscopy" 5, 71 
UV-VIS spectroscopy is one of the oldest methods of molecular spectroscopy and 
the introduction of UV spectroscopic analysis in the 1930s was an important 
milestone in analytical chemistry. UV-VIS spectroscopy can give useful information 
about the electronic structure of the complex studied. In this work, UV-VIS 
spectroscopy was routinely used as a means of characterising the complexes 
synthesised. 
2.2.1 Experimental Technique Overview 
In UV-VIS spectroscopy absorption of electromagnetic radiation in the UV-VIS 
region (200-800 nm) causes transitions between the electronic energy levels of the 
bonds of a molecule. Electrons are thus excited from their ground electronic state to 
an excited electronic state, see Figure 2.2. 
LUMO 	
hv 	 .,t. 
HOMO  
Ground State 	 Excited State 
Figure 2.2. After absorbing a photon with the same energy as the HOMO-LUMO 
gap, the electronic configuration of the corresponding excited state that arises is due 
to the promotion of an electron from the HOMO to the LUMO. 
Although electronic transitions arise between ground and excited states of the entire 
molecule, the transition can usually be assigned to parts of the molecule (called 
chromophores) where valence electrons are found (e.g. non-bonding n-electrons or it-
electrons). 
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Absorption of UV-VIS light is typically seen as broad absorption maxima and not as 
sharp lines corresponding representing the absorption in an extremely narrow range. 
This is because there are vibrational levels associated with each electronic level. 
Thus excitation can occur to any of the vibrational levels of the excited electronic 
states, leading to a large number of lines for each transition. In practice, however, 
the lines overlap so that a continuous band is observed. 
2.2.2 Allowed and Forbidden Transitions 
In UV-VIS spectroscopy we not only measure the energy of exciting a molecule 
from its ground electronic state to its electronically excited state but also the 
probability of this transition. This is represented by the molar extinction coefficient 
(e) which is a measure of the ease of the transition caused by the absorption of the 
radiation. [81 
The molar extinction coefficient can be determined by the Beer-Bouger-Lambert 
Law, which states that the proportion of light absorbed by a transparent medium is 
independent of the intensity of the incident light and proportional to the number of 
absorbing molecules through which the light passes: 
log (b/I) = ccl 
where 10 is the intensity of incident light, I is the intensity of transmitted light, e is the 
molar extinction coefficient, c is the concentration and 1 is the path length (cm). 
Since log (loll)  is defined as absorbance (A) the equation simplifies to A = ccl. Thus 
by measuring the absorbance at a known concentration, the extinction coefficient can 
be determined. 
Electronic transitions are classed as allowed (intense) or forbidden (weak) according 
to their extinction coefficient. There are three rules that govern allowed or forbidden 
transitions. 
The spin selection rule, which states that transitions between states of different 
spin multiplicity are forbidden since electrons cannot undergo spin inversion during 
the change of the electronic state i.e tS=O. 
The change in angular momentum must be 0, or ±1 
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(3) The symmetry selection rule, or the Laporte selection rule, which states that in a 
centrosymmetric molecule or ion, the only allowed transitions are those accompanied 
by a change in parity. 
Whilst coupling of spin and angular momenta can relax the spin selection rule, the 
transitions are much weaker than the spin allowed transitions. The Laporte selection 
rule is much easier to relax since a complex may depart from perfect centrosymmetry 
or may undergo an asymmetrical vibration, both resulting in destroying the center of 
inversion. Thus Laporte-forbidden transitions tend to be more intense than spin-
forbidden transitions. 
2.2.3 Experimental Methods 
A Perkin-Elmer Lambda-16 UV/Vis spectrophotometer was used with 1 cm path 
length quartz cuvettes (0.5 mL volume) and a PTP1 Peltier temperature controller. 
Spectra were recorded at 298 K (unless otherwise stated) from 800-200 nm at a scan 
rate of 420 nm / min and at 1 nm intervals. In all cases, the solvent used was double 
distilled water, unless otherwise stated. Spectra were processed using UV-Winlab 
software for Windows' 95. 
2.2.3.1 Determination of Molar Extinction Coefficients 
Molar extinction coefficients (e) were calculated using the Beer- B ouger-Lambert 
Law (vide supra) where a plot of absorbance versus concentration for a single 
wavelength should be linear and pass through the origin and the gradient of this line 
gives. c. Thus for each UV-VIS band, a plot of absorbance measured at Xmax Vs. 
concentration for five separate concentrations of sample, gave as the gradient, E. 
2.3 Electrochemistry [9, 10] 
Electrochemistry involves the study of electron transfer reactions between electrodes 
and reactant molecules in a solution phase. Three electrochemical techniques were 
used to help to characterise several of the complexes studied in this thesis. 
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2.3.1 Cyclic Voltammetry 
In cyclic voltammetry, the current is measured as the electrode potential is swept 
from a potential E 1 to a potential E2 then back to E 1 . A reduction causes a decrease 
in the measured current (electrons going into the electroactive species), and an 
oxidation causes an increase in the measured current (release of electrons to 
surroundings). Redox reactions can be classed as reversible, quasi-reversible or 
irreversible, and there are diagnostic tests that can be used to distinguish between all 
three cases. Furthermore, chemical reactions can follow reductions/oxidations and 
these can similarly be assigned on the basis of diagnostic tests. 
A three-electrode configuration was used whereby current is passed through the 
working/counter electrode circuit whilst the potential of the working electrode is 
measured relative to the reference electrode. This results in little/no current being 
passed through the working electrode/reference electrode loop giving a more 
accurate potential. 
2.3.2 Differential Pulse Polarography (DPP) 
Differential pulse polarography provides an enhanced sensitivity compared to cyclic 
voltammetry and was used in this thesis to confirm the number of redox processes 
occurring in a system. The same three-electrode configuration is used, but in DPP, 
the pulse height is kept constant (50 mV) and the base potential is swept slowly with 
time. The current shortly before the pulse is applied, and that at the end of the pulse 
are measured and the difference between these values as a function of the potential is 
recorded. 
2.3.3 Constant Potential Coulometry 
This technique is used to determine the overall number of electrons involved in an 
electrode process. In the experimental set up, a divided cell is used in which the 
working electrode compartment is separated from the secondary electrode by a glass 
frit. The working electrode compartment is fitted with a magnetic stirrer and filled 
with a known number of moles of electro-active species. The potential of the 
working electrode is fixed (usually just past the redox potential in question) and the 
current is monitored as a function of time until the current falls to Ca. 1% of its initial 
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value. The total charge consumed at the end of the experiment, q(ci) can be 
extrapolated to i(t) = 0 and this is related to the number of electrons involved in the 
process by: 
q(oo) = nFm 
Where F is Faraday's constant and m is the number of moles added. 
2.3.4 Experimental Methods 
Electrochemical studies were performed with General Purpose Electrochemical 
System (GPES) Version 4.5 software connected to an Autolab system containing a 
PSTAT20 potentiostat. All of the electrochemical techniques used a three-electrode 
configuration. The reference electrode used was Ag/AgCl in a solution of 0.1 M 
[TBA][BF4] in DMF against which E112 for the ferrocinium/ferrocene couple was 
measured to be +0.55 V. The working and counter electrodes were a platinum 
microdisc (0.5 mm diameter) and a large surface area platinum wire respectively. 
Coulometric experiments were performed in a conventional H-type cell using large 
surface-area Pt working and counter electrodes. All solutions were purged with dry 
nitrogen prior to electrochemical study. 
2.4 Electrospray lonisation Mass Spectrometry (ESI-MS) 1,41 
ESI-MS is a solution-based mass spectrometrric technique, so compounds can be 
studied directly in aqueous solutions. ESI-MS was used routinely in this work to 
characterise complexes synthesised and also to assign products of reactions. 
2.4.1 Experimental Technique 
The sample must be present as an ion in solution and this can be achieved (if species 
is not already charged) by adding a small amount of acid to protonate (ESI positive) 
or base to deprotonate (ESI negative). Molecules are taken directly from the solution 
to the gas phase ionised state by passing the solution through the exit of a fine needle 
held at a potential of around 4 kV. The solution disperses into a fine mist of ionised 
droplets which quickly lose their solvent leaving behind an aerosol of (de)protonated 
sample which is then desorbed into the gas phase and interfaced with the vacuum for 
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mass spectrometric analysis. Ion analysis was performed using a quadrupole mass 
spectrometer. 
In a quadrupole mass filter, ions drift through an assembly of four cylindrical metal 
parallel rods in which DC voltages of opposite sign are applied to opposite rods. An 
oscillating (AC) radiofrequency field is also applied to opposite rods, which 
successively reinforces and then overwhelms the DC field. The effects of AC and 
DC potentials on the trajectory of ions as they pass through the channel between the 
rods explain the filtering capability of the quadrupole: 
The pair of positive rods act as a high pass mass filter. In the absence of a DC 
potential, ions in the channel will converge in the centre of the channel during the 
positive half of the AC cycle and diverge during the negative half (where, if it strikes 
the rod the charge is neutralised and the resulting charge carried away). Whether or 
not an ion strikes the rod will depend on the rate of movement of the ion along the 
motion direction, its mass-to-charge ratio and the frequency and magnitude of the 
AC signal. In the presence of the DC signal, because of EK = ½ my2 , it becomes 
more difficult to deflect a heavier ion than deflect a lighter one. Thus if an ion in the 
channel is heavy and/or the frequency of the AC potential is large, the ion will not 
respond significantly to the alternating potential and will be influenced largely by the 
dc potential. Under these circumstances the ion will tend to remain in the space 
between the rods. In contrast, if the ion is light and/or the frequency is low, the ion 
may collide with the rod and be eliminated during the negative cycle of the ac signal. 
The pair of negative rods (orthogonal to positive rods) act as a low pass mass 
filter. In the absence of the AC potential, all positive ions are drawn to the rods 
where they are annihilated and neutralised. However, for lighter ions, this may be 
offset by the positive excursion of the AC potential. 
Thus in order for an ion to travel through the quadrupole it must have a stable 
trajectory in both planes (i.e. not be too heavy that it will be eliminated by high pass, 
nor too light so that it is not eliminated from the low pass filter). Varying the 
electrical signals to the quadropole varies the range of m/z values transmitted, thus 
spectral scanning becomes possible. 
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2.4.2 Experimental Methods 
ESI-MS were obtained on a Micromass Platform II Mass Spectrometer or a 
Micromass ZMD Mass Spectrometer (Micromass, Manchester, UK). Solutions were 
infused directly at a rate of 3-30 pL/min. The capillary voltage was 3.5 kV and the 
cone voltage was either varied between 15 to 40 V, depending on the solution. The 
source temperature was dependent on the solvent used, and different mass ranges 
were scanned, again depending on the solution. 
2.5 Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES)t 4 ' 
11,121 
ICP-OES is a very sensitive technique that can be used to determine concentrations 
of elements in both aqueous and organic solutions. Here, it was used to determine 
the ruthenium, sulfur, iron and iodide concentrations in aqueous solutions. 
2.5.1 Experimental Technique 
ICP-OES uses inductively coupled argon plasma to dissociate a sample into its 
constituent atoms or ions, and then thermally excite them to a level where they emit 
visible or UV light of a characteristic wavelength. Atomic emission occurs when a 
valence electron in a higher-energy atomic orbital returns to a lower-energy atomic 
orbital. The intensity of the emission line is proportional to the number of atoms 
populating the excited state. 
In an argon plasma (containing argon ions and electrons), once formed, the argon 
ions absorb sufficient power from an external radiofrequency source so that the 
temperature is maintained at a level at which further ionisation sustains the plasma 
indefinitely. The sample is introduced into the hot plasma causing atomisation and 
emission can then be monitored. 
2.5.2 Experimental Methods 
A Perkin Elmer Optima 5300 DV ICP-OES machine was used. Standard solutions 
(0.1-100 ppm) were prepared from stock 1000 ppm solutions (ruthenium, iron, 
sulfur, Sigma Aldrich, iodide prepared by dissolving KI to 1000 ppm) and run to 
give a calibration curve from which unknown concentrations of the element could be 
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determined. Ruthenium emissions were followed at 240.272 and 349.849 nm and the 
average concentration determined from these two emissions was used. For iron the 
emissions were averaged from 238.204 and 239.562 rim, for sulfur 181.975 and 
180.699 nm and for iodide 206.188 and 182.976 nm 
2.6 X-ray Diffraction (XRD) 13 ' 141 
X-ray diffraction is the most widely used and least ambiguous method for the precise 
determination of the position of atoms in molecules in the crystalline solid state. 
XRD was used in this thesis to characterise the crystal structure of several 
synthesised compounds. 
2.6.1 Experimental Technique 
X-rays are electromagnetic radiation with wavelengths of the order 10.10  m. In 1912, 
Max von Laue suggested that x-rays might be diffracted when passed through a 
crystal since their wavelength was comparable to the separation of lattice planes. In 
a crystal there are a large number of identical molecules that are held together in a 
regular arrangement and together this gives significant x-ray scattering, and it is the 
electrons in the atoms that cause x-ray scattering. 
The x-ray diffraction data pattern contains important information. Firstly the pattern 
has a particular geometry which is related to the lattice and unit cell geometry of the 
crystal and so can give information about repeat distances between molecules. 
Secondly the pattern has symmetry which is closely related to the unit cell of the 
crystal structure (i.e. crystal system and space group). Thirdly the intensities of the 
pattern holds all the information about the positions of atoms in the unit cell of the 
crystal structure since it is the relative atomic positions which, through the 
combination of their individual interactions with the x-rays, generate different 
amplitudes for different directions of scattering. The structure is solved using 
Patterson/Direct methods to determine approximate positions of all / most non-
hydrogen atoms. This approximate structure is then refined by varying numerical 
parameters describing the structure to produce the 'best' agreement between the 
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diffraction pattern calculated from it by a Fourier transform and the observed 
diffraction pattern. 
2.6.2 Methods Used 
All diffraction data were collected by Professor Simon Parsons and colleagues at The 
University of Edinburgh on a Bruker Smart Apex CCD Diffractometer using Mo Ka 
radiation (X = 0.71073A) equipped with an Oxford Cryosystems device operating at 
150 K. Structures were solved by Professor Simon Parsons and colleagues using 
either Patterson (dirdif) or direct (SHELXS-97) methods, as indicated in the text. 
Structures were refined against F 2 using either SHELXL-97 or CRYSTALS, as 
indicated in the text. 
2.7 High Performance Liquid Chromatography (HPLC)4' 111 
HPLC is the most widely used of all the analytical separation techniques. In this 
thesis HPLC was used to separate reaction mixtures of ruthenium complexes for 
subsequent analysis. 
2.7.1 Experimental Technique 
The technique used in this thesis was Reverse Phase-HPLC (RP-HPLC). 
Compounds bind to RP-HPLC columns from high aqueous mobile phases and are 
eluted with a high organic mobile phases. 
The column used was a Polymer-Reverse Phased PLRP-S column which comprises a 
rigid non-polar macroporous styrene/divinylbenzene polymer as the stationary phase, 
where an analyte is retained on the surface by physical adsorption. The use of a 
polar eluent (e.g. water) favours the migration of a polar compound over a non-polar 
one through the column and under these conditions non-polar substances will be 
retained. By decreasing the polarity of the mobile phase (by increasing the 
percentage of organic phase) less polar substances are eluted. 
The separation of easily-ionised compounds can be improved by adding 
trifluoroacetic acid (TFAH) to the mobile phase. This induces the formation of 
dipole-dipole interactions between the compounds rendering them less polar and 
relatively stable and hence their retention on the reversed phase column is increased. 
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2.7.2 Experimental Methods 
A Hewlett-Packard series 1100 quaternary pump and a Rheodyne sample injector 
with a 0.1 mL (analytical) or 1 .0-mL (semi-preparative) loop, a HP 1100 series UV-
vis detector and HP 1100 series Chemstation was used. Analytical separations were 
carried out on PLRP-S reversed-phase column (250 mm x 4.6 mm, 100 A, 5 pm, 
Polymer Labs) and semi-preparative separations on a PLRP-S reversed-phase 
column (250 mm x 7.5 mm, 100 A, 8 pm, Polymer Labs) with detection at 286 nm. 
The mobile phases were mobile phase A: water (for HPLC application, Fisher 
Chemicals) containing 0.1% TFAH; mobile phase B: acetonitrile (for HPLC 
application, Fisher Chemicals) containing 0.1 % TFAH. The flow rate was either 1.0 
mL min' (analytical) or 3.5 mL min' (semi-preparative). Gradients were dependent 
on the analysis mixture and are reported in the subsequent chapters. 
2.7.3 Fast Protein Liquid Chromatography (FPLC) 15 
FPLC is a form of column chromatography used to separate or purify proteins from a 
complex of mixtures. In this thesis, an anion exchange resin was used whereby the 
resin is positively-charged and attracts negatively-charged molecules. As the protein 
is introduced to the column, it diffuses to the stationary phase surface, displacing the 
counter anion. The binding of the protein to the resin is based upon the competition 
between the charged groups on the surface of the protein and the charge on the 
counter anions, and the bound protein will be displaced when the counter anion is 
concentrated enough to overcome the attraction between the protein and the ion 
exchange resin. The concentration of the counter anion can thus be increased 
gradually using a salt gradient. It is important to note that the protein will bind to an 
anion exchange resin only when there is sufficient charge on the protein, i.e. above 
its p1 value. 
FPLC was performed on an AKTA FPLC system (Amersham Biosciences) using a 5 
mL Hi-Trap Capto Q column (GE healthcare) with help from Dr Arindam Mukherjee 
(The University of Warwick). The samples were first concentrated to I mL in Tris - 
HCl buffer (pH 8) and injected into the loop (1 mL). The solvents were thoroughly 
degassed before use and were A: 5 mM Tris-HC1 (pH 8) and B: 50 mM Tris-HC1 pH 
Chapter 2. Experimental Section 
8, 5 mM NaHCO3, 800 mM NaCl. The flow rate used was 5 mlJmin and the 
gradient used was 0% B to 100% B over 60 minutes. 
2.8 Cell Culture [161 
The following section outlines some more general cell experiment procedures used in 
this thesis although individual chapters contain details about more specific 
experiments. 
2.8.1 Experimental technique 
The major purpose of cell culture is to allow cells to be removed from their complex 
interactions in the organism and hence attempt to reproduce in vitro the 
environmental conditions that the cells experience in vivo. Cells are attached to a 
substratum and are covered with a thin layer of cell medium which approximates the 
extracellular fluid of the organism. The cells are kept at physiological pH using a 
bicarbonate (HCO 3 ) buffering system because this is the closest to the physiological 
medium that surrounds cells in an organism. The bicarbonate is in equilibrium with 
the CO2 in the air and so to maintain the correct concentration of bicarbonate that 
provides the appropriate pH, the concentration of CO2 in the environment must be 
kept higher than its concentration in air. Cells are thus grown by incubation at 310 
K, 5% CO2 and at a high humidity (to prevent any evaporation). 
2.8.2 Materials and Maintenance of Cell Lines 
All cell lines were obtained from the ECACC (European Collection of Cell 
Cultures). DMEM, RPM! and MEM media, L-glutamine, penicillin/streptomycin 
and foetal bovine serum were obtained from Sigma Aldrich. McCoys 5A medium 
and 0.25% trypsinlEDTA were obtained from Invitrogen. The A549 human lung 
cancer cell line was grown in DMEM medium supplemented with 10% foetal bovine 
serum, 1% penicillin/ streptomycin and 2mM L-glutamine. The A2780 human 
ovarian cancer cell line was grown in RPM! medium supplemented with 5% foetal 
bovine serum, 1% penicillin/ streptomycin and 2mM L-glutamine. The HCTI16 
(WI) human colon cancer cell line (wild type) was grown in McCoys 5A medium 
supplemented with 10% foetal bovine serum. The HCTI 16 (p53W) human colon 
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cancer cell line (p53 null) was grown in McCoys 5A medium supplemented with 
10% foetal bovine serum. The W138 human lung fibroblast cell line was grown in 
MEM medium supplemented with 10 % fetal bovine serum, 1% penicillin/ 
streptomycin and 2mM L-glutamine. 
All cells were split twice weekly before 100% confluence was reached using 0.25% 
trypsinlEDlA. All cells were kept incubated at 310 K, 5% CO2 , high humidity. 
2.8.3 Determination of IC 50 values 
All IC50 values against the W138 non-cancerous cell line, and IC 50 values against the 
A2780 and A549 cell line for compounds 1, 4, 5, 8, 9, 10, 11, 13 and 16 and ligand 
azpy-OH were determined as part of this thesis work. All other IC 50 data were 
determined by Ms Emily Jones or Mr Daniel Cole (Oncosense Ltd). The 
concentration of complex added to the cells which causes 50% inhibition of cell 
growth is termed IC 50 . These experiments were performed in 96-well plates. 
A2780 cancer cells were plated out at 5 x 104 cells/well (3.33 x 106  cells/mL) 
(±10%) and incubated for 48 h before compound addition. A549 cancer cells and 
W138 normal cells were plated out at 2x 10 4 cells/well (1.33 x 106  cells/mL) (±10%) 
and incubated for 24 h before drug addition. 
The test compounds were dissolved in DMSO to give a stock solution of 20 mM and 
serial dilutions were carried out in DMSO to give concentrations of drug in DMSO 
of 10, 2, 1, 0.2 and 0.02 mM. These were added to the wells to give the six testing 
concentrations (100, 50, 10, 5, 1 and 0.1 pM) and a final concentration of DMSO of 
0.5% (v/v) with a total volume of drugs and media to be 200 p1. Each concentration 
was tested in triplicate and a cisplatin control was added to the plate, since cisplatin 
gave reproducible values in the cell lines used. The cells were exposed to the drug 
for 24 hours then, after drug removal and washing the wells twice with PBS, fresh 
medium was given and the cells were incubated for 96 hours recovery time. 
The remaining biomass after this time was determined using the Sulforhodamine-B 
(SRB) assayJ' 7' SRB is a bright pink aminoxanthene dye with two sulfonic acid 
groups. Under mildly acidic conditions it binds to proteins basic amino acid residues 
in proteins and under more basic conditions the dye is liberated and can be 
quantitatively extracted for measurement of optical density (X ax = 568 nm). 
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Briefly to each well 50.tL 50% (w/v) TCA was added and the wells were incubated 
at 277 K for one hour to fix the remaining biomass. This was stained with 100 PL 
0.4% (w/v) sulforhodamine B in 1% acetic acid. This dye was solubilised with Tris 
Buffer and the absorbance was read using a BMG Fluostar microplate reader at 595 
nm. A baseline correction at 690nm was subtracted from the absorbance values. 
The absorbance value taken as 100% cell survival was the averaged triplicate 
absorbance for the 0.1 laM dosed wells. The percentage cell survival relative to this 
control could then be determined. IC 50 values were calculated using XL-Fit version 
4.0 (IDBS, Surrey, UK) by plotting percentage cell survival against compound 
concentration and noting the concentration that leads to 50% cell survival. 
2.9 pH measurements 
The pH meter used was a Corning pH meter 145 calibrated with pH 4, pH 7 and pH 
10 buffer solutions (Sigma Aldrich) equipped with a Therom microcombination KC1 
(chloride) / KNO3 (chloride free) electrode. The pH values were recorded at room 
temperature. The pH meter readings for D20 solutions were recorded without the 
correction for the effect of deuterium on the glass electrode, and are termed pH*. 
2.10 CHN (Carbon-Hydrogen-Nitrogen) Elemental Analysis [41 
CHN elemental analysis provides a means for assessing the purity of a sample, by 
determining the percentage of carbon, nitrogen and hydrogen and comparing to the 
theoretical value. 
2.10.1 Experimental Technique 
Pre-weighed samples are combusted in an oxidising atomosphere (at high 
temperatures, Ca. 1170 K) and this produces a gaseous mixture of CO, CO2, H20, N 2 
and N-oxides. The gaseous mixture is swept with a stream of helium to a reduction 
reactor which reduces N-oxides to elemental N2 , CO to CO2 and removes the extra 
oxygen. The products move to a mixing chamber, where they are brought to a 
constant temperature and analysed by passing through three thermal conductivity 
detectors, which generate electrical signals proportional to the concentrations. 
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Hydrogen (H) is analysed from the water content by passing the mixture through a 
magnesium perchiorate absorption trap. Carbon (C) is analysed from the CO 2 and N2 
is analysed from the elemental N 2 present. 
2.10.2 Methods Used 
CHN analyses were carried out either by The University of Edinurgh using an Exeter 
Analytical Elemental Analyser (CE440), or at the The Univeristy of St. Andrews 
using a Carlo-Erba CHNS Analyser. 
2.11 Synthesis of Starting Materials 
The ruthenium dimers [(i 6-arene)RuC 12]2 and {(i 6-arene)Ru 12]2 are used as starting 
materials for the synthesis of ruthenium complexes studied in this thesis. 
2.11.1 Materials 
RuC13.xH20 was purchased from Precious Metals Online, 1 ,4-cyclohexadiene, a-
terpenine, hexamethylbenzene, biphenyl and ammonium hexaflüorophosphate 
(NH4PF6) were purchased from Sigma Aldrich and all other reagents were obtained 
from commercial suppliers. Ethanol was dried by distilling over Mg/I 2 and 
tetrahydrofuran was dried by distilling over Na. 
2.11.2 Methods 
The precursors 	[( 6-biphenyl)RuC1 21 2 , 	[( 6-benzene)RuC1 2} 2 and [(7e-p- 
cymene)RuC1 2] 2 can be conveniently prepared from the reaction of RumC13  and the 
1,3- or 1,4-cyclohexadiene by refluxing in ethanol 118, 191 Whilst 1,4-cyclohexadiene 
(to form [(116-benzene)RuC12]2,  and cL-terpenine (to form [( 6-p-cymene)RuC1 2 1 2) are 
commercially available, the Birch reduction of biphenyl 1201  afforded l-phenyl-2,5-
cyclohexadiene which could then be used to form the corresponding dimer. Arene 
exchange of p-cymene for hexamethylbenzene in [(q 6-p-cymene)RuC1 2] 2 afforded 
[(i16 hexamethylbenzene)RuC1 2] 2 U 9l and [(
11
6- thn)RuC 12]2 (thn = 
tetrahydronaphthalene) was prepared previously. 1211 The corresponding iodide dimers 
[( 6-arene)RuI2]2 were synthesised easily from [( 6-arene)RuC1 2 ] 2 and excess KI. 
50 
Chapter 2: Experimental Section 
2.11.3 Synthesis and Characterisation 
2.11.3.1 1,4-Dihydrobiphenyl 
Ammonia gas (1 L) was condensed into a flask cooled with dry ice/acetone to 197 K 
under an argon atmosphere. Biphenyl (17.50 g, 0.114 mol) was dissolved in distilled 
and dried tetrahydrofuran (250 mL) and added to the ammonia via canulla. Lithium 
metal (1.99 g, 0.287 mol) was cut into small pieces and added. The reaction mixture 
was stirred for 30 min and the solution turned green then red. NH 4C1 (22 g, 0.411 
mol) was added to quench the reaction and the colour turned to white. The vessel 
was left overnight to allow excess ammonia to evaporate. Water (300 mL) was 
added and the solution was extracted with diethyl ether ( 3 x 200 mL). The 
combined organic fractions were re-extracted from water (5 00 mL) saturated with 
NaCl. The organic layer was dried over magnesium sulphate and the solvent was 
removed to leave a yellow oily crude product. This was distilled at 10' mbar, 371 K 
to give colourless oil. Yield 14.40 g (81.3%). 'H NMR (CDC1 3 ): 5 7.28 (m, SI-I), 
5.79 (m, 4H), 3.98 (t, 1H), 2.77 (m, 211). 
2.11.3.2 ftr 6-bipheny1)RuC1 2]2 
RuC13.xH20 (5 g, 0.024 mol) was dissolved in distilled and dried ethanol (85 mL) 
and l-phenyl-2,5-cyclohexadiene (4.3 g, 0.028 mol) was added drop-wise. The 
resulting mixture was heated to reflux for 48 h during which time a brown precipitate 
had formed. The solution was cooled to room temperature, filtered and the brown 
precipitate was washed with ethanol and dried overnight in vacuo. Yield 6.43g 
(82.2%). (Found C, 43.40; H, 2.85. Calcd for Ru2C2 4H20C14 C, 44.19; H, 3.09 %). 
'H NMR (DMSO-d6): 5 7.86 (d, 2H), 7.54 (m, 3H), 6.47 (d, 211), 6.11 (m, 3H) 
2.11.3.3 [(116-benzenel)RuCl2]2 
RuC13 .xH20 (3 g, 0.015 mol) was dissolved in distilled and dried ethanol (80 mL) 
and 1,4-cyclohexadiene (11.6 g, 0.145 moles) was added drop-wise. The resulting 
mixture was heated to reflux for 4 h during which time an orange/brown precipitate 
had formed. The solution was cooled to room temperature, filtered and the resulting 
precipitate was washed with cold ethanol and then diethyl ether and dried overnight 
/ 
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in vacuo. Yield 1.98 g (27.3%). (Found C, 27.84; H, 2.09. Calcd for R11 2C 12H, 204 
C, 28.82; H, 2.42 %). 'H NMR (DMSO-d6): 6 5.99 (s, 6H) 
2.11.3.4 [(q6-p-cymene)RuC 2]2 . 
RuC13.xH20 (3.54 g, 0.017 mol) was dissolved in distilled and dried ethanol (100 
mL). To this solution a-terpinene (25.11g. 0.202 mol) was added drop-wise and the 
solution was heated to reflux for 24 h. During this time the solution changed from 
brown to red. After cooling to room temperature the solution was filtered to give a 
red/orange precipitate which was washed with diethyl ether until the filtrate was 
clear and dried overnight in vacuo. Yield 3.51 g (67.4%). (Found C, 39.37; H, 4.21. 
Calcd for Ru2C20H 28 C14 C, 39.23; H, 4.61 %). 'H NMR (CDCI3): 6 5.50 (d, 4H), 
5.35 (d, 4H), 2.95 (septet, 111), 2.15 (s, 6H), 1.30 (d, 12H) 
2.11.3.5 ftt6-hexamethyIbenzene)RuCl2]2 
The dimer [(ij6-p-cymene) RuC1 21 2 (1.98 g, 3.23 mmol) and hexamethylbenzene (20 
g, 123 mmol) were placed in a flask and heated to 456 K for 3 hours where the 
solution gradually turned from orange-red to orange-brown. During heating 
hexamethylbenzene solidified around the top of the flask and this was continually 
scraped back down into the solution. The reaction mixture was cooled, filtered and 
washed with hexane (200 mL) and diethyl ether (200 mL) to give ,a dull brown solid. 
Excess hexamethylbenzene can be removed by sublimation, although in this instance 
instead the solid was repeatedly dissolved in hexane and filtered until there was no 
hexamethylbenzene present in the filtrate. The brown solid left was filtered through 
celite and washed with chloroform (400 mL) until the filtrate turned clear. The 
solvent from the filtrate was removed on a rotary evaporator to leave a reddish brown 
solid. Yield 1.37 g (63.5%). (Found C. 45.22; H, 5.52. Calcd for Ru 2C24H3 6C14 C, 
43.12; H, 5.43 %). 'H NMR (CDC1 3): ö 2.03 (s, 6H) 
2.11.3.6 [(ij 6-biphenyl)Ru12]2 
The dimer [(,6.  biphenyl)RuC1 2] 2 (0.3 g, 0.40 mmol) was stirred at ambient 
temperature in water (250 mL) for 30 minutes. The solution was filtered and KI 
(2.12 g, 0.013 mol) was added to the filtrate. A brown/red precipitate immediately 
formed. This was filtered off and washed with cold ethanol and diethyl ether. Yield: 
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388 mg (38.8%). (Found C, 28.38; H, 1.98. Calcd for Ru 2C24H20I4 C, 28.31; H, 1.61 
%). 'H NMR (DMSO-d6): 6 7.84 (d, 2H), 7.54-7.46 (m, 311), 6.66 (d, 2H), 6.38 (t, 
111), 6.12 (d, 2H) 
2.11.3.7 [(g 6-p-cymene)Ru12] 2 
The dimer [( 6-p-cymene) RuC1 2 1 2 (0.65 g, 1.06 mmol) was refluxed in water (200 
mL) for 1 h. The solution was hot filtered and K! (4.45 g, 0.027 mol) was added to 
the filtrate. A brown/red precipitate immediately formed. This was filtered off and 
washed with cold ethanol and diethyl ether. Yield: 841 mg (81.1%). (Found C, 
24.70; H, 2.50. Calcd for R11 2C20H28 14 C, 24.56; H, 2.59 %). 'H NMR (DMSO-d 6): 
5.87 (d of d, 4H), 3.16 (septet, 1H), 2.40 (s, 3H), 1.22 (d, 6H). 
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3.1 	Introduction 
Ruthenium complexes have potential as anticancer d rugs .t 11  Previous work has 
shown that ruthenium(II) arene complexes of the type [( 716-arene)Ru"(XY)ZIj, where 
XY is a chelating diamine and Z is a leaving group exhibit cytotoxicity against 
several cancer cell lines including cisplatin-resistant cells.t2' 31  Increased 
hydrophobicity of the arene increases cytotoxicity and complexes containing 
chelating di-amines were more active than complexes containing only monodentate 
ligands. It has been proposed that hydrolysis of the reactive ruthenium-chloride bond 
may activate the complex for DNA binding, [41  and that distortions of DNA may 
contribute to the mechanism of action. 15J  In these types of complexes, ruthenium is 
stabilized in the +2 oxidation state by the it-acidic 1 6-arene and in the case of 
ethylenediamine (en), the chelating diamine N ligands are a donors. 
Azo ligands such as 2-phenylazopyridine (azpy), which contain the -N=N-C=N-
linkage have unusual properties. 16J The pyridine ring is an intermediate i-acceptor 
and its nitrogen is a weak a-donor. The azo group has low cr-donor ability to the 
metal, but possesses enhanced it-accepting ability through the azo ir' orbital. 
Consequently chelating ligands of this type are able to stabilise metals in their lower 
oxidation states. Several ruthenium(II) compounds containing such ligands have 
been reported previously. t7, 81 For example, the cytotoxic properties of isomers and 
derivatives of [Ru(azpy) 2C1 2] have been investigated in several cancer cell lines.t 9121 
In particular, a-[Ru(azpy) 2C12] (a = trans pyridines, cis azo nitrogens and cis 
chlorides) was found to be highly active against abroad range of cancer cell lines, 
with cytotoxicities comparable to cisplatin and 5-fluorouracil, and superior activity 
in faster-growing cell lines. 
In this Chapter the effects of changing the nature of the bonding by the N,N-
chelating ligand (from a donor to a it-acceptor) on the properties of Ru arene 
complexes is studied. Thus the synthesis, characterization, aqueous solution 
chemistry and cytotoxicity of a series of novel ruthenium(II) complexes containing 
both an ri6-coordinated  arene and a chelated 2-phenylazopyridine or 
phenylazopyrazole derivative are reported. The molecular structures of the 
complexes studied in this Chapter are shown in Figure 3.1. 
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Compound Arene N-N 
1 p-cym azpy 
2 thn azpy 
3 bz azpy 
4 bip azpy 
5 p-cym azpy-N Me2 
6 thn azpy-NMe 2 
7 bz azpy-N Me2 
8 bip azpy-NMe2 
9 p-cym azpy-OH 
10 thn azpy-OH 
11 bz azpy-OH 
12 bip azpy-OH 
13 p-cym azpyz-NMe2 
14 thn azpyz 7 NMe2 
15 bz azpyz-NMe2 
16 bip azpyz-NMe2 
Figure 3.1. General structure of the complexes synthesized in this work as PF 6 salts. 
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3.2 	Experimental 
3.2.1 Materials 
The preparations of the starting materials [(i 6-arene)RuC 12]2 (arene = p-cymene, 
tetrahydranapthalene, benzene, biphenyl) is reported in Chapter 2. 4-(2-Pyridylazo)-
N, N-dimethylaniline (azpy-NMe 2), aniline, NaNO2, 2-cyanoethyihydrazine, N, N-
di methylani line, ortho-phosphoric acid, benzoquinone, 2-hydrazi nopyri dine and 
nitrosyl sulfuric acid were purchased from Sigma-Aldrich. Ethanol and methanol 
were dried over Mg/I 2 or anhydrous quality was used (Sigma-Aldrich). The 
ruthenium ICP-OES standard (1000 ppm) was purchased from Sigma Aldrich. All 
other reagents used were obtained from commercial suppliers and used as received. 
3.2.2 Synthesis 
3.2.2.1 2-(Phenylazopyridine) (azpy) 
The solid 2-aminopyridine (5.49 g, 0.0583 mol) was added to NaOH (27.06 g, 0.677 
mol) in 30 mL water containing 5 mL benzene. Over a 15 min period, 
nitrosobenzene (6.08 g, 0.0567 mol) was added whilst the mixture was warmed on an 
oil bath. The mixture was heated under reflux for a further 10 min and was then 
extracted 3 x with 100 mL portions of toluene. The organic layer was dried with 
magnesium sulfate and treated with decolourising charcoal. The toluene was 
removed on a rotary evaporator, the solid residue dried in vacuo under argon, and 
recrystallisation from petroleum ether was attempted. The solid was dissolved in 500 
mL of hot petroleum ether (313-323 K), leaving a brown residue which was decanted 
off. The solution was cooled in a container of dry ice overnight in an attempt for 
solid to precipitate out. Recrystallisation from petroleum ether (313-323 K) was 
repeated twice and the red solid product was used for further synthesis without 
further purification. Yield: 3.773 g (36.3%). 'H NMR (CDC13): 58.76 (d, 1H), 8.08-
8.05 (m, 2H), 7.93 (t, 1H), 7.85 (d,1H), 7.57-7.53 (m, 3H), 7.42 (t, IH) ESI-MS: 
Calcd for C,,H9N3 [MJ mlz 184. 1, found 184.2. 
3.2.2.2 4-(2-Pyridylazo)phenol (azpy-OH) 
Benzoquinone (0.493 g, 4.56 mmol) was dissolved in 50 mL water and 3.6 mL 60% 
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perchioric acid. Hydrazinopyridine (0.504 g, 4.62 mmol), dissolved in 8 mL water 
was added dropwise and the solution gradually turned brown/orange. The solution 
was stirred at ambient temperature for I h and filtered to leave an orange crystalline 
precipitate, which was dissolved in 25 mL methanol and 1.5 mL formic acid and 
ammonia gas was bubbled through the mixture until re-precipitaion occurred. The 
product was filtered and left to dry overnight in vacuo. A second crop was obtained 
by reducing the volume of the solvent of the filtrate. Yield 213 mg (23.4%) 'H NMR 
((CD 3 )2S0): 6 8.73 (d, 1H), 8.13 (t, 1H), 7.91 (d, 2H), 7.75 (d, 1H), 7.61 (t, 1H), 7.01 
(d, 2H). ESI-MS: Calcd for C,,H9N 30 [MJ rn/z 200. 1, found 200.2. 
3.2.2.3 3-Amino-pyrazoline hydrochloride 
Sodium metal (0.096 g, 4.17 mmol) was added to 15 mL dry ethanol. 2-
Cyanoethylhydrazine (2.5 g, 29.4 mmol) was added dropwise and the mixture was 
heated under reflux for 4 h. The reaction mixture was left to cool and 50 mL .37% 
HC1 was added dropwise. The reaction mixture turned green/yellow and a white 
precipitate formed at the bottom of the flask. The flask was kept cool by surrounding 
in ice and the solution was filtered through a frit under suction. The crude product - 
was dissolved in acidified water where NaCl impurities precipitated out. These salts 
were removed by filtration, water was removed on the rotary evaporator and the 
white solid product was dried overnight in vacuo. Yield: 2.48 g (68%). 'H NMR 
((CD3)2S0): 67.09 (br s, 1H), 3.42 (t, 2H), 2.85 (t, 2H) 
3.2.2.4 3-Amino-1-nitroso-2-pyrazoline 
The solid 3-amino-pyrazoline hydrochloride (1 g, 8.23 mmol) was suspended in 8 
mL acetic acid and the flask was cooled by surrounding in ice. NaNO2 (0.57 g, 8.23 
mmol) was dissolved in 1 mL water and added dropwise to the cooled solution over 
70 mm. The solution was stirred at 273 K for 4 h. The solvent was removed and the 
orange solid was re-dissolved in 3 mL water. The flask was kept cold by 
surrounding in ice and the mixture was filtered under suction. The orange powder 
obtained was dried overnight in vacuo. Yield: 204 mg (22%). ESI-MS: Calcd for 
C3H6N40 [M] m/z 114. 1, C3H6N 3 [M-NO] 84. 1, found 114.6, 84.6. 
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3.2.2.5 4-(1H-pyrazol-3-ylazo)-N,N dimethylaniline (azpyz-NMe2) 
3-Amino-1-nitroso-2-pyrazoline (353 mg, 3.07 mmol) was dissolved in 3 mL o-
phosphoric acid and stirred at 298 K. H2SO4 (2.4 mL of 18 M) was added slowly to 
this mixture so that the temperature did not exceed Ca. 313 K. Once the mixture has 
stopped bubbling a solution of NOHSO 4 (0.98 g of 40% wt) in H2SO 4 (0.98 g) was 
added over 1 h. The reaction was subsequently stirred at 321-323 K for 1.5 h then 
poured onto 35 g ice. N,N-dimethylaniline (0.361 g, 3 mmol) was dissolved in 20 
mL water. To this solution the diazotised mixture was added dropwise and the pH 
was kept between 4 and 5 by addition of sodium carbonate (saturated solution). The 
yellow solution was filtered and the precipitate was washed with water. The yellow 
solid was dried overnight in vacuo. Yield: 375 mg (57%). 'H NMR (D 20) 68.05 (d, 
2H), 7.84 (d, 1H), 7.75 (d, 2H), 6.76 (d, lH), 3.37 (s, 6H) ESI-MS: Calcd for 
C  1H13N5 [M] mlz 216. 1, found 215.5. 
3.2.2.6 [( 6-p-cym)Ru(azpy)C1]PF6  (1) 
The dimer [(tj6-p-cym)RuC1 2] 2 (257.6 mg, 0.421 mmol) was dissolved in 25 mL 
methanol and left to stir at room temperature until the solution turned clear. Azpy 
(155.7 mg, 0.850 mmol) dissolved in 10 mL methanol was added drop-wise and the 
solution gradually turned from brown to deep red. The solution was stirred at room 
temperature for one hour. The volume of solvent was reduced to about lOmL by 
removal of methanol on a rotary evaporator. NH 4PF6 (417 mg, 2.773 mmol) was 
then added and the solution was placed in the freezer for one hour. A black powder 
precipitated out and this was filtered off and washed with ether. Yield: 408 mg 
(80.9%) (Found: C, 42.09; H, 4.02; N, 7.03. Calc for RuC21H23N3C1PF6: C, 42.07; 
H, 3.87; N, 7.01). 'H NMR (CDC13): 6 9.45 (d, IH), 8.58 (d, 1H), 8.27 (t, 1H), 8.09 
(rn, 2H), 7.90 (t, 1H), 7.77 (t, 1 H), 7.67 (t, 2H) 6.24 (d, 111), 5.90 (d, 1H), 5.77(d of 
d, 2H), 2.53, (m, 1H), 2.23 (s, 3H), 1.06 (d of d, 6H). 
3.2.2.7 [(i 6-thn)Ru(azpy)Cl]PF 6  (2) 
The dimer [(ij 6-thn)RuC1 2 ] 2 (99.8 mg, 0.164 mmol) was dissolved in 20 mL methanol 
and left to stir at room temperature until the solution turned clear. Azpy (60.09 mg, 
0.332 mmol) dissolved in 10 mL methanol was added drop-wise and the solution 
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gradually turned from orange to dark brown. The solution was stirred at room 
temperature for one hour. The volume of solvent was reduced to about half by 
removal of methanol on a rotary evaporator. NH 4PF6  (166 mg, 1.020 mmol) was 
then added and the solution was left at room temperature for one hour. A black shiny 
powder precipitated out and this was filtered off and washed with ether. Yield: 166 
mg (86.7%) (Found: C, 41.35; H, 3.67; N, 6.98. Caic for RuC20H21 N3CIPF6: C, 
41.02; H, 3.62; N, 7.18). 'H NMR (CDC1 3 ): 6 9.14 (d, IH), 8.63 (d, 1H), 8.27 (t, 1H), 
8.07 (m, 2H), 7.83 (t, 1H), 7.72 (t, 1H), 7.66 (t, 2H), 6.01 (d, IH), 5.84 (t, IH), 5.56 
(d, 1H), 5.34 (t, 1H), 2.92-2.64 (m, 4H), 2.03-1.76 (m, 4H). 
3.2.2.8 [(i 6-bz)Ru(azpy)Cl}PF 6 (3) 
The dimer [(tj 6-bz)RuC1 2 ] 2 (51.1 mg, 0.102 mmol) was dissolved in 25 mL methanol 
and left to stir at room temperature until the solution turned clear. Azpy (37.74 mg, 
0.206 mmol) dissolved in 10 mL methanol was added drop-wise and the solution 
gradually turned from light to dark brown. The solution was stirred at room 
temperature for one hour. The volume of solvent was reduced to about 15 mL by 
removal of methanol on a rotary evaporator. NH 4PF6 (112 mg, 0.690 mmol) was 
then added and the solution was left in the freezer overnight. The volume was then 
reduced to around 10 ml, and a dark brown powder precipitated out. This was 
filtered off and washed with ether. Yield: 81.6 mg (73.7%) (Found: C, 37.82; H, 
2.73; N, 7.63. Calc for RuC17H,5N 3CIPF6: C, 37.57; H, 2.78; N, 7.74). 'H NMR 
((CD 3 )2C0): 8 9.80 (d, 1H), 8.90 (d, 1H), 8.61 (t, IH), 8.31 (m, 2H), 8.03 (t, 1H), 
7.82-7.79 (m, 3H), 6.43 (s, 6H). 
3.2.2.9 [(t 6-bip)Ru(azpy)CI]PF6 (4) 
The dimer [( 6-bip)RuC12 ] 2  (101.6 mg, 0.156 mmol) was dissolved in a solution of 
40 ml, methanol and 10 mL water. The solution was refluxed under argon for 2 
hours and was hot-filtered to remove a black residue. Azpy (62.75 mg, 0.343 mmol) 
dissolved in 5 mL methanol was added drop-wise and the solution almost 
immediately turned from orange to deep red. The solution was stirred and left to cool 
to room temperature for one hour. The volume of solvent was reduced to about 25 
ml, by removal of methanol on a rotary evaporator. NH 4PF6 (189 mg, 1.16 mmol) 
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was then added and the solution was left in the fridge overnight during which time a 
light brown powder precipitated out. This was filtered off and washed with ether. 
Yield: 130 mg (68.3%) (Found: C, 44.11; H, 2.92; N, 6.85. Caic for 
RuC23H, 9N3C1PF6 : C, 44.59; H, 3.09; N, 6.79) 'H NMR ((CD3)2C0): 8 9.55 (d, 1H), 
8.88 (d, IH), 8.57 (t, 1H), 8.10 (d, 2H), 7.95 (t, 1H), 7.80 (t, 1H), 7.76 (d, 2H), 7.67-
7.59 (m, 3H), 7.53 (t, 211), 6.82-6.77 (m, 2H) 6.69 (d oft, 2H), 6.45 (t, 1H). 
3.2.2.10 ftt 6-p-cym)Ru(azpy-NMe2)CI]PF 6  (5) 
The dimer [(ij 6-p-cym)RuC1 2] 2  (255.8 mg, 0.418 mmol) was dissolved in 25 mL 
methanol and left to stir at room temperature until the solution turned clear. Azpy -
NMe2  (184.7 mg, 0.816 mmol) dissolved in 15 mL methanol was added drop-wise 
and the solution immediately turned from brown to dark blue. The solution was 
stirred at room temperature for one hour. The volume of solvent was reduced to 
about 10 mL by removal of methanol on a rotary evaporator. NH 4PF6 (470 mg, 
2.883 mmol) was then added and the solution was placed in the freezer overnight. A 
black microcrystalline product precipitated out and this was filtered off and washed 
with ether. Yield: 480 mg (91.8%) (Found: C, 43.19; H, 4.52; N, 8.62. Calc for 
RuC23H27N4C1PF6 : C, 43.05; H, 4.24; N, 8.62). 'H NMR (CDC1 3): 5 9.22 (d, 1H), 
8.2-8.15 (m, 3H), 8.07 (t, 1H), 7.62 (t, 1H) 6.82 (d, 211), 6.03 (d, 1H), 5.85 (d, 1H), 
5.76 (d of d, 211), 3.31 (s, 6H), 2.48 (m, 1H), 2.27 (s, 3H), 1.43 (d, 3H), 0.61 (d, 3H). 
3.2.2.11 [(q 6-thn)Ru(azpy-NMe 2)C1]PF6 (6) 
The dimer [(0 6_thn)RuCI212 (104.9 mg, 0.173 mmol) was dissolved in 25 mL 
methanol and left to stir at room temperature until the solution turned clear. Azpy -
NMe2 (74.94 mg, 0.331 mmol) dissolved in 10 mL methanol was added drop-wise 
and the solution immediately turned from orange to dark blue. The solution was 
stirred at room temperature for one and a half hours. The volume of solvent was 
reduced to about half by removal of methanol on a rotary evaporator. NH 4PF6 (172 
mg, 1.056 mmol) was then added and the solution was left at room temperature for 
one hour. A green powder precipitated out and this was filtered off and washed with 
ether. Yield: 188 mg (90.6%) (Found: C, 42.40; H, 4.22; N, 8.81. Caic for 
RuC22H26N3C1PF6 : C, 42.03; H, 4.17; N, 8.92). 'H NMR (CDC1 3 ): 6 9.03 (d, 1H), 
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8.21 (m, 3H), 8.09 (t, 1H), 7.61 (t, 111), 6.83 (d, 2H), 5.89 (t, 1H), 5.83 (t, 1H), 5.79 
(m, 2H), 3.31 (s, 6H), 2.74-2.39 (m, 4H), 1.79-1.58 (m, 4H). 
3.2.2.12 ft116-bz)Ru(azpy-NMC2)CJ]pF6 (7) 
The dimer {(ij6-bz)RuC12] 2 (51 .1 mg, 0.102 mmol) was dissolved in 25 mL methanol 
and left to stir at room temperature until the solution turned clear. Azpy-NMe 2 
(45.65 mg, 0.200 mmol) dissolved in 10 mL methanol was added drop-wise and the 
solution immediately turned from orange to dark blue/purple. The solution was 
stirred at room temperature for one hour. The volume of solvent was reduced to 
about half by removal of methanol on a rotary evaporator. NH 4PF6 (106 mg, .650 
mmol) was then added and the solution was left in the freezer overnight. A dark 
brown powder precipitated out and this was filtered off and washed with ether. 
Yield: 86 mg (73.4%) (Found: C, 39.05; H, 3.29; N, 9.48. CaIc for 
RuC, 9H20N4C1PF6: C, 38.91; H, 3.44; N, 9.56). 'H NMR ((CD 3 )2C0): 8 9.56 (d, 
1H), 8.43-8.33 (m, 4H), 7.72 (t, 1H), 7.05 (d, 2H), 6.35 (s, 6H), 3.39 (s, 6H). 
3.2.2.13 [(q6-bip)Ru(azpy-NMe 2)C1]PF6 (8) 
The dimer [(rj 6-bip)RuC12 ] 2  (105.1 mg, 0.161 mmol) was dissolved in a solution of 
40 mL methanol and 10 mL water. The solution was refluxed under argon for 2 
hours. Azpy-NMe 2  (78.15 mg, 0.345 mmol) dissolved in 5 mL methanol was added 
drop-wise and the solution immediately turned from brown to very dark blue. The 
mixture was hot filtered and left to cool to room temperature whilst stirring. After 
thirty minutes, the volume of solvent was reduced to about 15 mL by removal of 
methanol on a rotary evaporator. NH 4PF6  (187 mg, 1.14 mmol) was then added and 
the solution was left in the fridge overnight. The black crystalline powder 
precipitated out and was filtered off and washed with methanol until the filtrate 
turned blue. Yield: 130 mg (61.1%) (Found: C, 45.31; H, 3.56; N, 8.44. Calc for 
RuC25H24N4C1PF6 : C, 45.31; H, 3.61; N, 8.46) 'H NMR ((CD3)2C0): 6 9.25 (d, IH), 
8.36 (d, 1H), 8.29 (t, 1H), 8.22 (d, 2H), 7.75-7.71 (m, 2H), 7.60-755 (m, 2H), 7.54-
7.48 (t, 211), 6.91 (d, 2H), 6.75 (d, IH), 6.65 (d, IH), 6.57 (d of d, 2H), 6.38 (t, 1H), 
3.36 (s, 6H). 
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3.2.2.14 [(1 6-p-cym)Ru(azpy-OH)CI]PF 6  (9) 
The dimer [(xj 6-p-cym)RuC1 2 ] 2  (40 mg, 0.048 mmol) was dissolved in methanol (15 
mL) and left to stir at room temperature until the solution turned clear. Azpy-OH (21 
mg, 0.096 mmol) dissolved in methanol (10 mL) was added drop-wise and the 
solution gradually turned from brown to deep brown/red with a yellow tinge. The 
solution was stirred at room temperature for 3 h. The volume of solvent was reduced 
to about 10 mL and NH4PF6  (80 mg, 0.49 mmol) was added and the solution was 
placed in the freezer overnight. A black powder precipitated out and this was filtered 
off and washed with diethyl ether. The product was dried overnight in vacuo. Yield: 
50 mg (84.7%) 'H NMR ((CD3)2S0): ö 9.49 (d, 1H), 8.55 (d, 1H), 8.37, (t, 1H), 8.12 
(d, 2H), 7.80 (t, 1H), 6.99 (d, 2H), 6.40 (d, IH), 6.16 (t, 2H), 6.06 (d, 1H), 2.37 
(septet, lH), 2.23 (s, 3H), 0.88 (dd, 6H). ESI-MS: calcd for RuC2 1 1123N30 [MJ m/z 
470. 1, found 469.9. 
3.2.2.15 ftq6-thn)Ru(azpy-OH)CIJPF6 (10) 
The dimer [(ij 6-thn)RuCL2 ] 2  (30 mg, 0.049 mmol) was dissolved in methanol (15 mL) 
and left to stir at room temperature until the solution turned clear. Azpy-OH (21 mg, 
0.098 mmol) dissolved in methanol (5 mL) was added drop-wise and the solution 
immediately turned from orange to deep purple. The solution was stirred at room 
temperature for 1 h. The volume of solvent was reduced to about half by removal of 
methanol on a rotary evaporator. NH 4PF6  (166 mg, 1.020 mmol) was then added and 
the solution was placed in the freezer overnight. A black powder precipitated out 
and this was filtered off and washed with diethyl ether. The product was dried 
overnight in vacuo. Yield: 45 mg (73.4%) (Found: C, 40.79; H, 3.19; N, 6.78. Calcd 
for RuC21H2 1 N3C1OPF6 : C, 41.15; H, 3.45; N, 6.86).'H NMR (DMSO-d6) 5 9.49 (d, 
IH), 8.71 (d, 1H), 8.45 (t, 1H), 8.16 (d, 2H), 7.94 (t, 1H), 7.08 (d, 2H), 6.39 (d, 1H), 
6.25 (t, 1H), 6.095 (t, 1H), 6.06 (d, 1H), 2.71-2.62 (m, 1H), 2.62-2.5 (m, 1H), 2.34-
2.25 (m, 1H), 2.15-2.06(m, 1H), 1.62-1.49 (m, 2H), 1.33-1.11 (m, 211). 
3.2.2.16 [(q6-bz)Ru(azpy-OH)CI]PF6 (11) 
The dimer {(0 6-bz)RuC12] 2  (25 mg, 0.05 mmol) was dissolved in methanol (20 mL) 
and warmed to ca. 323 K until the solution turned clear. Azpy-OH (20 mg, 0.1 
M. 
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mmol) dissolved in methanol (10 mL) was added drop-wise and the solution turned 
from brown to deep brown/red with a yellow tinge. The solution was cooled to room 
temperature and stirred for 4 h. The volume of solvent was reduced to about 10 mL 
by removal of methanol on a rotary evaporator. NH 4PF6 (80 mg, 0.5 mmol) was then 
added and the solution was left in the freezer overnight. Diethyl ether was added 
drop-wise to the flask to precipitate out the product as a black solid. This was 
filtered off and washed with diethyl ether. The product was dried overnight in 
vacuo. Yield: 35 mg (62.6%) (Found: C, 36.65; H, 2.50; N, 7.60. Calcd for 
RuC17H, 5N3C1OPF6 : C, 36.54; H, 2.71; N, 7.52) 'H NMR ((CD3)2S0): 8 9.66 (d, 
1H), 8.71 (d, 1H), 8.44 (t, 1H), 8.19 (d, 2H), 7.89 (t, 1H), 7.05 (d, 2H), 6.29 (s, 6H). 
3.2.2.17 [(i 6-bip)Ru(azpy-OH)CL]PF 6 (12) 
The dimer [(tj 6-bip)RuCl2] 2  (33 mg, 0.05 mmol) was dissolved in methanol (40 mL) 
and water (10 mL) and heated to reflux for 2 h. Azpy-OH (20 mg, 0.1 mmol) 
dissolved in methanol (5 mL) is added and the solution was refluxed for a further 1 h. 
The solution was hot-filtered, the solvent was removed and the solid was re-
dissolved in methanol (Ca. 20 mL). NH4PF6 (84 mg, 0.5 mmol) was added and the 
solution was placed in the freezer overnight. A brown solid precipitated out and this 
was filtered and washed with diethyl ether. The product was dried overnight in 
vacuo Yield: 45 mg (46.0%) 'H NMR ((CD 3)2S0): ö 9.41 (d, 1H), 8.63 (d, 1H), 8.36 
(t, 1H), 7.99 (d, 2H), 7.74 (t, IH), 7.63 (d, 2H), 7.54 (t, 1H), 7.46 (t, 2H), 6.90 (d, 
2H), 6.79 (d, 2H), 6.78 (d, 2H), 6.57 (t, 1H), 6.49 (t, 114), 6.30 (t, IH). ES! MS: 
Calcd for RuC23H19N30 [M] m/z 491.0, found 489.75. 
3.2.2.18 [(t 6-p-cym)Ru(azpyz-NMe2)C1]PF6  (13) 
The dimer [(ij6-p-cym)RuC1 2]2 (103 mg, 0.17 mmol) was dissolved in methanol (30 
mL) and left to stir at room temperature until the solution turned clear. Azpyz-NMe 2 
(69 mg, 0.32 mmol) dissolved in methanol (10 mL) was added drop-wise and the 
solution immediately turned from brown to deep purple. The solution was stirred at 
room temperature for 1 h. The volume of solvent was reduced to about 10 mL and 
NH4PF6 (103 mg, 0.63 mmol) was then added and the solution was placed in the 
freezer overnight. A black powder precipitated out and this was filtered off and 
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washed with diethyl ether. The product was dried overnight in vacuo. Yield: 126 mg 
(62.4%) (Found: C, 40.35; H, 4.06; N, 10.56. Calcd for RuC2 1 H27N5C1PF6 : C, 39.98; 
H, 4.31; N, 11.10). 'H NMR (CDC1 3) 68.02 (d, 2H), 7.95 (d, IH), 7.07 (d, IH), 6.77 
(d, 2H), 6.34 (dd, 2H), 5.68 (dd, 211), 3.22 (s, 6H), 2.4-2.33 (m, 4H), 0.92 (dd, 6H). 
3.2.2.19 [( 6-thn)Ru(azpyz-NMe 2)C1]PF6  (14) 
The dimer [(r16-thn)RuC 12]2 (30 mg, 0.049 mmol) was dissolved in methanol (15 mL) 
and left to stir at room temperature until the solution turned clear. Azpyz-NMe 2 (21 
mg, 0.098 mmol) dissolved in methanol (5 mL) was added drop-wise and the 
solution immediately turned from orange to deep purple. The solution was stirred at 
room temperature for 1 h. The volume of solvent was reduced to about 10 mL and 
NH4PF6  (166 mg, 1.020 mmol) was then added and the solution was placed in the 
freezer overnight. A black powder precipitated out and this was filtered off and 
washed with diethyl ether. The product was dried overnight in vacuo. Yield: 46 mg 
(74.6%) 'H NMR (CDC1 3) 6 8.15 (m, 3H), 7.21 (d, 111), 6.93 (d, 2H), 6.35 (d, IH), 
6.0-5.8 (m, 3H), 3.24 (s, 6H), 3.0-1.5 (m, 8H). ESI MS: calcd for RuC 2 ,H25N5Cl 
[Mt] mlz 484. 1, found 483.9 
3.2.2.20 [(,6-bz)Ru(azpyz-NMe2)CJ]PF 6 (15) 
The dimer [(716-bz)RuC 12]2 (50mg, 0.1 mmol) was dissolved in methanol (30 mL) and 
left to stir at room temperature until the solution turned clear. Azpyz-NMe 2 (42.3 
mg, 0.2 mmol) dissolved in methanol (15 mL) was added drop-wise and the solution 
immediately turned from brown to deep purple. The solution was stirred at room 
temperature 2 h. The volume of solvent was reduced to about 10 mL and NH 4PF6 
(117 mg, 0.7 mmol) was then added and the solution was left in the freezer 
overnight. The volume of solvent was further reduced and a black powder 
precipitated out. This was filtered off and washed with diethyl ether. The product 
was dried overnight in vacuo. Yield: 92 mg (80.0%) (Found: C, 34.89; H, 2.68; N, 
12.18. Calcd for RuC 1 7H,9N5C1PF6: C, 35.52; H, 3.33; N, 12.18). 'H NMR 
((CD3 )2C0): 6 8.31 (d, 111), 8.21 (d, 211), 7.31 (d, 111), 6.96 (d, 211), 6.29 (s, 6H), 
3.28 (s, 6H). 
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3.2.2.21 [(i 6-bip)Ru(azpyz-NMe2)C1]PF 6  (16) 
The dimer [(Tl 	(100 mg, 0.17 mmol) was dissolved in a solution of 
methanol (40 mL) and water (10 mL). The solution was refluxed under argon for 2 h 
and was hot-filtered to remove a small amount of black residue. Azpyz-NMe 2 (74 
mg, 0.35 mmol) dissolved in methanol (10 mL) was added dropwise and the solution 
immediately turned from orange/brown to deep purple. The solution was stirred and 
left to cool to room temperature for 3 h. The volume of solvent was reduced to about 
20 mL and NH 4PF6 (134 mg, 82 mmol) was then added and the solution was left in 
the fridge overnight, during which time a dark powder precipitated out. This product 
was filtered off and washed with diethyl ether. The product was dried overnight in 
vacuo. Yield: 153 mg (67.2%) (Found: C, 42.97; H, 3.50; N, 11.70. Calcd for 
RuC23H23N5C1PF6: C, 42.44; H, 3.56; N, 10.76) 'H NMR ((CD3)2C0): 6 8.21 (d, 
1H), 8.04 (d, 2H), 7.71-7.34 (m, 5H), 7.29 (d, 1H), 6.81 (d, 2H), 6.71 (d, 1H), 6.66-
6.55 (m, 2H), 6.52 (t, 1H), 6.31 (t, 1H), 3.25 (s, 6H). 
3.2.3 Methods 
3.2.3.1 X-Ray Crystallography 
The crystal structure of 1 was solved using direct methods (SHELXS)' 3 and was 
refined against F2 using SHELXL.' 4' The crystal structures of 4 and S were solved 
using Patterson methods (DIRDIF) 1151 and were refined against F2 using SHELXL or 
CRYSTALS.LI 6] In all cases the hydrogen atoms were placed in calculated positions 
and non-H atoms were refined with anisotropic displacement parameters. Crystals of 
4 formed in clump-like aggregates. The diffraction pattern from the sample selected 
for data collection was indexed on the basis of two orientation matrices. The 
relationship between these matrices (the 'twin law') could be expressed with the 
matrix 
—0.955 —0.011 —0.111 
—0.428 —0.482 0.574 
—0.404 1.282 0.456 
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The data set used for structure elucidation was taken from the more strongly 
diffracting of the two domains. X-rat crystallographic data for complexes 1, 4 and 5 
can be found on the enclosed cd. In addition, The crystal structures of 1, 4, and 5 
have been deposited in the Cambridge Crystallographic Data Centre under the 
accession numbers CCDC 616620, 616621, and 616622, respectively 
Crystal Data for Complex 1. Crystals suitable for X-ray diffraction were obtained 
by diffusion of diethyl ether into an acetone solution at ambient temperature. The 
sample was dark brown of dimensions 0.23 x 0.22 x 0.18 mm 3 : triclinic, space group 
P-I; a = 9.1789(10), b = 9.7628 (11), c = 13.0987(14) A; a = 84.6880(10), 3 = 
72.951(2), y = 89.7950(10) 0;  V = 1117.1(2) A3 ; Z = 1; Dcaic = 1.781 Mg m 3 ; t = 
0.958 mm'; F(000) = 600. The final conventional R factor [RI, based on IFI and 
3651 data with F > 4(F)] was 0.0350, and weighted R2 (based on F2 and all 5695 
unique data from 0 = 1.63 - 25.00°) was 0.0872. The final AF synthesis extremes 
were +0.84 and -0.54 e A 3 . 
Crystal Data for Complex 4. Crystals suitable for X-ray diffraction were obtained 
by slow evaporation of an acetone/toluene solution at ambient temperature. The 
sample was red of dimensions 0.66 x 0.43 x 0.20 mm 3 : orthorhombic, space group 
Pbca; a = 10.0146(4), b = 17.6860(7), c = 25.9129(10) A; a = 90, 3 = 90, 'y = 90 0;  V 
= 4589.6(3) A3 ; Z = 8; Dcaic = 1.791 Mg m 3 ; ji = 0.936 mm'; F(000) = 2464. The 
final conventional R factor [RI, based on IFI and 5751 data with F > 4a(F)] was 
0.0646, and weighted R2 (based on F2 and all 36328 unique data from 0 = 1.572 - 
28.970°) was 0.1534. The final AF synthesis extremes were +3.32 and -0.78 e A 3 . 
Crystal Data for Complex 5. Crystals suitable for X-ray diffraction were obtained 
by slow evaporation of an acetone/toluene solution at ambient temperature. The 
sample was dark green of dimensions 0.76 x 0.46 x 0.16 mm 3 : triclinic, space group 
P-i; a = 8.2676(2), b = 12.2633(4), c = 12.8805(4) A; a = 84.8160(10), p = 
83.i510(10), y = 80 . 5010(10)0 ;  V = 1275.50.(7) A3 ; Z = 2; Dca i c 1.672 Mg m 3 ; t = 
0.846 mm'; F(000) = 648. The final conventional R factor [RI, based on IFI and 
5879 data with F> 4a(F)] was 0.0484, and weighted R2 (based on F2 and all 12210 
unique data from 0 = 1.60 - 28.890) was 0.1300. The final AF synthesis extremes 
were +2.00 and -1.70 e A 3 . 
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3.2.3.2 Determination of pK a* Values 
The pH*  values of NMR samples in D 20 were measured at 298 K directly in the 
NMR tube before and after recording NMR data to give an average pH* value. The 
pH* values were adjusted with NaOD and DO or HC10 4 . pKa * values were 
determined by plotting the change in chemical shift against pH*  and fitting the curve 
to the to the Henderson-Hasselbaich equation (equation 1) using the program 
KALEIDOGRAPH (version 3.09., Synergy Software: Reading, PA, 1997) with the 
assumption that the observed chemical shifts are weighted averages of the 
populations of the protonated and deprotonated forms. 
6obs = XH[XHI + x [XI / [XHJ + [X] 	(1) 
where sobs is the observed chemical shift, 8XH is the limiting chemical shift of the 
fully protonated form and ox is the limiting chemical shift of the deprotonated form. 
The errors are estimated as ±0.05 pK units. pKa* values were determined using the 
titration curves for a minimum of two 'H resonances for each complex and the mean 
value was taken. The proton resonances followed (see Figure 3.2 for labels) were 
Ha and Hc for azpy, Hf and Hg for azpy-NMe 2, Hb and Hf for azpy-OH, Ha and Hc 
for [( 6-p-cym)Ru(azpy-OH)C1]PF 6 9, and Hg and CH 3 proton in p-cym arene for 
[( 6-p-cym)Ru(azpyz-NMe2)OH 2]2 , 13A. 
For determination of the pKa*  value of aquated complex 13A, complex 13 was 
dissolved in D20 and 0.98 mol equiv of AgPF 6  was added. The solution was stirred 
for 24 h at 298 K and AgCl was removed by filtration. 
3.2.3.3 Aqueous Solution Chemistry 
3.2.3.3.1 	Speciation of the complexes 1-4 and 13-15 after 24 h 
Samples were dissolved in 90% H20/ 10% D20 (pre-warmed to 310 K), filtered, the 
pH was recorded (pH1), the NMR spectra were recorded initially and after 24 h and 
then the pH was re-measured (pHf). Between acquisitions, they were kept in the 
water bath at 310 K. The pH values measured were 1: pH 1 6.40 pHf 6.51, 2: pH1 7.25 
Chapter 3.' Mononuclear Ruthenium(II) Arene Chloride Azo Complexes 
pHf 6.49, 3: pH 1 6.29 pHf 6.11, 4: pH 1 6.30 pHf 6.03, 13: pH i 5.12 pH,' 4.84, 14: pH1 
4.80 pHf 5.05 and 15: pH, 4.75 pH,' 4.94. 
	
3.2.3.3.2 	Rate of arene loss from complexes 1 - 4 
Complexes were dissolved in methanol and diluted with water to give Ca. 100 .tM 
solutions (95% 1-120, 5% MeOH). The absorbance was recorded at 3 mm / 5 mm 
intervals at 375 nm over 24 h at 310 K. The pH values of the solutions were 6.03 
(1), 6.27 (2), 6.58 (3) and 6.30 (4). Plots of the change in absorbance with time were 
fitted to the appropriate equation for pseudo-first order kinetics using Origin version 
7.5 (Origin Lab Corporation) to give the half-life and rate constant for arene loss. 
3.2.3.3.3 	Rate of decomposition of complexes 5 - 12 
The complexes were dissolved in 90% H 20/ 10% D20 (or 100% D 20, complex 6) to 
give concentrations of Ca. 100 jiM. The solutions were sonicated for Ca. 10 min to 
ensure complete dissolution, and then filtered. The pH was recorded (pH,) and 'H 
NMR spectra were recorded over 24 h at selected time intervals. The samples were 
kept at 310 K in a water bath between NMR data acquisitions. After 24 h the pH was 
re-recorded. The pH values were: (5 pH, 7.34 pHf 6.61, 6: pH*  7.38, 7: pH1 7.17 
pHf 6.05, 8: pH, 6.42 pHf 5.61, 9: pH, 5.14 pHf 5.65, 10: pH1 6.34 pHf 6.15, 11: pH, 
6.29 pHf 6.16 and 12: pH, 6.22 pH f  5.46). The percentages of species present in 
solution were determined by integration of the azo ligand Ha proton resonance (see 
Figure 3.2) for the ligand present in the chloride, aqua and arene loss complexes. 
The decay of percentage of chloride species present over time was plotted and data 
were fitted to the appropriate equation for pseudo-first order kinetics using Origin 
version 7.5 (Origin Lab Corporation) or version 6.1 (Microcal Software Ltd) to give 
an approximate half-life and rate constant. 
3.2.3.3.4 	Rate of hydrolysis of complexes 13-16 
Complexes were dissolved in methanol and diluted in acidified H20 (pH adjusted to 
2.27 by addition of HCI04) to give a Ca. 50 jiM solution (95% H2O, 5% MeOH). 
The absorbance was recorded at I min intervals at 620 nm over 24 h at 310 K. The 
measured pH values of the solutions were 2.21-2.25. Plots of the change in 
absorbance with time were fitted to the appropriate equation for pseudo-first order 
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kinetics using Origin version 7.5 (Origin Lab Corporation) to give the half-life and 
rate constant. 
3.2.3.3.5 	Reactions of complex 13 with 9-EtG 
The aqua adduct 13A was prepared by dissolving 13 in methanol-d 4 and diluting with 
D20 to give a Ca. 100 !tM solution (95% D20, 5% MeOD), adding AgPF 6 (0.98 mol 
equiv), stirring the solution for 24 h at ambient temperature and then filtering to 
remove AgC1. The pH* of the solution was adjusted to 7.42 by addition of 
NaOHJHC1O4  and then incubated at 310 K. To this solution 9-ethylguanine (Ca. 100 
jiM, 95% D20, 5% MeOD, at 310 K) was added to give a 1:1 molar ratio of 13A and 
9-ethylguanine (50 jiM) with a pH*  of 7.46. The reaction of the two species was 
followed by 1 H NMR over 24 h with readings taken every hour. The extent of 
reaction of 13A with 9EtG was determined by integration azpyzNMe 2 Hb (see 
Figure 3.2) 1 H NMR peaks for 13A and the 9-EtG adduct. 
3.3 	Results 
Sixteen chlorido Ru" arene complexes containing the chelated phenylazopyridine or 
phenylazopyrazole ligands azpy, azpy-OH, a±py-NMe 2 and azpyz-NMe 2 were 
synthesized and the structures of complexes 1, 4 and 5 were determined by X-ray 
crystallography. Electronic absorption spectra of the complexes in aqueous solution 
are compared to those of the free azo ligands. The pKa* values of the pyridine 
conjugate acids of azpy, azpy-NMe 2  and azpy-OH have been determined. The 
aqueous solution chemistry of the complexes was investigated, mainly with respect 
to hydrolysis and arene loss, but also in relation to acidity of coordinated water 
(complex 13A) and the phenolic OH (complex 9). Finally the cytotoxicity of these 
complexes towards the A2780 human ovarian and A549 human lung cancer cells 
was investigated. 
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Synthesis and Characterisation 
The chelating ligands used and their hydrogen numbering schemes are shown in 
Figure 3.2. 
e g 
N 	 azpy 
ajb' d 
c 	e-"1 













Figure 3.2. Molecular structures of chelating azo ligands, ligand abbreviations and 
hydrogen atom numbering schemes. 
3.3.1.1 2-Phenylazopyridine (azpy) 
This ligand was synthesised in moderate yields using a literature procedure"" in a 
base-induced condensation reaction between 2-aminopyridine and nitrosobenzene 
(Figure 3.3). 
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• 	-0 R N NH, ONR\ 
NaOH, benzene 
reflux 	 N 
+ 	
- HO 	 N 
N 6-- 
Figure 3.3 The reaction scheme for the formation of azpy. 
The ligand was characterised by 'I-I NMR and ESI-MS. 
3.3.1.2 2-p-Phenolazopyridine (azpy-OH) 
This ligand was synthesised in good yields using a literature procedure.t 181 The 
reaction scheme is shown in Figure 3.4. 
0 
N 	NH—NH2 




Figure 3.4. The reaction scheme for the formation of azpy-OH 
In this reaction, the first step is attack on a ipso carbon of the benzoquinone by the 
nucleophilic NI-12 group of hydrazinoquinone. Protonation of the oxygen causes 
OH2  to be lost from the benzene ring with simultaneous aromatization. The 
remaining (now) phenolic oxygen is then protonated under the acidic conditions of 
the reaction. The product formed was characterised by NMR and ESI-MS. 
3.3.1.3 3(5) - 4 dimethylphenylamino(phenylazo) pyrazole (azpyz-NMe2) 
This ligand was synthesised in a moderate yield from literature procedures [ 19 ' 	The 
reaction scheme is shown in Figure 3.5. 
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HCI 	 HCI 	
[ NH2 
H2SO 
NOHSO HN N 	
0 [H ±] 
I 	L.,z>_ 
Figure 3.5. The reaction scheme for the formation of azpyz-NMe 2 
The first step of this reaction is a base-induced intramolecular cyclisation of 2-
cyanoethyihydrazine. In the second step the endocyclic nitrogen is attacked to form 
the nitrosopyrazoline using sodium nitrite. The third step uses acidic conditions to 
de-nitrosate with simultaneous aromatisation and azo formation to generate the diazo 
intermediate. The final step is the azo coupling reaction with dimethylaniline to 
form the product. The product was characterised by NMR and ESI-MS. 
3.3.1.4 Ruthenium complexes 
The complexes were typically synthesis7ed by direct reaction of the ruthenium arene 
dimer and the azo ligand (Figure 3.6). The dimer was first dissolved in methanol 
causing the weak dichioro bridges to break. The ligand was then added drop-wise 




+ 	N7 	MeOH, RI Ru 
/ \ - 









Figure 3.6. Reaction scheme for the formation of complexes of the type ftq6-arene-
R)Ru(azpy-R)Cl]PF6 
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All compounds were synthesised in high yields and were characterised by 'H NMR 
and CHN; where CHN was not available ESI-MS was carried out. In general the 'H 
NMR resonances for the arene protons of Ru" arene complexes are shifted downfield 
compared to the corresponding starting ruthenium dimers. For example for 
complexes containing the chelating azo ligand azpy-OH, the p-cym proton 
resonances for [(71  (9) are shifted downfield by Ca. 0.6 
ppm, thn resonances for complex 10 by Ca. 0.5 ppm, biphenyl resonances for 
complex 11 by ca. 0.2 ppm, and benzene resonance for complex 12 by ca. 0.2 ppm. 
Figure 3.1 (p  59) shows the complexes studied in this Chapter. 
3.3.2 X-ray Crystallography 
The molecular structures of the ruthenium complexes 1 and S were determined by 
single crystal X-ray diffraction. The crystal structure of 4 was determined from a 
twinned crystal, which accounts for the slightly higher conventional R value of 
6.46%. Selected bond lengths and angles are listed in Table 3.1 and the structures 
along with their atom numbering schemes are shown in Figure 3.7. 
Table 3.1. 	Selected bond lengths (A) and angles (deg) for ft9 6-p- 
cym)Ru(azpy)]CIPF 6 (1), {( 6-bip)Ru(azpy)C1]PF6 (4) and, [( 6-p-cym)Ru(azpy-
N1V1e2)Cl]PF6 (5). aCent = centroid of 1 6-arene. 
Bond length I Angle 1 4 5 
Ru(1)-N(28) 2.026(3) 2.046(5) 2.040(3) 
Ru( I )-N(25) 2.052(3) 2.067(5) 2.053(3) 
Ru(l)-Cl(l) 2.3704(9) 2.3830(15) 2.3705(9) 
Ru(1)-C(l 1) 2.256(4) 2.236(5) 2.263(3) 
Ru( 1 )-C( 12) 2.226(4) 2.238(6) 2.217(3) 
Ru(1)-C(13) 2.220(4) 2.192(5) 2.221(3) 
Ru(l)-C(14) 2.241(4) 2.170(6) 2.213(3) 
Ru(1)-C(15) 2.181(4) 2.208(6) 2.176(4) 
Ru(1)-C(16) 2.230(4) 2.254(6) 2.224(3) 
Ru(l )- cent' 1.7203(16) 1.707(2) 1.7107(15) 
N(27)-N(28) 1.280(4) 1.271(6) 1.290(4) 
N(28)-Ru(1)-N(25) 75.41(12) 75.27(19) 75.61(11) 
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Figure 3.7. X-ray structures of the cations of (A) [( 6-p-cym)Ru(azpy)C1]PF6 (1), 
(B) [( 6-bip)Ru(azpy)Cl]PF6 (4) and (C) [( ij  (5). 
Thermal ellipsoids show 30% probability. The hydrogen atoms have been omitted 
for clarity. 
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The structures are similar and complexes adopt the 'piano stool' type geometry 
common to several other ruthenium(II) arene structures. 12' 21]  The ruthenium - arene 
centroid ring distances (1 1.7203(16) A, 4 1.707(2) A and 5 1.7107(15) A) are longer 
than for analogous ruthenium(II) arene complexes containing chelated 
ethylenediamine ligands (e.g. [(TI  1.6692(14)  
bip)Ru(en)Cl]PF6 1.662(3) A). 21 ' 
Furthermore, the five-membered ring formed by the chelating phenylazopyridine 
ligand and ruthenium is quite strained (N (28) —Ru (1) - N (25) angle Ca. 75.5°) in all 
cases. In analogous ruthenium(II) arenes containing ethylenediamine as the 
chelating ligand, the angle was 78.2_79.20.12h1 
It is interesting to note that the Ru( 1) - N(28) azo bonds in these arene complexes, 
which range from 2.026(3) A- 2.046(5) A, are longer than in the crystal structures of 
Ru'1  phenylazopyridine structures a-{Ru(azpy) 2Cl2], (1.977(4)-2.0084(4) A), 3-
[Ru(azpy) 2C12] (1 .958(9)-2.003(9) A) and 'y- [Ru(azpy)2C 12] (1.986(5)-l.988(5) A).'6 ' 
22] 
 Ru (1) - N (25) pyridine bond lengths, however, are within the same range as the 
[Ru(azpy) 2C12] complexes. In all three structures, the Ru (1) - Cl (1) bond lengths 
(2.37041(9) A - 2.3830(15) A) are comparable to other ruthenium(II) 
phenylazopyridine complexes, but shorter than analogous ruthenium arene 
complexes containing the chelating ligand en, for which distances are in the range Ca. 
2.39-2.45 A.'2 ' 21 ' 
Intermolecular ic-ic stacking interactions are present in crystals of 1 between phenyl 
rings of the azo ligand, with arene centroid-centroid intermolecular distances of 
3.732(2) A and an angle of 12.35° between the centroid-centroid vector and the 
vector normal to the plane of one of the rings. For complex 4, all four aromatic rings 
are involved in stacking interactions with neighbouring molecules (see Figure 3.8) 
with parameters listed in Table 3.2. 
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Figure 3.8. 7t-lt stacking interactions in crystals of [(1 6-bip)Ru(azpy)Cl]PF6 (4) 
(distances are centroid-to-centroid). 
Table 3.2. Intermolecular t-ir stacking interaction parameters for complex 4 










c29_c210-c211 - N25-C24-C23-C22- 
3.959(3) 	17.08 
C212-C213-C214 c21-c26 
a For atom numbering see Figure 3.7 (B) . b Centroid-to-centroid. 
C Between normal to 
the plane of ring(1) and ring(1)-ring(2) centroid-to-centroid vector. 
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3.3.3 UV-Vis Spectroscopy 
3.3.3.1 Azo Ligands 
The wavelengths and intensities of the bands in the electronic absorption spectra of 
the free azo ligands in methanol are summarized in Table 3.3. Each free ligand 
exhibits a it—ir' transition above 300 nm centred primarily on the azo group. The 
assignment this transition (as ir—*ir', opposed to n- 1r*) was confirmed by solvent 
effects. Upon changing solvent from methanol to 90% water / 10% methanol (i.e. to 
a more polar solvent) the transition shifted to a longer wavelength. This trend is 
characteristic for m*it* transitions [231  and is caused by attractive polarization forces 
between the solvent and the absorber, which lowers the energy levels of both the 
excited and unexcited states. The effect is greater for the excited state and so the 
energy difference between the excited and unexcited states is slightly reduced - 
resulting in a small red shift. In contrast, n* 7t* transitions are characteristically 
shifted to shorter wavelengths with increasing solvent p olarity . 1231  This is due to 
increased solvation of the lone pair, which lowers the energy of the n orbital. 
The ?ax of this band shifts to longer wavelengths with increasing a-donating ability 
of the para substituent on the benzene ring (NMe 2 > OH> H), and on changing the 
heterocycle from pyrazole to pyridine, i.e. ?ax azpy-NMe2 432 nrn, azpyz-NMe 2 402 
nm, azpy-OH 358 nm, and azpy 318 nm. The peaks below 300 nm are also 
tentatively assigned to lr_*lr*  transitions. Azpy displays a weak n3 7r * (forbidden) 
transition at 445 nm. 
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Table 3.3. Wavelengths of maximum absorbances, extinction coefficients and 
assignments for azo ligands in methanol ((asym) = asymmetric peak) 
Ligand XTflOX mm c /M'cm Assignment 
Azpy 218 10600 
318 18400 
445 420 n—t 
Azpy-NMe2 272 10700 
432 35900(asym)a 
Azpyz-NMe 2 267 12200 
402 33000(asym )a 
Azpy-OH 246 10000 
358 25200 
The effect of deprotonation of the OH group in azpy-OH on the UV-Vis spectrum 
was investigated. Figure 3.9 compares the UV-Vis spectrum of azpy-OH in water at 
Ca. pH 7 and ca. pH 13. Upon deprotonation of azpy-OH the ir*ir* transitions shift 
from 246 and 358 nm to 268 and 435 nm. This shift to longer wavelength correlates 
with the increased cr-donation from 0 vs. OH into the benzene ring of the ligand. 
Ell 
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Figure 3.9. UV-Vis spectra for aqueous solutions of azpy-OH at pH Ca. 7 	and 
Ca. 13 ( 	) showing the dependence of itir  transitions on pH. 
3.3.3.2 Ruthenium Complexes 
The wavelengths and intensities of the bands in the electronic absorption spectra of 
fresh aqueous solutions of the ruthenium complexes containing azpy, azpy-NMe2 and 
azpyz-NMe2 are summarised in Table 3.4, and those for azpy-OH and its 
corresponding deprotonated form in Table 3.5. All complexes display intense 
transitions in the visible region assignable to MLCT (Metal-to-Ligand-Charge-
Transfer) from the filled 4d-orbitals of Ru n to the empty it ligand orbitals (4d6 Ru—' 
lt*). Both the position and the intensity of these transitions are highly dependent on 
the chelating ligand. For example, the effect on the UV-Vis spectrum of changing 
the chelating ligand in ruthenium p-cym complexes is shown in Figure 3.10. The 
wavelength of the MLCT increases from azpy-OH (469 nm) -. azpy (471 nm) < 
azpyz-NMe2 (577 nm) < azpy-NIMe2 (626 nm). This increase in wavelength is also 
accompanied by an increase in the molar extinction coefficient, i.e. 1 (c = 6000 M 
1 cm 1 <9(7000 M 1 cm 1 ) < 13 (22100 M'cm') <5(42700 M 1 cm 1 ). There are also 
small differences in both the position and the intensity of the MLCT bands when the 
arene is changed, for a given series with the same chelating ligand. There appears, 
however, to be no simple correlation between the position and intensity of the MLCT 
band and the arene. The UV-Vis spectra of these ruthenium complexes also display 
similar intraligand it— r transitions to those in the free ligands, but shifted to longer 
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wavelengths for the complexes. Specific features of the spectra of the various 
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Figure 3.10. 	UV-Vis spectra for fresh aqueous solutions of ftr 6-p- 
cym)Ru(azpy)C1JPF6 (1, 58 jtM, 	), [(1 6-p-cym)Ru(azpy-NMe2)Cl]PF6 (5, 54 
pM, 	
), 
[( 6-p-cym)Ru(azpy-OH)CljPF 6 (9, 49 pM 
, 	 ), 
and [(1 6-p- 
cym)Ru(azpyz-NMe2)CIIPF6 (13, 56 1iM, 	) showing the effect of variations in 
the azo ligand on the absorption spectrum. 
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Table 3.4. Wavelengths of maximum absorbance, extinction coefficients and 
assignments for Ru" arene complexes containing ligands azpy, azpy-NMe 2 and 
azpyz-NMe 2  in Water (sh = shoulder. IL = Intraligand). 
Compound mm € I M' cm' Assignment 
1 262 9500 
370 18000 
471 6000 Ru (4d6) 
2 268 9500 ILr_t* 
368 17100 
471 5900 Ru (4d) _* 
3 359 12200 IL 7r-7r* 
465 4000 Ru (4d6) _* 
4 269 14100 
364 14000 
470 5000 Ru (4d 6) _ir* 
5 294 10000 
457 9100 
584 36000(sh) Ru (4d6) -* 
626 42700 Ru (4d 6) —*m 
6 296 15300 
458 13400 
584 39400(sh) Ru (4d6) - i" 
627 46700 Ru (4d 6) —m 
7 295 10000 ILlt_+ir* 
452 8200 
584 38700(sh) Ru (4d) -*ir 
620 44200 Ru (4d) -*ir 
8 295 13100 
452 11000 
584 53700(sh) Ru (4d) —m 
621 63700 Ru (4d6) 
13 302 8900 
469 14300 
577 22100 Ru (4d6) _*i* 
14 303 7800 IL7r_*ir* 
481 11900 
581 22500 Ru(4d6)_it* 
is 303 8000 
469 13200 
573 20600 Ru (4d 6) _*ir* 
16 295 12800 
481 13000 
592 	- 25700 Ru (4d6) .* 
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Table 3.5. Wavelengths of maximum absorbance, extinction coefficients and 
assignments for Ru ff, arene complexes containing protonated azpy-OH or 
deprotonated azpy-0 in Water ((sh) = shoulder, IL = intraligand) 
Compound mm c / M' cm' Assignment 
9 (OH) 264 5100 IL 1r.7r* 
432 9500 
469 7000(sh) RU (4d6) —ne 
9(0 -) 280 4600 IL 7t..7t* 
457 4900(sh) IL itit* 
560 15100 Ru(4d6)_.it* 
588 15600 RU (4d6 ) 
10 (OH) 267 5600 IL it—.tt 
430 10200 IL ir—.tt 
469 7600(sh) RU (4d6) - 
10(o - ) 280 4800 IL Jr_7r* 
460 5100(sh) IL n.r* 
563 16700 Ru (4d6) —.ie" 
587 16500 Ru(4d6).ir* 
11 (OH) 260 5800 
429 11100 
469 8000(sh) Ru (4d6) 	* 
1I(0) 278 5700 1L7r__.7r* 
454 5600(sh) IL it.ir* 
557 18900 Ru (4d) 
587 19900 Ru (4d6) 	* 
12 (OH) 267 9900 IL t-*ir 
430 10800 
469 8600(sh) Ru (4d6) —m 
12(0 -) 269 9100 ILit_.it* 
457 5500(sh) IL it+it* 
561 17400 Ru(4d6)__t** 
591 19000 Ru(4d6).it* 
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Azpy Complexes (1-4). The UV-Vis spectra display a symmetrical MLCT band at 
Ca. 470 nm and the extinction coefficient varies slightly (between 4000 M' cm' and 
6000 M' cm ') when the arene is changed from bz, to bip, to p-cym and thn. The 
intraligand transitions shift from 218 nm and 318 nm for the free ligand to Ca. 
266 nm and 365 nm for the complex. 
Azpy-NMe 2 Complexes (5-8); The UV-Vis spectra display an intense unsymmetrical 
MLCT band at Ca. 624 nm with a shoulder at 584 nm. The extinction coefficient of 
this band varies significantly with the arene; 5/p-cym (c 42700 M' cm 1 ), 7fbz (c 
.44200 M' cm -1 ), 6/thn (c 46700 M cm') and 8/bip (c 63700 M' cm'). The ititK 
intraligand transitions shift by ca. 20 nm to longer wavelengths compared to the free 
azpy-NMe2 ligand. 
Azpy-OH Complexes (9-12). The complexes containing the azpy-OH ligand display 
interesting pH dependent spectra. The UV-Vis spectra for all complexes at pH 2.5, 
where the ligand is fully protonated, display a MLCT band at Ca. 469 nm with an 
extinction coefficient which varies between 7000 M' cm' and 8600 M' cm' as the 
arene is changed from p-cym, to thn and bz, to bip. This transition is partially 
obscured by the intraligand ir—ir* transitions, which have shifted from 246 nm and 
358 nm for the free ligand to Ca. 265 nm and 430 nm for the complex. Raising the 
pH of the aqueous solutions to Ca. 10.5 led to deprotonation of the azpy-OH ligand, 
and dramatically changed the UV-Vis spectrum. For example, the MLCT band of 12 
shifts from 469 nm to Ca. 588 nm with a shoulder at Ca. 560 nm (Figure 3.11). For 
these deprotonated forms, the extinction coefficient increases from 15100 M - 1 cm- 1 to 
18900 M - 1  cm as the arene is changed from p-cym, to thn, to bip, to bz. The intense 
intraligand ir— t transitions also shift to longer wavelengths (to Ca. 277 nm and 457 
nm). 
Azpyz-NMe2 Complexes (13-16). The UV-Vis spectra display an intense symmetrical 
MLCT band at Ca. 581 nm. The extinction coefficient of this band increases from 
20600 M' cm' to 25700 M' cm' on changing the arene from bz, to p-cym, to thn, 
to bip and the intense ir—*ir' intraligand transitions shift to longer wavelengths by ca. 
3Onm. 
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Figure 3.11. UV-Vis spectra for aqueous solutions of [(il  
(12, 42 tM) at pH Ca. 2.5 ( 	) and Ca. 10.5 ( 	), showing the dependence of 
and MLCT transitions on pH. 
3.3.4 Aqueous Solution Chemistry 
3.3.4.1 Phenylazopyridine ligands 
The variation in I  NMR chemical shifts with pH*  allowed for determination of the 
pKa* values for the ionisable groups of the chelating phenylazopyridine ligands in an 
aqueous solution. Thus the pKa*  values for the conjugate acids of the pyridine 
nitrogens of the free ligands were determined as 2.47 for azpy, 3.06 for azpy-OH, 
4.60 for azpy-NMe 2 and for the OH of azpy-OH 8.08 and NHMe 2 in azpy-NMe 2 
2.11 (Figure 3.12). 
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Figure 3.12. Dependence of the 'H NMR chemical shifts on pH for (A) azpy, (B) 
azpy-NMe 2 , and (C) azpy-OH. The curves represent best fits to the Henderson-
Hasselbalch equation giving pKa* values of 2.47 for azpy, 3.06 for azpy-OH and 4.60 
for azpyNMe2 . 
3.3.4.2 Aqueous Solution Chemistry of Ruthenium complexes 
The aqueous solution chemistry (with respect to hydrolysis and arene loss) of 
complexes 1-16 was studied at 310 K, typically over 24 h. In general, the complexes 
were found to undergo a mixture of slow hydrolysis and arene loss (to give products 
in which the three coordination sites originally occupied by the arene are now 
occupied by solvent). Exchange between species present in solution was slow on the 
NMR timescale; separate sets of peaks were observed for the chlondo, aqua and 
arene-loss species. For example, Figure 3.13 shows the 'H NMR spectrum recorded 
for complex 5 Ca. 30 minutes after dissolution and after Ca. 24 h at 310 K where 
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distinct peaks corresponding to the intact cation (A), the ruthenium complex after 
arene loss (C) and the hydrolysed product (D) are observed. 
A 
(b) 	 A+C+D 	C+D 
D 
	
C+DD B A 	D 
IA 	C C 	 Ilk It iI A 
A A A 
(a) 1 A I I A A J 	II 
10 	9 	8 	7 	6 ppm 
Figure 3.13. 'H NMR spectrum of complex 5 in 90%H20/10%D20. (a) at-3 10 K 35 
min after dissolution, (b) at 310 K 24 h after dissolution. Peak assignments: A intact 
chloride complex 1, B free p-cymene, C a ruthenium phenylazopyridine complex 
after arene loss, and D aquated 5. Assignment was aided by 2D- H TOCSY NMR 
techniques. 
Hydrolysis was confirmed by adding excess NaC1 (100 mM) and noting the decrease 
in the intensity of the aqua peaks as the water is replaced by chloride. Arene loss 
was inferred by the presence of resonances for free p-cym (ca. 6 7.23 (d of d)), free 
biphenyl (ca. 6 7.9 (d), 7.70 (t), 7.45 (t)), free benzene (ca. 6 7.27 (s)) or free 
tetrahydronapthalene (6 7.15 (s)) in the aromatic region of the 'H NMR spectra. 
3.3.4.2.1 	Speciation after 24 h incubation at 310 K 
Initially the speciation after 24 h incubation at 310 K of an aqueous solution (90% 
H20/ 10 % D20) containing 100 iM ruthenium was determined (vide infra, 
summarised in Figure 3.14). The aqueous solution chemistry of the complexes was 
found to be dependent on the chelating azo ligand and more detailed solution 
chemistry of each set of complexes is given below. 








azpy 	azpy-NMe2 	azpy-OH 	azpyz-NMe2 
Complex 
Ligand 
Figure 3.14. Speciation of ruthenium complexes 1-15 (100 PM) after 24 h 
incubation at 310 K in an aqueous solution. Complex 16 was too insoluble for this 
study. Key: Blue intact cation, Yellow arene loss species, Red hydrolysed species, 
Grey Undefined. 
3.3.4.2.2 	Complexes 13-15 
Complexes 13-15, containing the phenylazopyrazole ligand azpyz-NMe 2 were all 
found to only undergo hydrolysis of Ru-CI in an aqueous solution (100 P  Ru, 310 
K). The rates of hydrolysis were determined by UV-Vis spectroscopy (50 pM Ru, 
pH 2.3 95% H20, 5% MeOH ) by first plotting a difference spectrum to find an 
optimum wavelength to use then following that optimum wavelength with time to 
derive kinetic data (see Figure 3.15 for 13 as an example). 
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Figure 3.15. Hydrolysis studies of [( 6-p-cym)Ru(azpyz-NMe 2 )C1]PF6, 13: (a) the 
UV-Vis difference spectrum shows the biggest change in absorbance occurs at Ca. 
620 nm, and inset (b) the change in absorbance at 620 nm with time from which 
kinetic data were derived. AA = A - A 0 where A = absorbance at time t and A 0 = 
absorbance at t = ca. 20 s i.e. after dilution of methanol solutions in water. 
The rates of hydrolysis, corresponding half lives and speciation after 24 h are shown 
in Table 3.6. A half-life for hydrolysis for 16 could also be determined although the 
shape of the curve suggested a second process occurring after hydrolysis, thought to 
be arene loss (observed in 1 H NMR, data not shown). 
Table 3.6. Observed rate constants (k0b), half lives of hydrolysis (t112) (50 PM, 310 
K) and speciation after 24 h dissolution (% intact, % hydrolysed) for complexes 13-
16(100 pM, 310 K). nd = not determined due to poor aqueous solubility 
Complex k. 	/ h' t,,I h % intact % hydrolysed 
13 0.3233 (±0.0004) 2.14 5 95 
14 0.3310(±0.0026) 2.09 0 100 
15 0.2617 	0.0007) 2.67 26 74 
16 0.2866(±O.0012) 2.42 nd nd 
Thus all four complexes appear to hydrolyse at similar rates with the half lives for 
hydrolysis rates in the following order thn <p-cym < hip <bz. 
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3.3.4.2.3 	pKa* of aquated 13 (13A) 
The pKa * value for the aqua adduct of 13 was determined as 4.60, see Figure 3.16. 
This would mean at physiological pH (close to 7) the complex exists almost 
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Figure 3.16. pH* titration showing the change in chemical shift for the H7 (NMe 2) 
protons with pH*  for ruthenium complex [(1 6 pcym)Ru(azpyzNMe2)on 2/oH] 24 
which gave a pKa * value of the coordinated water as 4.60. The decrease in chemical 
shift at Ca. pH 8 is thought to correspond to deprotonation of the pyrazole NH proton. 
3.3.4.2.4 	Reaction of 13A with 9-Ethyl guanine (9-EtG) 
The reaction between 13A and I mol equiv of 9-ethylguanine (9EtG) at pH*  7.46 
(where the aqua adduct is predominantly in the hydroxo form (pK2*=4.60  vide 
supra)) was followed by 'H NMR spectroscopy. The coordination of 9-EtG to the 
ruthenium complex gave rise to new peaks in the 'H NMR spectrum corresponding 
to the ruthenium-9-EtG complex. The reaction reached equilibrium after Ca. 10 h 
when Ca. 28% of the ruthenium was bound to 9-ethylguanine. Figure 3.17 shows the 
variation in time in the amount of 13A which reacted with 9-EtG. 
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Figure 3.17. Variation in the percentage of [(16-p-cym)Ru(azpyz-NMe2)(OH)J 
(13A) bound to 9-ethylguanine with time (as determined by integration of the Hb 
peak of the azpyz-NMe 2 ligand (see Figure 3.2)) during a 1: 1 mol ratio (50 PM) 
reaction at pH*  7.46, at 310 K followed over 24 h. 
3.3.4.2.5 	Complexes 1-4 
Complexes 1-4, all containing the phenylazopyridine ligand azpy, form one new 
species in aqueous solution which involves arene loss from the complex (hydrolysis 
of i6  arene - ruthenium bonds). No species corresponding to simple hydrolysis of 
Ru-CI was observed. 
Figure 3.18 shows the HPLC chromatogram of a solution of complex [(116-p-
cym)Ru(azpy)Cl]PF 6, 1 (100 pM, 100% H20) after 24 h incubation at 310K. Two 
main peaks are present ((a) and b)) and these were thought to correspond to the arene 
loss species and the intact cation. Subsequent analysis of each fraction by ESL-MS 
revealed that peak (a) corresponds to the cation [Ru(azpy)(MeCN) 3 (TFA)} (TFA = 
trifluoroacetic acid) , ESI-MS: calcd for RuCi9H8N602F3 [M 1 ] mlz 521.05, found 
521.1 and peak (b) to [( 6-p-cym)Ru(azpy)Cl]PF6, ESI-MS: calcd for 
RuC2 1 H23N3C1+ [M] mlz 454.07, found 456.2. Thus the ruthenium-bound arene and 
chloride are both lost from the phenylazopyridine complex. 
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(b) 	 1. 
0 	 5 	 10 	 15 	 20 
time /min  
Figure 3.18. HPLC chromatogram (X = 254 nm) for an aqueous solution of 1 after 
24 incubation at 310 K. Gradient: 30% B (MeCN, 0.1% TFAH) to 90% over 30 
minutes. Fractions were collected, freeze dried then re-dissolved in MeCN for ES!-
MS analysis. Molecular structures show the assignment of the peaks based on ES!-
MS analysis. 
The rates and half-lives of arene loss, determined by UV-Vis spectroscopy, are listed 
in Table 3.7 along with the speciation results after 24 h incubation at 310 K. 
Table 3.7. Observed rate constants (k0b ), half lives of arene loss (tIQ) and speciation 
after 24 h dissolution for complexes 1-4 (100 iM, 310 K). 
Complex k b, (h') t 1, 2 (h) % intact % arene loss 
1 0.0601 (±0.0004) 11.6 50 50 
2 0.0576 (±0.001) 12.0 68 32 
3 0.0381 (±0.004) 18.2 26 74 
4 0.0782 (±0,007) 8.9 33 67 
Thus the data show that arene lability follows the order bz> bip > p-cym > thn. 
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3.3.4.2.6 	Complexes 5-12 
These complexes, containing the phenylazopyri dine ligands azpy-OH and azpy-
NMe2 , were generally found to undergo a mixture of hydrolysis of both Ru-Cl and 
Ru-ij bonds. Approximate rate constants and half-lives were determined by 
plotting the decrease in the percentage of intact chloride complex with time. Figure 
3.19 shows the speciation over 24 h for complex {(11 6-p-cym)Ru(azpy-OH)C1]pF6 (9) 
and the corresponding pseudo first order plot from which the rate constant and the 
half life was determined. The rates and half-lives of decomposition of the cation are 
listed in Table 3.8 along with the speciation results after 24 h incubation (100 PM, 
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Figure 3.19. (a) Speciation distribution over 24 h for 100 tM solution of 9 as 
determined by the ratio of the integrals of the Ha proton resonance (see Figure 3.2) 
of the phenylazopyridine ligand in the different environments and (b) decay of the 
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Table 3.8. Observed rate constants (k obS), half-lives for decomposition of the intact 
cation (t,,2) and speciation after 24 h dissolution (% intact, % hydrolysed, % arene 
loss) for complexes 5-12 (100 .iM, 310 K). (nd =not determined). 
Compound kObS I h' t 1 	/ h % intact % hydrolysed % arene loss 
5 0.078 (± 0.014) 8.90 23 55 22 
6 nda nd' 18 - - 
7 0.113(±0.009) 6.16 18 47 35 
8 0.034 (± 0.007) 20.27 24 9 67 
9 0.033 (± 0.006) 21.03 36 34 30 
10 0.068(±0.003) 10.19 39 0 61 
11 0.094 (± 0.004) 7.39 28 0 72 
12 0.053 (± 0.007) 13.05 31 5 64 
a 
the products of the reaction of complex 6 in were not observable by 'H NMR. 
3.3.4.2.7 	pKa * of Phenolic group in [( 6..p..cym)Ru(azpy0H)Cl]PF(9) 
A pKa* value of 6.48 was determined for deprotonation of the phenol group of azpy-
OH in complex 9 (Figure 3.20) 
Figure 3.20. Variation of the 'H NMR chemical shifts with pH* for complex 9. 
The pKa* value was determined by fitting the data points to the Henderson-
Hasselbalch equation, corresponding to a pK a *Of 6.48. 
3.3.5 Cytotoxicity 
The 10 50 values for complexes 1-16 against the A2780 human ovarian and A549 
human lung cancer cell lines are given in Table 3.9. All complexes appeared to be 
95 
Chapter 3: Mononuclear Ruthenium(II) Arene Chloride Azo Complexes 
soluble at the testing concentrations with the exception of complex 16 at 100 riM. 
However, none of the cells survived even at 50 jiM of 16. 
Table 3.9. IC50  values for Ru" arene complexes against the A2780 human ovarian 
and A549 human lung cancer cell lines and comparison with cisplatin 
Complex IC50  (PM) 
A2780 A549 
1 >100 >100 
2 >100 >100 
3 >100 >100 
4 >100 >100 
5 >100 >100 
6 >100 >100 
7 >100 >100 
8 44 49 
9 58 >100 
10 34 63 
11 >100 >100 
12 18 56 
13 18 41 
14 57 >100 
15 88 >100 
16 24 32 
cisplatin 5 5 
None of the Ru" arene complexes with the chelating azo ligand azpy (1-4) were 
cytotoxic to either cell line, and of the complexes containing azpy-NMe 2 (5-8), the 
bip complex 8 was cytotoxic in both the A2780 and A549 cell lines with IC 50 values 
of Ca. 45 jiM. All the complexes containing the azpyz-NMe 2  (13-16) ligand exhibit 
cytotoxicity against the A2780 cancer cell line, the most potent being the p-cym and 
bip complexes, which also displayed good cytotoxicity in the A549 cell line. With 
the exception of the benzene complex 11, all Ru complexes containing azpy-OH 
exhibited activity against the A2780 cancer cell line, with 10 and 12 also displaying 
moderate cytotoxicity against A549 cancer cells. 
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3.4 	Discussion 
The introduction of chelating azopyridine and azopyrazole ligands into chiorido Ru' 1 
arene complexes has given rise to highly coloured complexes, which exhibit new 
properties in comparison with complexes containing diamines such as en as chelating 
ligands. In the literature there are several examples of ruthenium azpy complexes 
(vide supra), but there appear to be no reports of ruthenium complexes containing the 
chelated ligands azpy-NMe 2, azpy-OH or azpyz-NMe 2. Furthermore, to the best of 
my knowledge, this is the first example of azpyz-NMe 2  being used as a chelating 
ligand for any metal. 
3.4.1 Structures of complexes. 
The relatively long Ru —N(28) azo bonds in the X-ray crystal structures of 
azopyridine complexes 1, 4, and 5 can be ascribed to back-bonding competition for 
the ruthenium 4d6  electron density by the azopyridine and arene it-acceptor ligands. 
Such an effect has also been oberved in the crystal structure of [Ru(azpy) 3](PF6)2 . 1121 
Further evidence for such competition in complexes 1, 4 and 5, is the lengthening of 
the Ru-arene centroid distances by Ca. 0.04A compared to analogous ruthenium(II) 
arenes with ethylenediamine as the chelating ligand (a non-it acceptor) is also 
observed. 
The phenyl-phenyl and phenyl-pyridyl it-it intermolecular interactions all fall within 
the commonly observed range for stacks of aromatic groups, with approximately 
parallel planes, separation distances of 3.3-3.8 A and angles between the normal to 
one ring and the centroid vector of Ca. 16-400. 1141 Polarisation of the phenyl ring of 
the ligand in 1 and 4 by the electron-withdrawing azo group is likely to enhance its 
ability to stack. Similarly, the it-electron deficiency of the pyridine ring in 4 is also 
likely to favour stacking. 
The ability of the 16-arene to stabilise Ru 11 by it-acceptor intera ctions t 251  is evident 
from the 'H NMR resonances of the metal-coordinated 1 6-arenes. These are shifted 
to a lower frequency due to increased electron density on the ring, compared with the 
uncoordinated arene. 1261  It is noteworthy that the protons of the 11 6-arenes in the azo 
compounds studied in this work are deshielded (resonance moved by between 0.2 - 
0.6 ppm to a higher frequency) compared to the corresponding starting dimers [(1 6 
97 
Chapter 3: Mononuclear Ruthenium(II) Arene Chloride Azo Complexes 
arene)RuC1 2 ] 2 , i.e. are shifted to a higher frequency (deshielded). This is consistent 
with a reduced electron density at the ring upon chelation indicating that the it-
accepting arene and it-accepting azo ligand are competing for Ru electron density. 
3.4.2 Electronic Absorption Spectroscopy 
The major differences in the UV-Vis spectra occur with changing the chelating 
ligand and these changes can be rationalised as follows. For the complexes 
containing phenylazopyridine, the introduction of electron-donating groups on to the 
phenyl ring (0 in azpy-0 and NMe2 in azpy-NMe2) decreases the it-acidity of the 
azo group [271 which causes an increase in the energy of the Ru n 4d6 orbitals and 
results in a smaller energy gap between the Ru 4d 6  bonding and azo ir orbitals. This 
is manifested in the spectrum as a progressive shift of the MLCT band to longer 
wavelengths with increased cs-donor strengths of the phenyl substituents on the 
ligand. The replacement of pyridine by pyrazole as a substituent results in a decrease 
in the wavelength of the MLCT, presumably the azopyrazole ir orbital must be at a 
higher energy. 
3.4.3 Acidity of ligands 
The pKa* values of the (conjugate acids) of the pyridine nitrogens for the free azo 
ligands are 2.77 (azpy), 2.18 (azpy-OH) and 0.64 (azpy-NMe 2) PKa units lower than 
for pyridine itself (5.24).t281 This is attributed to the electron-withdrawing effects of 
the azo group, which serves to reduce their basicity. 129J  The presence of the NMe 2 
and, to a lesser extent the OH substituent, on the phenyl ring increases the basicity of 
the pyridine nitrogen relative to azpy (H), due to electron donation by the 
dimethylamino/hydroxyl groups, which opposes the electron-withdrawing effect of 
the azo group on the pyridyl ring. 130) The relatively low pK a* values for the pyridyl 
ligands suggests that they are poor ci-donors, compared with, for example 
ethylenediamine, PKa1 = 7.08 and pKa2  = 9.89.128] Pyridine is a six-membered It-
electron deficient ligand and, besides being a ci-donor, can also act as a it-acceptor 
towards Ru". The pyridine ring in azpy is expected to be a better it-acceptor than the 
pyridine ring in azpy-NMe 2  since it is more electron deficient. Thus overall, azpy 
would be expected to give rise to a higher positive charge on Ru" / lower electron 
W. 
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density on Ru", compared to azpy-OH and azpy-NMe 2  since it is a weaker cy-donor 
and a stronger it-acceptor. Correlations between the substituents on pyridine rings 
and metal pyridine it-bonding have been discussed previously in the literature. 131 ' 321 
3.4.4 Aqueous Solution Chemistry. 
The complexes studied undergo a combination of hydrolysis and arene loss in water. 
Reactions are slow, with half-lives of the order of hours at 310 K (body temperature). 
The rates of ligand substitution in hexa-coordinated Ru ff complexes are known to 
span about ten orders of magnitude. 133J  The trend in rates correlates with the extent 
of back bonding 134J  from moderately fast exchange for non it-acceptor ligands (e.g. 
[Ru(H20)6] 2 ) to very inert behaviour with it-acceptor ligands (e.g. [Ru(MeCN) 6] 2 ). 
The inertness results from the high thermodynamic stability of the starting complex 
due to it back-bonding from Ru ff  4d6  to the ir* orbital of MeCN. Therefore the 
presence of both the arene and the azo ligand in the complexes studied here would be 
expected to give rise to more slowly reacting compounds. 
3.4.4.1 Arene Loss 
For complexes 1-4 (which undergo only arene loss) arene lability follows the order 
bz > bip > p-cym > thn. The presence of electron-donating alkyl groups on the 
bound arene strengthens the ruthenium-arene bond 1351 and therefore thn and p-cym 
are expected to be less labile arenes than bz. For example, the amount of arene loss 
from [( 6-bz)Ru(azpy)Cl]PF6  (1) is 74% after 24 h compared with 32% for [(16 
thn)Ru(azpy)Cl]PF 6  (4).Whilst the pendant phenyl ring in bip is electron 
withdrawing by inductive effects it is electron donating by resonance and this should 
make it a more labile arene (c.f. p-cym, thn). 
In the literature, there are several examples of the photochemical displacement of an 
71 6 arene from Ru,136' 371 but thermal displacement, especially under such mild 
conditions (low temperatures, aqueous solution), is uncommon, and most 
displacements occur in the presence of strong nucleophiles, these reactions still being 
relatively rare. 1381  The observed loss of arene in aqueous solution can be rationalized 
by considering the nature of the bonding of an il 6  arene to Ru ff , which is strengthened 
by it-back donation from the ruthenium centre. In the azopyridine complexes, the 
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arene is less tightly bound to ruthenium due to competition with the azo ligand for it-
electron density. 
3.4.4.2 Hydrolysis and Arene Loss 
The chloride complexes 5-8 and 9-12 containing the chelating azo ligands azpy-
NMe2  and azpy-OH tend to undergo a mixture of both hydrolysis and arene loss. 
There appears to be no correlation between the arene and the preference for arene 
loss vs. hydrolysis. However, complexes containing azpy-NMe 2  tend have a higher 
percentage of hydrolysed species compared with their azpy-OH analogues (for 
example compare [( 6-p-cym)Ru(azpy-NMe 2)Cl]pF6 (5) 55% hydrolysis and [(7 6-p-
cym)Ru(azpy-OH)ClJpF6  34% hydrolysis). The conjugate acid of the pyridine ring 
in the azpy-NMe 2 ligand has a higher pK a* than in the azpy-OH ligand and this 
should result in increased electron density at the ruthenium facilitating the 
substitution of chloride by water and disfavouring arene loss. 
3.4.4.3 Hydrolysis Only 
Complexes 13-16 all underwent hydrolysis, with no arene loss observed for 13-15. 
The rates of hydrolysis followed the order thn - p-cym < bip < bz which is in line 
with the notion that alkyl substituents on the arene increase electron density at Ru 
and this make the Ru-Cl bond weaker (vide supra). 
Thus there is a marked difference in aqueous solution chemistry between e.g. [(7-p-
cym)Ru(azpy-NMe 2)Cl] PF6 (5) and [(16-p-cym)Ru(azpzyNMe 2)Cl] PF6 (13) i.e. 
changing the chelating ligand from a phenylazopyridine to a phenylazopyrazole. 
Complex 13 undergoes more extensive and more rapid hydrolysis than 5 with no 
arene loss (Table 3.7, Table 3.8). Pyridine is a it-electron-deficient heterocycle, 
functioning as a cr-donor / it-acceptor ligand, whereas pyrazole is formally classed as 
a five membered it-electron rich heterocycle 139J and binds to metals primarily in a a - 
donor fashion. The lack of it-back-bonding ability of pyrazole has been noted in the 
literature. [40]  Thus phenylazopyrazole is a less efficient it-acceptor ligand, resulting 
in a subsequent increase in chloride lability and a decrease in arene lability. 
The half-lives for aquation of the chlorido ethylenediamine ruthenium(II) arene 
complexes, [(i 6-dha)Ru(en)C 1 ] +, ftq 6-tha)Ru(en)ClJ and [( 116-bip)Ru(en)C1], (dha = 
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dihydroanthracene, tha = tetrahydroanthracene) have been reported to be 1.7-2.9 mm 
at 310 K. 1411  The hydrolysis of 13-16 under comparable conditions is more than two 
orders of magnitude slower, with half lives of 2.08-2.67 h. 
It is well documented that the coordination of an 1 6-arene to Ru" increases the 
lability of the coordinated water in [(rj6arene)Ru(OH2)3]2f compared with 
[Ru(OH2 )6] 2  (by three orders of magnitude), and this phenomenon is ascribed to the 
differences in transition state properties and the strong trans-labilising effect of the 
aromatic ligand on the coordinated water. 1261  The rate of aquation for these types of 
complexes, however, decreases by two orders of magnitude when two of the aqua 
ligands are replaced by the it-acceptor chelating ligand bipy, attributable to a smaller 
trans effect due to competition between the arene and bipy for Ru 4d 6 electron 
density. 135]  The presence of the it-acceptor azo ligand in 13 decreases the rate of 
hydrolysis compared with the ethylenediamine analogues. 
3.4.4.4 Acidity of aquated complex 13 and 9-EtG binding 
The interaction of Ru(II) arene complexes with DNA is thought to be important with 
respect to their observed cytotoxicity.12' 5, 421 In aqueous solution, for example, [(16 
bip)Ru(en)Cl} binds specifically to guanosinet 41  and this reaction proceeds through 
the initial aquation of the chloride complex. The pK a  of the coordinated water of the 
aqua adduct [(ij  is 7.7 1,141] which means that at physiological pH 
(close to 7) the complex exists mainly in the aqua form. The increased reactivity of 
Ru-0142  versus Ru-OH towards guanine bases has been reported previously for other 
Ru(II) arene complexes. [4] 
In contrast, the pKa* of the aqua adduct 13A (4.60) is considerably lower. The high 
acidity of the coordinated water in 13A is indicative of a low electron density at 
ruthenium since the acidity of a coordinated water molecule increases with 
decreasing charge density on the metal .135J  At physiological pH (ca. 7) the complex 
would exist predominantly in the more inert hydroxo form. Hence it is perhaps not 
surprising that it has a lowered affinity for DNA bases. After 24 h, only Ca. 28% of 
13A reacted with 9EtG to form [(16-p-cym)Ru(azpzy-NMe2)(9EtG)} 
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3.4.4.5 pKa* of Phenol group in azpy-OH and complex 9 
The pKa* of the phenol group of azpy-OH in complex 9 (6.48) is 1.6 pK a units lower 
than that in the free ligand. This suggests that electron density from the phenolate 
group is more readily delocalised when azpy-0 is coordinated to Ru. At 
physiological pH (close to 7), the compound exists predominantly in the 
deprotonated form and so will bear no overall charge. 
3.4.5 Cytotoxidty 
None of the compounds containing the phenylazopyridine ligand azpy exhibited 
cytotoxicity against either A2780 human ovarian or A549 human lung cancer cells. 
With the ligands azpy-NMe 2 and azpy-OH, complexes 8, 10 and 12 show 
cytotoxicity in both cell lines, as do complexes 13 and 16 containing the azpyz-NMe 2 
ligand. The species responsible for the cytotoxicity could be the intact cation, the 
corresponding aqua/hydroxo complex or the Ru" phenylazopyridine complex 
produced after arene loss, since the speciation over 24 h suggests that all three 
species could be present in varying amounts. 
Intact cations might exert a cytotoxic effect by mechanisms which include 
modification of mitochondrial membrane permeability (as observed, for example, 
with lipophilic cations of Au(I) carbene complexes t431) or DNA intercalation by the 
arene (when extended) or the azopyridine ligand. Recently the cytotoxicity of 
several isomers of [Ru(azpy) 2(bipy)] 2  incapable of hydrolysis has been reported.' 12J 
Anticancer activity has also recently been reported for the complex [(1 6.. 
hmb)Ru(en)(SPh)] (hmb = ,hexamethylbenzene) which does not undergo 
hydrolysis. [441 
Loss of the 1 6-arene would create three potentially reactive sites on Ru" for 
interaction with DNA or other bio-molecules. Arene loss followed by binding to a 
14-mer oligonucleotide has been reported for the Ru" arenes [(TJ  
and [(p..cym)Ru(ptaM e)C1 2]C1 145 I (pta is 1,3,5-triaza-7-phosphatricyclo [3.3.1.1] 
decane). 
The aquated phenylazopyridine complexes may bind to DNA bases by a mechanism 
similar to that proposed for analogous Ru" arene complexes. t41 However, the pK a 
value of the coordinated water in azo arene complexes is predicted to be low as the 
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metal is more electropositive. This might give rise to a lowered affinity for DNA. 
Whilst the phenylazopyrazole complexes 13-16 undergo hydrolysis (and no arene 
loss) 13 binds to 9EtG to a limited extent only. 
3.5 Summary 
A series of intensely coloured Ru" arene complexes containing the chelating azo 
ligands azpy, azpy-NMe 2, azpyz-NMe2  and azpy-OH has been synthesized and 
characterized by X-ray crystallography, 'H NMR and UV-Vis spectroscopy. The 1 6 
arene in the pyridine complexes appears to be more labile than in Ru" arene 
complexes containing chelated ligands such as ethylenediamine. Arene loss is 
attributable to the strong it-acceptor character of phenylazopyridine ligands, which 
effectively compete with the arene for it-back donation from the metal. There is 
evidence for this competition in the crystal structures, where Ru to arene-centroid 
distances are longer than in the corresponding en complexes, and in NMR spectra 
where 'H NMR arene resonances are shifted to a higher frequency (lower field) upon 
chelation of phenylazo pyridine, compared with the corresponding starting dimers. 
For the p-cym complexes, hydrolysis was detected for 5 (azpy-NMe 2) and 9 (azpy-
OH) but not for 1 (azpy). Thus hydrolysis is favoured by an increase in the electron 
density on ruthenium (increase in the pK a  of the pyridine, increase in electron density 
on Ru), but arene loss is still competitive. Complexes 13-15, containing the 
azopyrazole ligand, hydrolyze fully and this can be rationalized by the inability of 
pyrazole compared to pyridine to act as a it-acceptor, so increasing the electron 
density on Ru further. This may also explain why no arene loss was detected for 13-
15: the arene experiences less competition for it-back donation. Several of these 
compounds exhibit cytotoxicity against both A2780 and A549 cancer cell lines and 
may have a novel mechanism of action compared to en Ru" arenes. 
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4.1 Introduction 
There is currently an increased interest in the design of dinuclear metal based 
complexes as anticancer agents since these complexes can exhibit different 
properties to their mononuclear analogues. For example the dinuclear platinum 
complex [{ trans-PtCI(NH3 )2  12 { JL-(NH2(CH2)6NH2) } J (NO 3)2 (BBR3005), which 
contains two mono-functional platinum centres with a hexane- 1 ,6-diamine linker was 
found to be active against cisplatin - resistant cell lines.1 1' 21 This work led to the 
synthesis of the trinuclear complex [{trans-PtC1(NH3)2 } 2 g-(trans-
Pt(NH3)2(H2N(CH2)6-NH 2)2)14 (BBR3464). 131  The third (central) platinum unit is 
unreactive, but it improves the solubility and the electrostatic interactions of the drug 
with DNA. This complex forms intrastrand adducts with DNA but, unlike cisplatin, 
it does not bend the DNA and the Pt-DNA adducts are not recognised by High 
Mobility Group (HMG) Proteins, again different to cisplatin. 141  This could be the 
reason for the ability of the complexes to overcome cisplatin resistance. BBR3464 
has undergone phase two clinical trials as an anticancer drug. 11,61 
Dinuclear ruthenium arene complexes have also been synthesised in our laboratory 
and their DNA interactions compared with the mononuclear analogues. For example 
consider the dinuclear ruthenium arene complex [((1 6 bip)RuCl(en))2(CH2)6] 2+ 
(Figure 4.1), in which two Ru" arene centres are linked with a flexible chain 
contains four stereogenic centres (Ru, N, N, Ru) which gives rise to ten potential 
configurations. [71 
Interestingly, in aqueous solution the complex exists as a diastereomeric mixture of 
AA/AB/BB (A = (R*RUR*N), B = (S*RUR*N) ) as 67.7:24.0:8.3 %. Analysis of the 
complex after reaction with 9-EtG (to give [(( 6-bip)Ru (N7-9-EtG)(en))2-(CJ-J2) 6} 2 ) 
showed that the B (S*RUR*N) configuration is highly favoured (ca. 95%) due to steric 
interactions Thus upon reacting with 9-EtG, a facile epimerization at Ru / N centres 
occurs to allow dynamic switching between these configurations leading to a high 
selectivity in the formation of G adducts. t71 
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Rut C 	, 
H2 N JN 
Figure 4.1. Dinuclear complex [(( 6-bip)Ru Cl (en))2-(CH 2)6}(PF6)2 . The four chiral 
centres are marked '. 
This dinuclear complex inhibits RNA synthesis more effectively 171 than the 
mononuclear complex [(1 6 bip)Ru(en)Cl] + . L 81  Binding to CT-DNA induced a 
positive CD band centered at 370-380 nm suggesting intercalation of the extended 
phenyl ring into DNA (as observed previously for the mononuclear complexes). 18] 
The dinuclear complex was able to unwind pSp73KB DNA with an angle of 310 
which was over double than that of [(1 6-bip)Ru(en)C1] (14°) suggeSting that cross-
linking of DNA and perturbation of DNA structure by the two pendant phenyl rings 
is important. Evidence of cross-linking came from the observations (a) that the 
efficiency of the interstrand cross-linking on a 213-bp EcoRI fragment of pSP73 
randomly modified by the dinuclear complex was similar to that of the known DNA 
cross-linker cisplatin, and (b) a site-specifically ruthenated 20-mer formed a 1,3-GG 
interstrand cross-link (20% frequency) and 1,2-GG and 1,2-GTG cross-links were 
also detected. 
In this Chapter, two { (ij 	} sub units are linked together via dinuclear bis- 
phenylazopyridine chelating ligands to create potentially bifunctional ruthenium-
arene complexes. The molecular structures of the complexes studied in this chapter 
are shown in Figure 4.2. In the examples discussed above, the linkers were flexible 
alkyl chains but here the ligands have a higher degree of rigidity due to the linker 
consisting of aryl residues. The cytotoxicity, solution chemistry and electrochemistry 
are investigated and compared to the corresponding mono-nuclear analogues. 
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Compound Arene n 
17 p-cym CH2 
18 hmb CH2 
19 p-cym 0 
20 hmb 0 
21 p-cym CO 
22 hmb CO 
Figure 4.2 Structure of the dinuclear ruthenium(II) arene complexes synthesised and 
studied in this Chapter. 
4.2 Experimental 
4.2.1 Materials 
2-Aminopyridine, N-chlorosuccinimide, dimethylsulfide, m-chloroperbenzoic acid, 
ammonium hexafluorophosphate (NH 4PF6), 4,4' -methylenedianiline, 5-
(diethoxyphosphoryl)-5-methyl- 1 -pyrroline-N-oxide (DEPMPO) and glacial acetic 
acid were purchased from Sigma-Aldrich and used as received. Ethanol and 
methanol were dried over Mg/I2  or anhydrous quality was used (Sigma-Aldrich) and 
methylene chloride was either dried over P20 5  0 % w/v) or anhydrous quality was 
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used (Fisher). All other organic solvents and reagents were obtained from 
commercial suppliers and used as received. 
4.2.2 Synthesis 
4.2.2.1 SS-dimethyl-N-(2-pyridyl)sulfijimine 
To a solution of 2-aminopyridine (9.4 g, 0.1 mol) and dimethyl sulfide (6.8 g, 0.11 
mol) in dry methylene chloride (100 mL), a solution of N-chlorosuccinimide (13.4 g, 
0.1 mol) in dry methylene chloride (250 mL) was added dropwise over a period of I 
h, while the temperature was maintained at 253 K (dry ice / ethanol). After the 
addition was complete, the reaction mixture was stirred at 253 K for 1 h and then for 
an additional hour at room temperature. A solution of sodium methoxide (9.5 g, 0.17 
mol) in methanol (75 mL) was added and the mixture is stirred for 10 mm. 
Subsequently, water (150 mL) was added and stirring continued for 4 h. The layers 
were separated and the aqueous layer was extracted three times with dry methylene 
chloride (50 mL). The combined organic extracts were washed with water, dried over 
Mg504  and evaporated to give thick yellow-brown oil which solidified upon being 
cooled. The product was purified by re-crystallisation from diethyl ether giving a 
cream-coloured solid. Yield: 3.95 g (25% after re-crystallisation) 'H NMR (CDC13): 
ö 7.95 (d, 1H), 7.30 (m, 1H), 6.65 (d, 1H), 6.45 (t, 1H), 235 (s, 6H). ES! MS: Calcd 
for C7HION2S [M] mlz 154. 1, found 155.1. 
4.2.2.2 2-Nitrosopyridine 
To a solution of m-chlorobenzoic acid (3.5 g, 0.023 mol) in dry methylene chloride 
(100 mL), cooled to 273 K, a solution of S,S-dimethyl-N-(2-pyridyl)sulfjljmine (1.95 
g, 0.013 mol) in dry methylene chloride (20 mL) was added at once. The mixture 
was stirred at 273 K for 90 min,dimethyl sulfide (0.6 g, 9.6 mmol) was added, and 
stirring continued for additional 30 mm. A saturated aqueous solution of sodium 
carbonate (100 mL) was added to the reaction mixture, the layers were separated, and 
the green Organic layer was washed with water and dried over MgSO 4 . Evaporation 
of the dried extracts gave a light tan solid which was stored in a freezer. Yield: 0.67 g 
(48%) 'H NMR ((CDCI 2)2, 398 K): 6 8.80 (d, lH), 8.10 (t, 1H), 7.70 (t, IH), 7.20 (d, 
1H). ES! MS: Calcd for C5H4N20 [Mt] mlz 109.0, found 109.9. 
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4.2.2.3 2,2 ' - [methylenebis(4,1-phenyleneazo)]bjspyrjdjne (CH2-(azpy)2) 
2-Nitrosopyridine (25 mg, 0.231 mmol) was dissolved in dry methylene chloride (10 
mL). 4,4'-Methylenedianiline (23 mg, 0.012 mmol) dissolved in dry methylene 
chloride (2 mL) and glacial acetic acid (1 drop) were added and the orange solution 
was stirred at room temperature overnight, while shielded from light. The solution 
was evaporated to dryness to provide an orange-red coloured solid. The product was 
purified by column chromatography using silica and 95% methylene chloride! 5% 
methanol as eluting solvent, collecting the first orange-coloured fraction. Yield: 4.0 
mg (93%) (Found: C, 71.14; H, 5.28; N, 20.12. Calcd for C23H,8N6 : C, 73.00; H, 
4.79; N, 22.21) 'H NMR (CDCI 3): 8 8.75 (d, 2H), 8.05 (d, 4H), 7.90 (t, 2H), 7.85 (d, 
2H), 7.40 (t, 4H), 7.35 (d, 4H), 4.20 (s, 2H). ES! MS: Calcd for C23H, 8N6 [M+H] 
mlz 379.4, found 379.1. 
4.2.2.4 2,2'-[oxybis(4,1-phenyleneazo)]bjs-pyridine (0-(azpy) 2) 
2-Nitrosopyridine (0.40 g 3.71 mmol) was dissolved in dry methylene chloride (160 
mL). 4-4'-Diaminodipheny1eher (0.37 g 1 .93mmol) dissolved in dry methylene 
chloride (30 mL) and glacial acetic acid (3 drops) were added. The orange solution 
was stirred at room temperature overnight shielded from the light. The solution was 
evaporated leaving an orange / red oil. The product was purified by column 
chromatography using silica and 95% methylene chloride! 5% methanol as eluting 
solvent, collecting the first orange-coloured fraction as an oil. The oil was 
subsequently washed with ether to extract an orange solid which was dried under 
vacuum. Yield: 0.28 g (40%) 'H NMR (CDC1 3): ö 8.76 (d, 2H), 8.13 (d, 4H), 7.93 (t, 
2H), 7.85 (d, 2H), 7.42 (t, 2H), 7.24 (d, 4H). ES! MS: calculated for C22H,6N60 
[M] mlz 380.4, found 380.87 
4.2.2.5 2,2 1 -[carbonylbis(4,1-phenylencazo)}bis-pyridine (CO-(azpy) 2) 
2-Nitrosopyridine (0.70 g 6.48 mmol) was dissolved in dry methylene chloride (250 
mL). 4-4'-diaminobenzophenone (0.68 g 3.24 mmol) dissolved in dry methylene 
chloride ( 50 mL) and glacial acetic acid (3 drops) were added. The green solution 
was stirred at room temperature for 48h shielded from the light. The reaction mixture 
was filtered to remove any un-reacted solid and subsequently any remaining solvents 
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evaporated off leaving an orange / red oil. The oil was washed with a mixture of 
methanol and ether leaving an orange solid. The product was purified by column 
chromatography using silica and 95% methylene chloride! 5% methanol as eluting 
solvent, collecting the first orange coloured fraction was collected as an oil. This was 
washed with ether leaving an orange solid. Yield: 0.11 g (9%) 'H NMR (DMSO): 
8.81 (d, 2H), 8.17 (d, 4H), 8.14 (t, 214), 8.10 (d, 4H), 7.86 (d, 2H) 7.68 (t, 2H). ES! 
MS calculated for C23H16N60 [M] mlz 392.4, experimental value 392.82. 
4.2.2.6 [(11 6-p -cym)2 Ru2(CH2-(azpy) 2)C121 (PF6) 2 (17) 
The ligand (CH2-(azpy) 2) (25 mg, 0.065 mmol) dissolved in methanol (10 mL) was 
added dropwise to a solution of the ruthenium dimer [( 6-p-cymene)RuCl 2 ]2 (40 mg, 
0.065 mmol) in methanol (15 mL). The solution immediately changed colour from 
orange to brown while stirring at room temperature. After stirring for 2 h, the volume 
of solvent was reduced and NH 4PF6  (107 mg, 0.65 mol) was added. The brown 
precipitate, obtained after storage in a freezer for I h, was filtered off, washed with 
diethyl ether, and dried overnight in vacuo. The brown solid was recrystallised from 
methanol. Yield: 68 mg (87% before recrystallisation). (Found: C, 42.11; H, 3.88; 
N, 7.11. Calcd for Ru2Cl2C43H46N 6P2F, 2 : C, 42.69; H, 3.83; N, 6.95). 'H NMR 
(CD30D): 8 9.45 (d, 2H), 8.75 (d, 2H), 8.40 (t, 2H), 8.15 (d, 4H), 7.85 (t, 2H), 7.65 
(d, 4H), 6.30 (d, 411), 6.00 (m, 2H), 5.95 (s, 2H), 4.40 (s, 2H), 2.45 (sept, 2H), 2.25 
(s, 6H), 0.95 (m, 12H). ES! MS: Calcd for R112C431146N602 [M 2 ] m/z 461.1, found 
460.0 . * 
4.2.2.7 [(i 6-hmb)2 Ru2(CH2-(azpy) 2)C121 (PF6)2 (18) 
The ligand (CH2-(azpy) 2) (27 mg, 0.070 mmol) dissolved in methanol (10 mL) was 
added drop-wise to a solution of the ruthenium dimer [( 6-hmb)RuCl2] 2 (47 mg, 
0.070 mmol) in methanol (15 mL). The solution immediately changed colour from 
orange to red/brown while stirring at room temperature. After stirring for 2 h, 
NH4PF6  (115 mg, 0.70 mol) was added. The brown precipitate, obtained after storage 
The determined masses are Ca. one Dalton short of the theoretical mass. The reason for this anomaly 
is currently unknown. However, this mass spectrometric technique has been shown to produce 
artefacts in Ruthenium(II) arene complexes by modification of the structure and hence mass, see for 
example W. H. Ang, E. Daldini, C. Scolaro, R. Scopelliti, L. Juillerat-Jeannerat, P. J. Dyson, Inorg. 
Chem, 2006, 45, 9006-9013. 
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in a freezer for 1 h, was filtered off, washed with diethyl ether, and dried overnight in 
vacuo. Attempt to recrystallise from methanol resulted in decomposition of the 
complex and so the product was purified by passing through a Sephadex LH-20 
column (Amsersham Biosciences) with methanol as the elutent. Yield: 29 mg (87% 
before recrystallisation). (Found: C,44.56; H, 4.42; N, 6.46. Calcd for 
RU2C12C47H54N6P2F12 • C, 44.59; H, 4.30; N, 6.64 %). 'H NMR ((CD3) 2C0): 5 9.12 
(d, 2H), 8.80 (d, 2H), 8:50 (t, 2H), 8.08-8.02 (m, 5H), 7.82 (d, 4H), 4.52 (s, 2H), 2.11 
(s, 36H). ESI MS: Calcd for Ru2C4 7H54N6C12 [M2 ] mlz 489. 1, found. 487.5.* 
4.2.2.8 [(16-p-cym) 2  Ru2(0-(azpy))C1 21 (PF6)2 (19) 
The ligand (0-(azpy) 2) (40 mg 0.105 mmol) dissolved in dry methanol (10 mL) was 
added drop-wise to a solution of the ruthenium dimer [(i 6-p-cym)RuC 12]2 (63 mg 
0.105 mmol in dry methanol (20 mL). The solution immediately changed colour 
from orange to red / brown. The mixture was left to stir at room temperature for 2 h 
and was shielded from light. After this, the volume of solvent was reduced and ten 
equivalents of NH4PF6  (171 mg 1.05 mmol) was added. The solution was left in a 
freezer overnight after which a red / brown precipitate was collected. This was 
washed with methanol and then ether and allowed to dry in air. Yield: 35.9 mg 
(28%). (Found: C, 41.75; H, 3.67; N, 6.83. Calcd for Ru2C12C42H44N6Op2F 12 : C, 
41.63; H, 3.66; N, 6.94 %). 'H NMR ((CD3)2S0): 6 9.67 (d, 2H), 8.92 (d, 2H), 8.55 
(t, 2H), 8.32 (d, 4H), 8.04 (t, 2H), 7.61 (d, 4H), 6.58 (d, 4H), 6.29 (d, 4H), 2.48 (m, 
2H), 2.26 (s, 6H), 0.94 (d, 12H). ESI MS calculated for Ru2C42H 44N6C120 [M2 ] mlz 
462. 1, found 460.7.* 
4.2.2.9 [(11 6-hmb)2 Ru2(0-(azpy))C1 21 (PF6)2 (20) 
The ligand 0-(azpy) 2  (40 mg 0.105 mmol) dissolved in dry methanol (10 mL) was 
added dropwise to a solution of the ruthenium dimer [(7 6-hmb)RuC1 2 ] 2 (70 mg 0.105 
mmol in dry methanol (20 mL). The solution immediately changed colour from 
orange to red / brown. The mixture was left to stir at room temperature for 2 h and 
was shielded from light. After this, the volume of solvent was reduced and ten 
equivalents of NH4PF6  (171 mg 1.05 mmol) was added. The solution was left in a 
freezer overnight after which a red / brown precipitate was collected. This was 
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washed with ether and allowed to dry in air. The red / brown solid was then 
recrystallised from methanol. Yield: 93 mg (77% before recrystallisation). 'H NMR 
((CD3)2S0): 6 9.02 (d, 2H), 8.89 (d, 2H), 8.49 (t, 2H), 8.07 (d, 4H), 8.02 (t, 211), 7.62 
(d, 4H), 2.018 (s, 36H). ES! MS calculated for Ru2C46H 52N60C12 [M2 ] m/z 490. 1, 
found 489.8. 
	
4.2.2.10 	[(ij 6-p-cym) 2  Ru2(CO-(azpy))C121 (PF6)2 (21) 
The ligand CO-(azpy) 2 (59 mg 0.151 mmol),dissolved in dry methanol (10 mL) was 
added drop-wise to a solution of the ruthenium dimer [(7 6-p-cym)RuC1 21 2 (88 mg 
0.15 1 mmol) in dry methanol (20 mL). The solution immediately changed colour 
from orange to deep red/orange. The mixture was left to stir at room temperature for 
2 h and was shielded from light. After this, the volume of solvent was reduced and 
ten equivalents of NH4PF6  (246 mg 1.50 mmol) was added. The solution was left in a 
freezer overnight after which a deep red was collected. This was washed with ether 
and allowed to dry in air. Yield: 73 mg (40.4%). (Found: C, 42.94; H, 3.12; N, 6.77. 
Calcd for Ru2C12C43H44N6OP2F, 2 : C, 42.20; H, 3.62; N, 6.87 %). 'H NMR 
((CD3)2S0): 5 9.73 (d,211), 9.03 (d, 2H), 8.59 (t, 2H), 8.37 (d, 411), 8.26 (d, 4H), 
8.10 (t, 2H), 6.63 (d, 4H), 6.31 (d, 4H), 2.27 (s, 6H), 1.22 (m, 2H), 0.98 (d, 12H). 
ES! MS calculated for Ru2C 43H44N60C12 [M2 ] m/z 468. 1, found 466.8.* 
4.2.2.11 	[(s 6-p-hmb)2 Ru2(CO2-(azpy))C1 2] (PF6)2 (22) 
The ligand CO-(azpy) 2 (59 mg 0.151 mmol), dissolved in dry methanol (10 mL) was 
added drop-wise to a solution of the ruthenium dimer [( 6-hmb)RuCl2} 2 (101 mg 
0.151 mmol in dry methanol (20 mL). The solution immediately changed colour 
from orange to deep purple/red. The mixture was left to stir at room temperature for 
2 h and was shielded from light. After this, the volume of solvent was reduced and 
ten equivalents of NH4PF6  (166 mg 1.02 mmol) was added. The solution was left in a 
freezer overnight after which a red was collected. This was washed with ether and 
allowed to dry in air. Yield: 78 mg (41.1%). (Found: C, 44.00; H, 3.99; N, 5.73. 
Calcd for Ru2C12C 47H52N6OP2F, 2 : C, 44.10; H, 4.09; N, 6.57) 'H NMR ((CD3)2S0): 
9.07 (d, 2H), 8.98 (t, 2H), 8.53 (t, 211), 8.28 (d, 4H), 8.11 (d, 4H), 8.07 (d, 2H), 
1.98 (s, 3611). ES! MS calculated for RuC47H 52N60C12 [M2 ] m/z 496. 1, found 495.9. 
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4.2.3 Methods 
4.2.3.1 Electron Paramagnetic Resonance (EPR) Spectroscopy 
An EPR spectrum of complex 22 was obtained with the help of Dr Paul Murray (The 
University of Edinburgh). The spectrum was acquired using a Bruker ER200D 
spectrometer at 233 K in DMF by electrochemical reduction of the sample at Ca. -0.5 
V (vs Ag/AgC1 electrode). 
4.2.3.2 Aqueous Solution Chemistry 
Complexes were dissolved in (CD3)2C0 and diluted with D 20 (pre-warmed to 310 
K) to give a final concentration of 100 iM ruthenium complex (95% D20, 5% 
acetone-d 6). The pH* of the samples were measured and the 'H NMR spectra were 
recorded at selected time intervals over a 24 h time period. The measured pH* 
values were 6.90 (17), 7.70 (18), 7.16 (19), 6.43 (20), 6.77 (21) and 5.88 (22). 
4.2.3.3 Phosphorus-31 Spin Trap Experiment 
DEPMPO (0.01M) was dissolved in degassed 90% H 20/ 10% D 20 containing 0.2 M 
phosphate buffer pH 6.99 (filtered through Chelex 100 to remove iron) and 2 mM 
DTPA. Care was taken to ensure minimum light exposure. Complex 21 (0.3 M in 
(CD3)2C0) was added to give 0.075 M DEPMPO: 0.075 M 21 (25% (CD3)2C0), and 
in the positive control (0.075 M H202/Fe50 4) and the blank control (CD3)2C0 was 
added to the same volume. 3, P NMR spectra were recorded at 310 K. 
4.3 Results 
Six dinuclear Ru ll arene complexes containing bis-phenylazopyridine ligands have 
been synthesised and their cytotoxicity towards the A2780 human ovarian and A549 
human lung cancer lines has been evaluated. Their aqueous solution chemistry has 
been investigated at low (1iM) concentrations and two of the complexes have been 
further characterised by cyclic voltammetry and one complex also by EPR 
spectroscopy. 
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4.3.1 Synthesis and Characterisation 
4.3.1.1 Chelating bis-phenylazopyridine ligands 





)0a 	 N N N 	N 
CO-(azpy)2 	
b d 	 'TIIIIIJ 
C 
Figure 4.3. Chelating bis-phenylazopyridine ligands synthesised in this work along 
with their hydrogen numbering schemes. 
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4.3.1.1.1 	Nitrosopyridine 
The reaction scheme for the synthesis of 2-nitrosopyridine is shown in Figure 4.4. 
(CH 3 )2S, NCS 
DCM 	 mcpba 
NaOCH 3 	 DCM 
Figure 4.4. Reaction scheme for the formation of 2-nitrosopyridine 
The first step involves conversion to SS-dimethyl-N-(2-pyridyl)sulfihjmine with 
dimethylsulfide and NCS and this sulfimine derivative is converted to the 
corresponding heterocyclic nitroso compound by oxidation with a slight excess of m-
chloroperbenzoic acid in a second step. The 2-nitrosopyridine was obtained in a 
moderate yield and appeared to be light green in solution and tan-coloured in the 
solid state when stored at lower temperatures in a freezer. 
Previous reports suggested that 2-nitrosopyridine exists as a temperature dependent 






N 	NN 	N 
d 
Figure 4.5. Temperature-dependent solution state equilibrium of 2-nitrosopyridine; 
in = monomer, d = dimer. 
'H NMR studies on 2-nitrosopyridine at different temperatures confirmed the 
presence of this monomer-dimer equilibrium (Figure 4.6); the room temperature 'H 
NMR spectrum (298 K) of.2-nitrosopyridine in (CD2C12)2 comprised eight signals of 
approximately equal intensity. Heating the solution increased the amount of 
monomer present since the solution equilibria of aromatic C-nitroso compounds 
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favours monomeric species on heating," °' hence the major set of signals in the 
spectra at higher temperatures was attributed to the monomeric species. 
m 




d d d 	d 
8.6 	8.0 	7.4 	ppm 
Figure 4.6. Variable temperature 1 H NMR spectra of 2-nitrosopyridiñe in (CDC1 2 )2 
solution, showing the effect of temperature on the monomer-dimer equilibrium; m = 
monomer, d = dimer. 
The nitrosopyridine was found to be unstable upon contact with water and reactions 
with it had to be carried out under anhydrous conditions. The reaction of 
nitrosopyridine in water at room temperature irreversibly forms 1 -(2-pyridyl)-2( 1 H)-
pyridone." 
4.3.1.1.2 	Chelating Bis-Phenylazopyridine Ligands 
The chelating ligands were all synthesised by the reaction of nitrosopyridine and the 
desired functionalised diamine in an acid-induced condensation reaction (Figure 
4.7). 
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Figure 4.7. Reaction scheme for the formation of bis-azpy dinuclear chelating 
ligands. n = CH2, 0, Co. 
All ligands were purified by column chromatography but some small impurities still 
remained. The ligands were subsequently used without any further purification. 
4.3.2 Dinuclear Ru 11 arene chloride bis-complexes 
The complexes were synthesised by a similar route to the mononuclear analogues 
(Chapter 3) via the chloride-bridged dimers. Figure 4.2 (p  113) shows the dinuclear 
complexes studied in this Chapter. All complexes were characterised by 'H NMR, 
ESI-MS and CHN analysis. 
4.3.3 Characterisation by 'H NMR 
Because each ruthenium centre is chiral, due to the unsymmetrical nature of the 
chelating phenylazopyridine ligand, there exists the possibility of two sets of 
diastereoisomers (RR, SS and RS, SR) which may give rise to two distinct sets of 
peaks in the 'H NMR spectrum. Indeed it was found that the complexes existed as a 
mixture of diastereoisomers. For example, Figure 4.8 shows the high frequency 
region of the 2D-'H TOCSY NMR spectrum of complex [(1 6-hmb)2 Ru2(CO. 
(azpy))C12] (PF6) 2 (22) in (CD3)2C0. 
In the first diastereoisomer (which is arbitrarily assigned A), the two phenyl rings 
that are linked by the carbonyl unit have equivalent proton resonances (H e A , HfA) 
whereas in the second diastereoisomer (assigned as B) these two rings appear 
separately (H e B , HfB and HeB,  He") and one set (H C B ,  HB) are shifted significantly 
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to a lower frequency. In both sets of diastereoisomers, the peaks corresponding to 
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HAHtIeHI 10 	0 
8.0 	o 	I HeB• H?' 
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9.0 	 0 
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9.0 	 8.0 	 7.0 	6 'H /ppm 
Figure 4.8. 2D- 1 H TOCSY NMR (high frequency region, ((CD3)2C0) showing the 
different spin systems present in the diastereomeric mixture of complex 22. For 
atom numbering system please refer to Figure 4.3. 
Diastereoisomers usually have different chemical properties, which can allow them 
to be separated. For example, throughout the purification of [(i 6-hmb)2 Ru2(0-
(azpy))C1 21 (PF6) 2  (20) by recrystallisation, diastereoisomer A preferentially 
crystallised (Figure 4.9). 
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Al 
A 	 A 	A 
A 	II 
lB 
B 	ill B 
A 
A 	A 	A 	 A  
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Figure 4.9. 'H NMR ((CD3 )2C0) showing (a) the crude product of 20 and (b) 
complex 20 after recrystallisation with preferential crystallisation of isomer A. 
Table 4.1 shows the percentage of isomers A and B present for the six dinuclear 
complexes studied in this Chapter. In all cases the A isomer is preferred. However, 
the percentage of B isomer increases as the arene is changed from p-cym to hmb and 
as the ligand is changed from 0-(azpy) 2, to CH2-(azpy) 2  to CO-(azpy) 2 . 
Interestingly, -neither heating the NIMR solution, diluting it, nor leaving it over time 
caused any change in the speciation (data not shown) suggesting that, at least in 
acetone, the isomers are not readily interconverted. Furthermore, immediate 
dissolution in 95% D20 / 5% (CD3)2C0 showed the same percentage of isomers, 
indicating that the diastereomeric ratio is unaffected by solvent. 
Table 4.1. Percentage of diastereoisomers A and B present in dinuclear ruthenium 
complexes. Brackets indicates the speciation before purification. 
Complex Diastereoisomer A (%) Diastereoisomer B (%) 
17 100(78) 0(12) 
18 88 (57) 12 (43) 
19 100 0 
20 100 (70) 0 (30) 
21 75 25 
22 58 42 
BB 
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4.3.4 Aqueous Solution Chemistry 
The aqueous solution chemistry was studied at 100 p  Ru-dimer, over 24 h at 310 K 
as these conditions mimicked the concentration, exposure time and temperature used 
in the cell tests. All complexes appeared to undergo decomposition in water since all 
'H resonances corresponding to the starting material broadened and 
disappeared/decreased in intensity over time. No new peaks appeared in the spectra 
except those corresponding to free p-cymene or hmb in aqueous solution, the 
intensity of which also decreased with time. Furthermore the colour of the solution 
changed to near colourless over the 24 h. Figure 4.10, Figure 4.11 and Figure 4.12 
show the 'H NMR spectra recorded initially after dissolution (after Ca. 15 minutes) 
and after incubation at 310 K for Ca. 24 h for complexes 17 and 18, 19 and 20 and 21 
and 22, respectively. 
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10 	9 	8 	7 	6 5 1 H/ppm 
Figure 4.10. 'H NMR spectra (100 MM, 95% D20 / 5% acetone—d6) of complexes [(11
6-p-cym)2 Ru2(CH2-(azpy) 2 )C121 (PF6)2 (17) and [(i 6-hmb)2 Ru2(CH2-(azpy) 2)C121 
(PF6)2 (18) recorded soon after dissolution and after 24 h at 310 K. The peaks for the 
starting complexes significantly decrease in intensity over time. The peak labelled 
with an asterisk (*) is assignable to free p-cymene in aqueous solution. 
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Figure 4.11. 'H NMR spectra (100 i.iM, 95% D20 / 5% acetone—d6) of complexes 
[( 6-p-cym) 2 Ru2(0-(azpy)2)C121 (PF6) 2 (19) and [(r 6-hmb)2 Ru2(0-(azpy) 2)C121 
(PF6)2 (20) recorded soon after dissolution and after 24 h at 310 K. The peaks for the 
starting complexes decrease in intensity significantly over time. The peak labelled 
with an asterisk (*) is assignable to free p-cymene in aqueous solution. 
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Figure 4.12. 'H NMR spectra (100 tiM, 95% D20 / 5% acetone—d6) of complexes 
[( 6-p-cym) 2  Ru2(CO-(azpy) 2)C121 (PF6)2 (21) and [( 11 6-hmb)2 Ru2(CO-(azpy)2)C121 
(PF6)2  (22) recorded immediately after dissolution and after 24 h at 310 K. The 
peaks for the starting complexes decrease in intensity significantly over time. The 
peak labelled with an asterisk (*) is assignable to free p-cymene in aqueous solution 
The absence of well defined product peaks suggested that a simple hydrolysis of Ru-
Cl and /or Ru-arene bonds was not occurring since this should give rise to peaks in 
the 'H NMR spectra, such as those observed for the corresponding mononuclear 
complexes (see Chapter 3). The disappearance and broadening of peaks with time, 
and the decrease in intensity of the peak corresponding to free p-cymene in aqueous 
solution suggested that either an insoluble product was forming (which would not be 
observable by 'H NMR) or that radicals were forming (peaks for paramagnetic 
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and shifted). No observable precipitate was formed, although it must be remembered 
that the concentrations used were low (100 pM) and so precipitate may not be 
observable, even if present. 
4.3.5 Cyclic Voltammetry 
The electrochemical properties of complexes 21 and 22 were studied by cyclic 
voltammetry and differential pulse polarography. Both complexes displayed two 
electrochemical oxidations at ca. 1.08 and 1.30 V (vs. Ag/AgC1). On the reductive 
sweep, multiple reductions were observed up to the solvent cut off (Ca. -2 V) and 
these can be seen most clearly from the differential pulse polarogram (Figure 4.13). 
E/V 	 E/V 
Figure 4.13. Differential pulse polarograms for (a) complex 21 and (b) complex 22 
recorded in 0.1 M TBABF4 in DMF from 0 to -2 V showing multiple reductions 
occurring. 
The first two reductions were studied in more detail since these reductions occur at 
more biologically relevant potentials 
4.3.5.1 First Electrochemical Reduction 
Figure 4.14 shows the first electrochemical reduction recorded at different scan 
rates. The first electrochemical reduction occurs at E 1 ,2 = -0.06 V (complex 21) and 
E 1 1= 0.14 V (complex 22). 
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Figure 4.14. The variation of the first electrochemical reduction for (a) complex 21 
(0 —k -0.4 - 0.3 V) and (b) complex 22 (0 —
p -0.5 —), 0.2 V) with scan rates (0.01-1 
Vis) at ambient temperature. 
For complex 21 this reduction is not fully reversible whereas for 22, essentially it is. 
Diagnostic tests for a fully reversible reduction include the following. 121 
(a) A plot of the peak current density (aniodic and cathodic) versus the square root of 
the scan rate should give a straight line that passes through the origin whereas for a 
quasi-reversible system the current density increases with the square root of the scan 
rate but is not directly proportional to it. Figure 4.15 shows the plots obtained for 
the cathodic current density and Figure 4.16 shows the plots obtained for the aniodic 
current density. It can be seen that for complex 22 the goodness-of-fit (R 2 value) is 
much better than for 21 suggesting a higher degree of reversibility. 
(Is) A11C1• For complex 22, the average value (for all different scan rates) 
obtained was 1.052 whereas for complex 21 the average value was only 0.72. 
(c) E is independent of the scan rate for a fully-reversible system. In both cases 
there was found to be some variation in the peak potential. However, for complex 22 
this variation was much less than for complex 21; the average E values were 22: 
0.076 V (±0.004), 21: 0.064 (± 0.063). 
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Figure 4.15. Straight line fits (though origin) for the variation of the cathodic peak 
current density with the square root of the scan rate for the cyclic voltammograms of 





0.0 	 0.4 	 0.3 
Figure 4.16. Straight line fits (through origin) for the variation of the aniodic peak 
current density with the square root of the scan rate for the cyclic voltammogramS of 
complexes 21 and 22. The goodness of fit (R 2) values are given. 
The reductions are one-electron reductions, iE = 0.070 V (22), 0.1 VS-1 (ferrocene 
AEp  = 0.067 V) and the reduction is likely to correspond to addition of an electron 
into the ligands' it antibonding orbital centred on the azo moiety, in accordance 
with literature assignments for other ruthenium(H) phenylazopyridifle complexes. 113 
16] 
scan rate) I 'dy/s 
R2 = 0.8918 
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4.3.5.2 Second Electrochemical Reduction 
Figure 4.17 shows the electrochemical response as the complexes are taken through 
both the first and second electrochemical reductions at varying scan rates. The 
second reduction occurs at Ej = -0.64 V (complex 21) and Ed = -0.70 V (complex 
22). On the basis of similar peak heights to the first reduction, this reduction is 
assigned as a one-electron reduction too. 
* 
Figure 4.17. The variation of the first and second electrochemical reduction in (a) 
21 (0.1 -p -0.95 -p 0.4 V) and (b) 22 (0 - -1 -i 0.2 —*) with scan rates (0.01-1 V/s). 
This reduction is irreversible (no return peak observed), but on the oxidative return 
sweep a new peak marked * in Figure 4.17 grows in as the scan rate is increased. 
The first reduction remains unaffected by this second reduction (return peaks still 
observed). The second reduction appears to be undergoing an EC (electrochemical-
chemical) type reaction 
1171 whereby the species that is produced after reduction 
undergoes a chemical transformation which is re-oxidised at a different potential on 
the re-oxidation cycle. At present, this new product is unidentified. 
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4.3.6 EPR Spectroscopy 
Figure 4.18 shows the EPR spectrum obtained for the mono-reduced cationic radical 
of complex 22, [(16-hmb)2Ru2(CO-(azpy)2)Cl2] recorded in DMF at 233 K. The 
sample displayed an EPR signal centred on 3386 G at g = 1.99285 with a peak to 




Magnetic Field /G 
Figure 4.18. Solution EPR spectrum recorded for the mono-reduced cation of 
complex 22. 
4.3.7 31P Spin Trap Experiment 
Spin traps are species that are highly reactive towards free radicals and normally are 
nitrones or nitroso species which react with unstable free radicals to form a more 
stable free radical (radical adduct), which can be detected by EPR spectroscopy. [18] 
Unfortunately, these radical adducts degrade with time becoming diamagnetic and 
therefore EPR-undetectable. Recently research groups have been interested in 
utilising the 31 P NMR-active phosphorus atom in the spin trap and to follow the 
reactions of the trap with radicals in a technique called NMR spin trapping. 118211 
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Figure 4.19 shows the structure of DEPMPO, a spin trapping agent, and its reactions 
with radical R•. The radical formed is unstable and disproportionates to the 
corresponding hydroxylamine and a new nitrone. 
EtO > H 2  
0:-" 1 	I 
Ott 0 
DEPMPO 
2R 	 EtO 
H 
 O 2 
Ott 	0 . 
EtO 	 _____ EtO 	
R 
°I I. 	O:1 I 








Figure 4.19. Reactions of radical spin trap DEPMPO with radical R. 
The hydroxylamine, with R=OH, can lose a molecule of H20 to convert back to the 
starting material so the product observed by 31 P NMR is the nitrone (which can exist 
in two tautomeric forms). 91 Figure 4.20 shows the 31 P NMR spectrum recorded for 
the DEPMPO solution (0.075 M) after 3 h incubation with (a) H202/FeSO 4 (0.075 
M/0.075 M), (b) [( 6-p-cym)2 Ru2(CO-(azpy) 2 )C121 (PF6)2 (21, 0.075 M) and (c) 
blank control in 0.15 M phosphate buffer (pH 6.99) containing 1.5 mM DTPA and 
25% (CD3)2C0. 
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Figure 4.20. 31 P NMR spectra recorded after 3 h incubation at 310 K with (a) 
H202fFeSO4  to generate 'OH radicals, (b) complex 21 and (c) a blank control. All 
peaks were internally referenced to the phosphate buffer peak (3.80 ppm). 
All spectra show the peak corresponding to DEPMPO and a decomposition peak 
which appears over the three hours in all three cases (blank control included). For 
the H202IFeSO4  system (a) which uses Fenton type reactions to generate hydroxyl 
radicals, a new peak appears at Ca. 28 ppm which corresponds to the product of 
reaction of DEPMPO with •OH. 1191  An unknown species also appears at ca. 33 ppm. 
This may tentatively be assigned to the product of the reaction of the spin trap with 
the carbon-based -'COCH 3  radical formed when acetone and H 202 react together." 8' 
For the ruthenium system two new peaks also appeared, but at Ca. 29 and 30.5 ppm. 
This indicates that radicals are being formed in this system. These peaks, however, 
appear at a different ppm compared to the Fenton-control and it is not possible to say 
whether they correspond to the same paramagnetic products. It is noteworthy that 
the DEPMPO peak has shifted by ca. 0.5 ppm and the decomposition product by 
slightly less, in the spectrum containing the ruthenium compound, which may be a 
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result of paramagnetic ruthenium species being present in the solution. It is thus 
possible that the newly formed diamagnetic species could also be affected and appear 
with different chemical shifts. 
4.3.8 Cytotoxicity 
The cytotoxicity of complexes 17-22 against the A549 human lung and A2780 
human ovarian cell line is summarised in Table 4.2. 
Table 4.2. Cytotoxicity data for dinuclear ruthenium complexes and cisplatin 
against the A2780 and A549 cancer cell lines. nd = not determined 
Complex A2780 1050 (pM) A549 IC50  (PM) 
17 	>100 	 >100 
18 	 nd 	 nd 
19 	 nd 	 nd 
20 	 nd 	 nd 
21 	>100 	 >100 
22 	 38 	 85 
Cisplatin 	6 	 10 
To date, three of these dinuclear complexes have been tested for cytotoxicity. 
Complexes [( ij Ru2(CH2-(azpy)2)Cl21 (PF 6)2 17 and [(ij  Ru2(CO-
(azpy) 2)C1 2 1 (PF6)2  21, which contain the p-cymene arene, were not cytotoxic 
towards both cell lines. The hmb containing complex [(11 6-p-cym)2 Ru2(CO-
(azpy)2)Cl 2 1 (PF6)2  was moderately cytotoxicity towards the A2780 cancer cell line 
and somewhat less so towards the A549 cell line. 
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4.4 Discussion 
4.4.1 Synthesis of Nitrosopyridine 
The synthesis of 2-nitrosopyridine is highly desirable since the major synthetic route 
to phenylazopyridine complexes involves an acid/base cataylsed condensation 
reaction between a nitroso (NO) and amino (NH 2 ) group; thus either an 
aminopyridine can be reacted with a nitrosobenzene or a nitrosopyridine with an 
aminobenzene. Several aminobenzene derivatives are commercially available 
whereas there are not many nitrosobenzene derivatives available, thus a greater 
variety of ligands can be potentially synthesised from 2-nitrosopyridine and an 
aminobenzene derivative. 
Although aromatic nitroso compounds have been known since many years, only few 
heterocyclic nitroso compounds have been synthesised.t' OJ Direct nitrosation by 
electrophilic substitution is possible only with electron-rich systems, and 
heterocycles such as 2-aminopyridine are electron-poor systems that react with 
electrophiles at the ring nitrogen rather than on the exocyclic amino group. 
Electrophilic attack on the exocyclic amino group is made possible when electron 
density is concentrated at this position and this is achieved by first converting the 
amino group into a sulfilimine. The mechanism for this reaction has been debated in 
the literature and two reaction paths have been suggested. 
The first possible mechanism (Figure 4.21) involves the initial conversion of the 2-
aminopyridine to its mono-N-chlorinated derivative by using N-chlorosuccinimide as 
a chloride donor, followed by addition of dimethyl sulfide to produce the 
azasulfonium salt. After short treatment at low temperature with base, the sulfilimine 
is formed. 
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Figure 4.21. Possible reaction scheme for the formation of SS-dimethyl-N-(2- 
pyridyl)sulfihimine as proposed by Gassmann et al. in 1973.122] 
The second possible mechanism (Figure 4.22) involves activation of dimethyl 
sulfide (by N-chlorosuccinimide to give the corresponding sulfonium compound. 
Nucleophilic attack by the amine gives the azasolfonium salt and treatment with base 
forms the sulfihimine. 1231 
0 
NO 
CH,  CH3 
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Figure 4.22. Reaction scheme for mechanism of formation of S,S-dimethyl-N-(2-
pyridyl)sulfilimine proposed by Claus et al. in 1975.123] 
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The successful synthesis of nitrosopyridine was an important step for future 
syntheses of derivatised phenylazopyridine ligands. It will allow for a much wider 
range of ligands to be synthesised and thus build on structure-activity-relationships. 
4.4.2 Dinuclear complexes 
The complexes studied in this Chapter exist as diastereomers due to the chirality 
imposed at the ruthenium centres, and purification of these complexes through 
recrystallisation led to the preferential precipitation of one isomer (called isomer A). 
The isomers are not readily interconverted and this is perhaps not surprising since to 
convert, the phenylazopyridine ligand would have to detach and reattach to a 
ruthenium centre. Phenylazopyridine ligands coordinate strongly to Ru" centres and 
this bonding is strengthened by back donation from the metal to the azo ir orbital"" 
and so, the non-lability of the bis-phenyizopyridine chelating ligand may preclude 
any interconversion. 
4.4.3 Aqueous Solution Chemistry and 31P Spin Trap Experiment 
These complexes are much less stable in an aqueous solution at physiologically 
relevant concentrations compared to similar mononuclear analogues 124 J and appear to 
form no well defined products. 
Reaction of complex [(r6-p-cym) 2  Ru2(CO-(azpy) 2)C121 (PF6)2 (21) in a 75% aqueous 
solution containing the spin trapping agent DEPMPO showed that, through the 
production of new diamagnetic phosphorus species in the 31 P NMR, radicals were 
being produced in this reaction. It seems likely that a redox process is occurring in 
this system generating radicals. The redox process is unlikely to be an oxidation; the 
reactions were carried out in the absence of oxygen (thoroughly degassed), the 
coordination of an 1 6-arene disfavours oxidation of Ru(II) to Ru(III) by stabilising 
the Ru(II) oxidation state [251  and oxidation of the ligands (from azo to azoxy) was 
found to occur only at a relatively high potential (in DMF, 1.30 V. vs.Ag/AgC1). 
The redox process is more likely a reduction; reduction of the azo moiety in complex 
21 occurred at an easily accessible potential (in DMF, -0.06 V (vs Ag/AgCI) to form 
the azo anion radical) and phenylazopyridine ligands attached to ruthenium are 
reported to undergo electrochemical reductions (vide supra). The reductant, 
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presumably, is water. There are several examples where water takes on the role of a 
reductant: For example, photosynthetic organisms can use water as an electron 
source to reduce CO2, [261 and water has been used as a hydrogen-atom source for 
radical reductions mediated by [Cp 2TiC1].. 1271  The reduction of 21 by water may be 
a complex reaction; simple hydrogen abstraction from water to the azo group would 
generate HO., and in the 31 P DEPMPO spin trap experiment the same new 
diamagnetic species formed at 28 ppm as had formed in the positive control 
(generating HO. through fenton type reactions) would be expected to be present. 
Whilst new diamagnetic 31 P peaks are present, they appear at a slightly different 
frequency (29 and 30.5 ppm). 
4.4.4 Electrochemistry and EPR Spectroscopy 
Complexes 21 and 22 were studied by cyclic voltammetry and were found to 
undergo one electron reductions that occurred near to OV vs. Ag/AgCI electrode (-
0.06 V (21), -0.14 V (22)). The hmb complex was reduced at a slightly more 
negative potential and this trend, due to the increased electron donating effect of the 
arene substituents in hmb arene to the metal, was also observed for bis Os arene 
complexes containing the chelating ligand 2,2'-azobispyridine. 128' An EPR spectrum 
was also determined for the mono-reduced cationic radical of complex 22. The g-
value obtained for this radical is 99.8% of the free g value (2.0023) and signifies that 
this complex is an organic-based radical as opposed to a metal-based radical. 1291 
Based on the electrochemistry results, this radical is assigned as an azo-anion radical 
since the low-lying nature of the ir*  orbital makes the azo function susceptible to one 
electron reduction. 114' No ' 4N hyperfine coupling was observed; this is often the case 
for ligand based azo radicals on ruthenium since the ' 4N coupling constant is small 
and often difficult to observe. [14-161 
4.4.5 Cytotoxicity 
Three complexes were tested for cytotoxicity against both the A2780 and A549 
cancer cell lines. In general the complexes displayed a low/no cytotoxicity and no 
improvement of cytotoxicity was gained by linking the two ruthenium units together 
compared to the monomer alone. The hmb complex was more cytotoxic than the 
138 
Chapter 4: Dinuclear Ruthenium(II) Arene Chiorido Azo Complexes 
corresponding p-cym complexes and this may be due to its increased stability in 
aqueous solution, suggesting that the decomposition observed is not desirable for 
- good cancer cell cytotoxicity. 
4.5 Summary 
Six dinuclear ruthenium(II) arene complexes containing bis phenylazopyridine 
ligands and chlorido were synthesised and characterised by' 'H NMR, ESI-MS and 
CHN analysis. Two complexes were further characterised by cyclic voltammetry 
and one also by EPR spectroscopy. The complexes exist as diastereomeric mixtures 
and intriguingly decomposed rapidly in aqueous solution forming radicals 
(confirmed by the presence of new DEPMPO-diamagnetic adducts in the 31 P NMR) 
and undefined products; and do not appear to display a similar type of chemistry to 
analogous mononuclear analogues (i.e. hydrolysis and arene loss). The complexes 
exhibit no/low cytotoxicity towards both A2780 and A549 cancer cells. In this 
Chapter this synthesis of nitrosopyridine was also reported. This is a useful 
precursor for the synthesis of otherwise-unattainable 2-phenylazopyridine ligands 
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The orbital angular momentum 'of the unpaired electron gives a contribution 
to the total magnetic moment which produces a shift in the g-value from the 
free electron value. Large shifts are found for e.g. paramagnetic transition 
metal ions but in organic free radicals the orbital angular momentum is 
largely quenched so their g-values are within 1-2% of the free electron value. 
141 
Chapter 5: Ruthenium(II) Arene lodido Azo Complexes 
Chapter 5 
Ruthenium(II) Arene lodido Azo Complexes 
142 
Chapter 5: Ruthenium(I1) Arene lodido Azo Complexes 
5.1 Introduction 
Organometallic transition metal complexes have found widespread use in many areas 
of chemistry from materials chemistry to catalysis."" Research focussing on the use 
of organometallic complexes for medicinal purposes (bio-organometallic chemistry), 
and, in particular, as anticancer agents, has shown that there is great potential for 
these types of complexes to be used medicinally. Titanocence dichloride [Cp 2TiC12], 
for example, was the first organometallic to enter clinical trials as an anticancer 
drug [2, 3j and although disappointing phase II results halted its further development, 
several new titanocence dichloride derivatives show promising cytotoxicity and 
better chemical properties making them ideal candidates for further studies. [4-91 
Other organometallic complexes of current interest include ferrocene derivatives of 
tamoxifent' ° ' 21 which are responsive to both oestrogen receptor positive (ER+) and 
oestrogen receptor negative (ER-) cancer cell lines, unlike tamoxifen which is 
responsive to ER+ lines only. 
We are investigating organometallic half-sandwich Ru" arenes of the type [(71 6 
areneRu(YZ)(X)] where YZ is typically a chelating diammine ligand (e.g. 
ethylenediamine) and X is a halide (e.g. Q. These complexes exhibit promising 
anti-cancer activity in vitro and in vivo. 111, 14] Examples include YZ = en, X = Cl 
which, for arene = biphenyl and tetrahyrdoanthracene have 10 50 values of 5 and 0.5 
iM respectively in the A2780 human ovarian cancer cell line. As with most metal-
based anticancer drugs, the primary cellular target is thought to be DNA. The Ru-Cl 
bond is labile but hydrolysis (to form Ru-OH2) is suppressed extracellularly due to 
the high chloride concentration (ca. 104 mM). t151 Intracellularly the chloride 
concentration is much lower and hydrolysis occurs generating a reactive site on the 
ruthenium for subsequent DNA binding. The binding of ruthenium to DNA' 16-20J  is 
thought to lead to further 'downstream' effects ultimately resulting in cell death. 1211 
The following chapter reports the synthesis, characterisation and cytotoxicity of a 
series of novel ruthenium(II) arene complexes containing phenylazopyridine ligands. 
The mechanism of cytotoxicity is investigated along with some molecular signalling 
pathways and the results show that this class of complexes have a novel mechanism 
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Dichiorofluorescin diacetate (DCFH-DA), Glutathione (GSH) and N-acetylcysteine 
(NAC) were purchased from Sigma Aldrich. Ascorbic Acid was purchased from 
Alfa Aesar. Methanol was dried over Mg/I 2 , or anhydrous quality was used (Sigma-
Aldrich) all other reagents used were commercially available. The synthesis of Ii (Tl 6 
bip)Ru(en)Cl]PF6 and [( 6-tha)Ru(en)Cl]PF 6  is reported elsewhere. ' 3 ' 221 
5.2.2 Synthesis 
5.2.2.1 [(0 6-p-cymene)Ru(azpy-NMe 2)I]PF6 (23) 
The dimer [(0 6-p-cymene)Ru12] 2  (54.8 mg, 0.051 mmol) was dissolved in methanol 
(20 ml) and heated to Ca. 313 K until the solution turned clear. Azpy-NMe 2 (23 mg, 
0.102 mmol) dissolved in methanol (10 ml) was added drop-wise and the solution 
immediately turned from brown to dark blue. The solution was stirred at room 
temperature for 3 h. The volume of solvent was reduced to about 10 ml by removal 
of methanol on a rotary evaporator. NH 4PF6 (83 mg, 0.51 mmol) was then added 
and the solution was placed in the freezer overnight. A black microcrystalline 
product precipitated out and this was filtered off and washed with diethyl ether. The 
product was dried overnight in vacuo. Yield: 40.9 mg (68.2%) (Found: C, 37.74; H, 
3.25; N, 7.40. Calc for RuC23H27N4IPF6: C, 37.66; H, 3.85; N, 7.64). 'H NMR 
(CDC13) 89.17 (d, 1H), 8.22 (d, 1H), 8.15 (d, 2H), 8.03 (t, 1H), 7.54 (t, 1H), 6.77 (d, 
2H), 6.05 (d, 1H), 5.81 (t, 2H), 5.68 (d, 1H), 3.29 (s, 6H), 2.70-2.54 (m, 4H), 1.04 (d 
of d, 61-1). ESI MS: calcd for RuC 23H27N4I [M] mlz 589.04, found 589.2 [M]. 
5.2.2.2 [(q 6-biphenyl)Ru(azpy-NMe 2)I]PF6 , (24) 
The dimer [(ij 6-biphenyl)Ru12 ] 2 : (100 mg, 0.1 mmol) was dissolved in methanol (60 
ml) and water (20 ml) and heated to reflux for 2 h. 	Azpy-NMe2 (44.4 mg, 0.2 
mmol) dissolved in methanol (20 ml) was added drop-wise and the solution 
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immediately turned from brown to dark blue. The solution refluxed for a further 
hour, hot filtered and then the volume of solvent was reduced to about 15 ml by 
removal of methanol on a rotary evaporator. NH 4PF6 (160 mg, 1 mmol) was then 
added and the solution was placed in the fridge for 1 h. A black powder product 
precipitated out and this was filtered off and washed with cold ethanol then diethyl 
ether. The product was dried overnight in vacuo. Yield 121 mg (80.2%). (Found: 
C, 38.52; H, 2.67; N, 7.03. Calc for RuC2 5H24N4IPF6 : C, 39.85; H,3.21; N,7.74 %). 
'H NMR (DMSO-d6) 59.35 (d, 1H), 8.37 (d, IH), 8.15 (t, IH), 8.07 (d, 2H), 7.51- 
7.34 (m, 5H), 6.86-6.78 (m, 3H), 6.68-6.48 (m, 4H), 3.27 (s, 6H). ES! MS: calcd for 
RuC25H24N4r {M] mlz 609.03, found 609.2 [M t]. 
5.2.2.3 [(0 6-p-cymene)Ru(azpy.OH)I]PF 6  (25) 
The dimer [(ij 6-p-cymene)Ru12] 2  (73 mg, 0.07 mmol) was dissolved in methanol (70 
ml) was stirred until the solution turned clear. Azpy-OH (30 mg, 0.14 mmol) 
dissolved in methanol (10 ml) was added drop-wise and the solution immediately 
turned from brown to intense brown/yellow. Six drops of IM HC1 was added to the 
solution and the mixture was stirred for 4 h. The volume of solvent was reduced 
slightly and a black precipitate was filtered off. The resulting mixture was passed 
down a Sephadex LH20 column with methanol as the elutent. The intense 
brownlyellow fraction was collected and excess NH 4PF6 (160 mg, 0.1 mmol) was 
added. The solvent was removed and the product was re-dissolved in 
dichloromethane, where a white insoluble precipitate was filtered off. The solvent 
was removed to give a dark brown solid. The product was dried overnight in vacuo. 
Yield 33 mg (46.6 %). (Found: C, 34.48; H, 3.24; N, 5.74. Caic for 
RuC2 ,H23N301PF6 : C, 35.65; H, 3.28; N, 5.94 %). 'H NMR (DMSO-d6) ö 9.87 (d, 
1H), 8.92 (d, 1H), 8.78-8.65 (m, 3H), 8.07 (t, 1H), 7.37 (d, 2H), 6.83 (d, 1H), 6.64-
6.51 (m, 3H), 3.18 (septet, 1H), 3.11 (s, 3H), 1.53 (dd, 6H). ). ES! MS: calcd for 
RuC21H23N30r [Md] m/z 561.99, found 561.7 [Mt]. 
5.2.2.4 [(jj 6-biphenyl)Ru(azpy-OH)I]PF 6  (26) 
The dimer [(ij6-biphenyl)Ru!2 ] 2 (100 mg, 0.1 mmol) was dissolved in methanol (60 
ml) and water (20 ml) and heated to reflux for 2 h. Azpy-OH (37.5 mg, 0.2 mmol) 
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dissolved in methanol (20 ml) was added drop-wise and the solution gradually turned 
from brown to intense brown/yellow. The solution refluxed for a further 2 h, hot 
filtered and then the volume of solvent was reduced to about 15 ml by removal of 
methanol on a rotary evaporator. NH 4PF6  (160 mg, 1 mmol) was added and the 
solution was placed in the fridge for 2 h. A brown powder product precipitated out 
and this was filtered off and washed with cold ethanol then diethyl ether. T he 
product was dried overnight in vacuo. Yield 94.1 mg (66.1%). (Found: C, 38.03; H, 
2.14; N, 5.35. Caic for RuC 23H, 9N301PF6: C, 37.21; H, 2.14; N, 5.79). 'H NMR 
(DMSO-d6) ö 9.45 (d, 1H), 8.93 (d, 1H), 8.41 (t, 1H), 7.94 (d, 2H), 7.64-7.56 (m, 
3H), 7.60-7.45 (m, 5H), 7.43-7.33 (m, 2H), 6.89 (d, 1H), 6.75 (t, 1H), 6.70-6.54 (m, 
3H). ESI MS: calcd for RuC23H, 9N30I [M] m/z 581.65, found 582.1 [M]. 
5.2.2.5 [(j 6-p-cymene)Ru(azpy)I]PF 6  (27) 
The dimer [(tj6-p-cymene)Ru12] 2 (100 mg, 0.1 mmol) was dissolved in methanol (50 
ml) and heated to ca. 313 K until the solution turned clear. Azpy (38 mg, 0.2 mmol) 
dissolved in methanol (10 ml) was added drop-wise and the solution gradually turned 
from brown to brown/purple. The solution cooled to room temperature and stirred for 
3 h. The volume of solvent was reduced to about 10 ml by removal of methanol on a 
rotary evaporator. NH 4PF6 (160 mg, 1 mmol) was then added and the solution was 
placed in the freezer overnight. A black microcrystalline product precipitated out 
and this was filtered off and washed with ether. The product was dried overnight in 
vacuo. Yield 110 mg (79.6%). (Found: C, 36.90; H, 3.23; N, 5.96. Caic for 
RuC2 1 H23N3IPF6 : C, 36.54; H, 3.36; N, 6.09). 'H NMR (DMSO-d 6) 5 9.67 (d, 1H), 
8.93 (d, lH), 8.52 (t, 2H), 8.28 (d, lH), 7.95-7.86 (m, 2H), 7.77 (t, 2H), 6.55 (d, 1H), 
6.23 (t, 2H), 6.15 (d, lH), 2.76 (septet, 1H), 2.62 (s, 311), 1.08 (dd, 6H). ESI MS: 
calcd for RuC2 1 H23N3 1+  [Mi] m/z 545.98, found 546.1 [Mt]. 
5.2.2.6 [(0 6-biphenyl)Ru(azpy)I]PF6  (28) 
The dimer [(rj 6-biphenyl)Ru12] 2 (100 mg, 0.1 mmol) was dissolved in methanol (60 
ml)\and water (20 ml) and heated to reflux for 2 h. Azpy (37.5 mg, 0.2 mmol) 
dissolved in methanol (20 ml) was added drop-wise and the solution graduallyturned 
from brown to brown/purple. The solution refluxed for a further 2 h, hot filtered and 
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then the volume of solvent was reduced to about 15 ml by removal of methanol on a 
rotary evaporator. NH 4PF6  (160 mg, 1 mmol) was then added and the solution was 
placed in the fridge for 2h. A black powder product precipitated out and this was 
filtered off and washed with cold ethanol then diethyl ether. The product was dried 
overnight in vacuo. Yield 94.1 mg (66.1%). 'H NMR (DMSO-d 6) ö 9.45 (d, 1H), 
8.93 (d, 1H), 8.41 (t, 1H), 7.94 (d, 2H), 7.64-7.56 (m, 3H), 7.60-7.45 (m, 5H), 7.43-
7.33 (m, 2H), 6.89 (d, 1H), 6.75 (t, 1H), 6.70-6.54 (m, 3H). ESI MS: calcd for 
RuC23H 19N3I' [M'1] mlz 565.66, found 566.1 [M']. 
5.2.3 Methods 
5.2.3.1 Unbuffered Aqueous Solution Behaviour of Complexes 23-28 
Solutions of ruthenium complexes were prepared in 90% H20 / 10% D 20 (23 pH 
6.19, 26 pH 6.25, 25 pH 5.64, 24 pH 6.29) or 95% D20, 5% MeOD (used to aid 
solubilisation) (28 pH*7.09,  27  pH*6.51)  at 100 iM ruthenium. 'H NMR spectra 
were recorded at 310 K initially (time ca. 15 minutes) and after 24 h. The samples 
were kept in the water bath at 310 K between acquisitions. 
5.2.3.2 Buffered Aqueous Solution Behaviour of Complexes 23-28 
Solutions of ruthenium complexes in MeOD were diluted down in 10 mM phosphate 
buffer / D20 to give a final concentration of 100 iM ruthenium (95%D 20, 5% 
MeOD). 'H NMR spectra were recorded at 310 K initially (time ca. 15 minutes) and 
after 24 h. The pH*  of the samples was 7.35 (23), 7.38 (24), 7.38 (25), 7.40 (26), 
7.31 (27) and 7.32 (28). The samples were kept in the water bath at 310 K between 
acquisitions. After 24 h, ESI-MS was performed on samples 23, 24, 25 and 26. 
5.2.3.3 Investigating Substitution of Iodide by Chloride in Complex 24 
Complex 24 was dissolved in water, sonicated for 15 min to fully dissolve, filtered 
and then diluted down to Ca. 30 IIM. Sodium chloride was added from a 
concentrated stock solution to give 100 mM NaCl and the corresponding absorbance 
spectrum was recorded at hourly intervals over 24 h at 310 K. 
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5.2.3.4 Determination of the Rates of Reduction of complexes 23, 24, 25 and 26 
by ascorbic acid 
Ruthenium complexes were dissolved in MeOH and diluted with water to give a 50 
iM solution (95% H20/ 5% MeOH). Phosphate buffer (final cone. 10 mM, gave pH 
7.2-7.4) was added along with ascorbic acid (at four different excess concentrations, 
5-20 equivalents) and the change in absorbance was followed at selected 
wavelengths (568 nm for 25 and 26, 597 nm for 23 and 24) over a time period. A 
plot of the change in absorbance with time was fitted to the appropriate equation for 
pseudo-first order kinetics using Origin version 7.5 (OriginLab Corporation) to give 
the observed rate constant (k obS) for each concentration of àscorbate. A plot of k 0b 
against concentration of ascorbate gave a straight line, the gradient of which was the 
second order rate constant k', for the compounds showing behaviour dependent on 
the concentration of ascorbate. 
5.2.3.5 Reduction of complexes 23, 24, 25 and 26 by ascorbic acid followed by 
'H NMR 
The complexes were dissolved in MeOD and diluted in D 20 / 10 mM phosphate 
buffer (pH 7.3) to give 50 jiM Ru (5% MeOD). The 'H NMR spectra were 
recorded, 5 equivalents of ascorbic acid was added and the spectra were re-recorded 
at the half life (at 22 mm (26), 20 mm (24), and 88 mm (23 and 25)) and after the 
reaction had finished (after 3 h (24 and 26) and after 7 h (23 and 25). Each 
acquisition took 7 min 43 s to acquire and so the spectra recorded represent an 
average speciation over this time. 
5.2.3.6 Reactions of Ru-X with Glutathione (GSH) for complexes 8 and 24by 
UV-Vis Spectroscopy, HPLC and 'H NMR 
Aqueous Solutions / buffers used were filtered through Chelex- 100 to remove iron 
and degassed using N 2/Ar prior to dissolving GSH. After dissolution the pH of the 
GSH solution was adjusted to ca.7 by addition of dilute NaOH / HCl and solutions 
were degassed again. Solutions of GSH were made fresh for each experiment. [(TI 6_  
biphenyl)Ru(azpy-NMe 2)I]PF6 (24), and [( 6-biphenyl)Ru(azpy-NMe 2)Cl]PF6  (8), 
diluted in MeOH were added to GSH (final concentrations 50 jiM Ru, 5 mM GSH, 
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10 mM phosphate buffer; 95% HO, 5% MeOH), the pH was 7.06 (24) and 7.03 (8) 
for UV-Vis experiments and 7.88 (24) and 7.89 (8) for HPLC separations. 
The rate of substitution of Ru-X by GS was determined by UV-Vis spectroscopy, 
following the change in wavelength at 597 nm (298 K) with time and fitting the 
change in absorbance with time to the appropriate equation for pseudo-first order 
kinetics using Origin version 7.5 (OriginLab Corporation) to give the observed rate 
constant (kb) and the corresponding half life (t1,2). 
The extent of substitution of X in Ru-X by GS was followed by HPLC using the 
gradient 10-50% B to 30 mm, 50-90% B to 40 min using semi-preparative 
conditions. The new fraction appearing over time was collected and, analysed by 
ES I-MS. 
Isolation of the corresponding GS adduct of [(il 	was 
from collecting the HPLC fraction of an unbuffered solution (50 iM complex 24, 
4.75 mM GSH (pH adjusted to 7.4); 95% H20,5% MeOH). The GS adduct fraction 
was collected, the pH adjusted to 7.0, lyophilized, re-dissolved in 95% D20, 5% 
acetone-d6 (pH recorded as 8.1) and the 'H NMR spectra were subsequently recorded 
over 24 h. 
5.2.3.7 Detection of Oxidation of GSH to GSSG 
Aqueous solutions / buffers used were filtered through Chelex-100 to remove iron 
and degassed using N2/Ar prior to dissolving GSH. After dissolution the pH of the 
GSH solution was adjusted to ca. 7 by addition of dilute NaOH / HC1 and solutions 
were degassed again. Solutions of GSH were made fresh for each experiment. [(1 6W 
biphenyl)Ru(azpy-NMe 2)I]PF6  (24), [( 6-bipheny1)Ru(azpyOH)I]PF 6 (26), Azpy-
NMe2 and Azpy-OH dissolved in acetone-d 6 were added to GSH (final 
concentrations 100 iM Ru / ligand, GSH 10 mM (when ruthenium) / 9.5 mM (when 
ligand), 30 mM phosphate buffer; 10% D20, 85% H 2O, 5% acetone-d6), the 
measured pH was 7.62 (24), 7.57 (26), 7.55 (Azpy-NMe2) and 7.59 (Azpy-OH). 
Solutions of GSH alone (10 / 9.5 mM, 10% D20, 85% H20, 5% acetone-d 6) were 
also made up at the same time (measured pH 7.40 (control for 24 and 26) and 7.60 
(control for Azpy-NMe2 or Azpy-OH) to check the amount of auto-oxidation of 
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GSH, and these samples were kept in the water bath at 310 K for 24 h then the 'H 
NMR was run. 
5.2.3.8 Detection of Reactive Oxygen Species 
The experiment was based on earlier experimental protocols by Wang et. a11231 with 
some modifications. Dichiorofluorescein diacetate (DCFH-DA) was opened under a 
blanket of argon, aliquoted in DMSO and kept frozen. When used, care was taken to 
ensure minimum exposure to light. A549 cancer cells were plated out at a density of 
20x 103  cells per well into black 96 well plates and were incubated at 310 K, 5% 
CO2. high humidity for 24 h. Cells were loaded with DCFH-DA (10 PM, 0.5% 
DMSO (vlv)) and were incubated at 310 K, 5% CO 2 , high humidity for 30 mm. The 
probe was removed and the cells were washed twice with PBS (200 tL). The cells 
were then kept in Hanks Balanced Salt Solution (HBSS) and the ruthenium 
compounds were diluted with HBSS and added to the wells (25 pM, 0.5% DMSO 
(v/v)). Hydrogen peroxide (25, MM) was added as a positive control and the 
fluorescence was read every 200 s over a period of 6 h at 310 K by excitation at 480 
±10 nm and emission at 538 ±15 nm on a BMG Fluostar plate reader. 
5.2.3.9 Increasing Intracellular Thiol Levels 
For IC50  determinations for A549 cells with increased thiol levels, A549 cells were 
pre-incubated with 5 mM N-acetyl-L-cysteine for two hours, a concentration and 
time that had previously been reported not to be non-toxic for this cell line,124' 251  and 
this was confirmed by controls throughout the experiment. The NAC was removed, 
cells were washed twice in PBS, fresh cell medium was added and IC 50 
determination was subsequently determined as normal (see Chapter 2). 
5.2.3.10 Qualification of Cell Survival in HCT-116 (p53 +1-) Colon Cancer Cells 
HCT 116 (WT) and HCT1 16 (P53-) were plated out at 120 x 104  cells/well (40 x iO4 
cells/mL) and 93 x 104 cells/well (31 x 104 cells/mL) respectively and incubated for 
24 h before drug addition. The ruthenium compound was dissolved in DMSO to 
give a stock solution of 5 mM and serial dilutions were carried out in DMSO to give 
concentrations of drug in DMSO of 2, 1, 0.4, 0.2, 0.1 and 0.02 mM. These were 
added to the wells to give the six testing concentrations (25, 10, 5, 2, 1, 0.5 and 0.1 
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riM) and a final concentration of DMSO of 0.5% (v/v) with a total volume of drugs 
and media to be 3.015 mL. The cells were exposed to the drug for 24h, then, after 
drug removal, the cells were washed twice with PBS (3 mL) and the remaining 
biomass was fixed by adding cold MeOH (5 mL) and incubating at room temperature 
for five minutes. The methanol was removed and the plates were air-dried. The 
remaining biomass was visualised by adding Giemsa stain (diluted 1:20 with distilled 
water, 5 mL) to each well and incubating at room temperature for 20 minutes. The 
plates were washed with tap water (3 x 5 mL), left to dry then photographed for a 
visual indication of remaining biomass. 
5.2.3.11 p53  Immunochemical Assays 
All experiments were performed within ten passages of each other. Typically HCT-
116 cancer cells were plated out at a density of 15 x 10 4 cells / dish (15 x 10 
cells/mL) and the cells were incubated at 310 K, 5% CO2 , high humidity for 48 h. 
Ruthenium complex 24 was dissolved in DMSO, serially diluted and added to a dish 
at concentrations of 5, 2, 1, 0.5 and 0.1 iM (0.05% DMSO). DMSO only, a blank 
(no drug or DMSO) and a positive (7 Gy X-ray exposure, cells harvested 4 h after 
exposure) controls were also included. The cells were exposed to the 
complex/control for 24 h then the complex was removed, the cells were washed with 
PBS (10 mL) then harvested into ice-cold PBS (1 mL), centrifuged at 3000 rpm at 
277 K for 4 mm, the PBS removed and the pellet stored in liquid N 2. The cell 
lysate was collected by adding Ca. 70 IlL urea lysis buffer (7 M Urea, 0.1 M DTT, 25 
mM NaCl, 20 mM Hepes buffer (pH 7.6), 0.05% Triton X-100), pipetting to mix, 
incubating on ice for 30 mm, centrifuging at 13000 rpm at 277 K for 10 minutes and 
removing the lysate. The protein concentration of the lysate was determined by the 
Bradford Assay and the proteins in the lysate were separated using SDS-PAGE. 
Briefly 20 ig of protein was dissolved in 10 pL SDS sample buffer (4% SDS, 200 
mM Tris (pH 6.8), 10 mM EDTA, 20% glycerol, 60 iL/ml 1% bromophenol blue 
0.2 M DTT) and a low range loading marker was similarly prepared. The samples 
were heated for 5 min at 368 K and were separated using a 10% resolving gel (H20 
(1.9 mL), 1.5 M Tris pH 8.8 (1.3 mL), 10% SDS (0.05 mL), 10% ammonium 
persulfate (0.05 mL) and TEMED (0.002 mL) with loading on a 5% stacking gel 
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(H20 (3.4 mL), 1 M Tris (pH 6.8) (0.63 mL), 30% acrylamide mix (0.83 mL), 10% 
SDS (0.05 mL), 10% ammonium persulfate (0.05 mL) and TEMED (0.005 mL) with 
SDS PAGE running buffer. The gel was run at a constant voltage (180 V) for 50 
minutes or until the bromophenol blue had reached the bottom of the gel. The gel 
was transferred to a nitrocellulose membrane at 300 mA over 1 h using tris-glycine 
methanol transfer buffer. The unreacted sites on the membrane were blocked using 
5% Marvel Milk in PBS-Tween (100 mL) with 1 mL 1 M 3-glycerol phosphate by 
incubating for 1 h at room temperature with gentle shaking. The primary anti bodies 
were used were the p-53-specific Do-1 Mouse mAB (Novocastra, Newcastle upon 
Tyne, UK, 1:1000, 5% Milk - PBS-T), the p53 C-terminal phosphorylation site 
serine 392-specific FP-3 Mouse mAB (1:500 5% Milk-PBS-T ) and the p53 N-
terminal phosphorylation site serine 15 Mouse mAB (1:1000 5% Milk-PBS-T) (both 
New England Biolabs, Hitchin, UK) and the p21 WAFI (Dako, 1:500, 5% Milk-
PBS-T) Primary antibodies were added and incubated at 277 K overnight then at 
room temperature for a further 15 mm. The membrane was washed (3 x 5 mm in 
PBS-T) then the horse radish peroxidase (HRP) conjugated secondary antibody was 
added (polyclonal rabbit-anti-mouse RAM, 1:1000 5% Milk-PBS-T) for I h at RT, 
the membrane was washed (3 x 10 min in PBS-T). Blots were visualised by 
chemiluminescence and photographed. Actin immunoblots were used to confirm 
equal protein loading. 
5.3 Results 
Figure 5.1 shows the complexes synthesised and studied in this chapter. They were 
screened for cancer cell cytotoxicity and some analogues were found to be highly 
cytotoxic. Because the cytotoxicity of half sandwich Ru(II) arenes is thought to be 
due to hydrolysis of labile Ru - X bonds followed by binding to DNA (vide supra), 
hydrolysis studies were performed. In view of the unusual hydrolysis behaviour 
(vide infra) their redox chemistry was subsequently investigated electrochemically, 
inside cancer cells, with the biological reductant ascorbate and with the primary 
cellular antioxidant glutathione (GSH). Furthermore, cellular activation pathways 
were investigated for cancer cells after being exposed to one of the cytotoxic 
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complexes in order to gain some information about the 'downstream' effects of this 
class of complexes. 
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Figure 5.1. Molecular structure and numbering of ruthenium complexes studied in 
this Chapter. 
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5.3.1 Synthesis and Characterisation 
The complexes were characterised by 'H NMR, CHN and ESI-MS. In general the 
'H NMR spectra of the iodide complexes was similar to the corresponding chloride 
analogues. 
5.3.2 Aqueous Solution Chemistry 
5.3.2.1 Buffered Solutions 
The aqueous solution chemistry was studied by 'H NMR in 95% D20/5%MeOD at 
100 .iM ruthenium concentration in 10 mM phosphate buffer (pH 7.3) and at 310 K 
over 24 h. These conditions were chosen to mimic the concentration, pH, exposure 
time and temperature used for the biological cell tests. 
For complexes 23, 24, 25 and 26 no new peaks / peak shifts occurred in the spectra 
over 24 h suggesting that no hydrolysis had occurred; this hypothesis was confirmed 
by performing ESI-MS on the NMR solutions where only one mass corresponding to 
the intact cation was observed (23 found mlz 561.70 (Mt) calcd for 23 561.99, 24 
found m/z 588.75 (M) calcd for 24 589.04, 25 found mlz 581.65 (Mt) calcd for 25 
581.98, 26 found mlz 608.71 (Mt) calcd for 26 609.03). 
For complexes 27 and 28, however, changes in their 'H NMR spectra occurred over 
the 24 h time period (Figure 5.2 and Figure 5.3 respectively). For compound 28, 
after 24 h dissolution all peaks corresponding to the intact cation had disappeared 
and the only assignable peaks, in the spectrum were due to free biphenyl in solution. 
For compound 27 the peaks corresponding to the intact cation were still present 
although at a reduced intensity and a new peak corresponding to free p-cymene in 
solution was observed. 
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(a) 
10 	 9 	 8 	 7 	 6 ppm 
Figure 5.2. High frequency region 'H NMR (100 p  27, 95% D20, 5% MeOD, 10 
mM phosphate buffer, 310 K, internal reference dioxane (6 3.75)) at (a) 10 min and 
(b) 24 h after dissolution. The peaks corresponding to the intact cation in (a) are 
reduced in intensity in (b) and a new peak assignable to free p-cymene in solution 
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Figure 5.3. High frequency region 'H NMR (100 jiM 28, 95% D20, 5% MeOD, 10 
mM phosphate buffer, 310 K, internal reference dioxane ( 3.75)) at (a) 11 mm and 
(b) 24 h after dissolution. The peaks corresponding to the intact cation in (a) have 
disappeared in (b) and the only assignable peaks are due to free biphenyl in solution, 
marked *• 
The reactions of complex 28 and 29 (50 pM complex, 10 mM phosphate buffer, 310 
K, 24 h) were subsequently followed by UV-Vis spectroscopy where slow 
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Figure 5.4. UV-Vis spectra recorded for (a) 27 and (b) 28 (50 gM Ruthenium, 10 
mM phosphate buffer, pH 7.3, 95% H20, 5% MeOH) recorded every hour at 310 K 
over 24 h. In both cases there is a decrease in intensity of the UV-Vis bands over the 
time period and an increase in intensity between 600-800 nm. 
5.3.2.2 Unbuffered Solutions 
The solution chemistry was also studied in unbuffered aqueous solution. For 
complexes 23, 24, 25 and 26 again no new peaks / peak shifts occurred in the spectra 
over 24 h (data not shown) indicating that no hydrolysis had occurred. However, for 
complexes 27 and 28 after 24 h the intact cation accounted for Ca. 95% of the species 
in solution and there was only a small amount of free p-cymene / biphenyl detected 
(accounting for no more than Ca. 5% of the solution, determined by peak integration) 
suggesting that only a small amount of arene was lost from the complex (data not 
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shown) and that the complexes largely still existed as their intact cations. Thus the 
phosphate buffer appears to be accelerating the decomposition of these two 
complexes. 
5.3.2.3 Reaction of complex 24 with excess NaCI 
The reaction of 24 in 104 mM NaCl (to mimic extracellular [CI]) was investigated 
by UV-Vis spectroscopy over 24 h at 310 K in order to investigate if chloride 
displaces iodide when present in a large excess. No changes in the spectrum 
occurred (data not shown) indicating no substitution of iodide by chloride had 
occurred. 
5.3.2.4 pKa of Phenolic group in [(q 6 p-cym)Ru(azpy-OH)I]PF 6  (25) 
A PKa value of 6.50 was determined for deprotonation of the phenol group of azpy-
OH in complex 25 (Figure 5.5), and so at physiological pH (7.2-7.4) the complex 
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Figure 5.5. Plot of absorbance at 432 nm against pH for compound 25 and 
corresponding sigmoidial fit to give the PK a of the deprotonation of the phenolic OH 
as 6.50. 
5.3.3 Electrochemistry 
The electrochemical reductions of all six ruthenium complexes were studied by 
cyclic voltammetry in DMF containing 0.1 M TBABF 4 as the supporting electrolyte. 
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Generally the complexes displayed two electrochemical reductions, the first 
reduction occurred at ca. -0.2 to -0.4V and a second at ca. - 0.7 to -1 V. There were 
further reductions observed near to the solvent cut off (Ca. -2V) but these were not 
considered any further. The reduction potentials are summarised in Table 5.1. 
Table 5.1. 	Irreversible electrochemical reduction potentials for ruthenium 
complexes 23-28 recorded in DMF with 0.1 M TBABF4 at 0.1 Vs-  referenced to the 





















0 . 67a 
a two subsequent reductions of reduced intensity were observed at ca. -0.90 V and - 
1.17 V, thought to be due to the instability and reduction of the di-anion 
decomposition products. 
5.3.3.1.1 	First Electrochemical Reduction 
This reduction was confirmed as a one electron reduction for complex 27 using 
constant potential coulometry, see Figure 5.6. It was assumed, on the basis of this 
result that the first reduction for all six complexes was also a one electron reduction. 
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Figure 5.6. Constant potential (held at -0.40 V) coloumetry results showing current 
increasing with time for the reduction of 6.6 .tmoles of complex [(ij 6-p-
cymene)Ru(azpy)1IPF6, 27. For n = 1, theoretically i = 0.636 therefore n = 0.98 (1). 
The reduction potential becomes more positive as the arene is changed from p-
cymene to biphenyl and also as the chelating azo ligand is changed from azpy-NIMe2, 
to azpy-OH to azpy (Table 5.1). Based on literature assignments of the reduction of 
ruthenium-phenylazopyridifle complexes, 2628  this reduction can be assigned to the 
addition of an electron into the phenylazopyridine ligands 7t* orbital centred on the 
azo group to form the azo anion radical, equation (1) 
-N=N-+e- -* (-N-N-Y' 	(1) 
The relative order therefore, reflects the decreasing it-acceptor capability of the 
substituted azpy ligands due to the addition of electron donating groups onto the 
phenyl ring. [291 
In all cases the reduction is essentially irreversible (no return peak observed, 0.1Vs 1 , 
RT) and the complexes undergo an Electrochemical - Chemical type reduction; the 
electrochemically reduced product is not stable and so reduction is followed by a 
chemical reaction/transformation, where the major peak that appears on the return 
oxidative sweep (marked * on Figure 5.7) is the re-oxidation of the product formed 
after subsequent reaction of the reduced species, and not the reversible re-oxidation 
of the reduced species. Faster scan rates increased the reversibility of the reduction 
slightly with a corresponding decrease in the re-oxidised product. 
159 
Chapter 5: Ruthenium(H) Arene lodido Azo Complexes 
	
0.4 	 * 
- 





-0.75 	 0 	 0.75 
E /V 
Figure 5.7. Cyclic voltammogram for complex 23 recorded in 0.1 M TBABF4 in 
DMF (sweep from 0 -* -0.75 - +0.5 - 0 V) as the scan rate is varied from 0.01 - 1 
Vs-lat ca. 298 K. The reaction becomes slightly more reversible at higher scan rates 
but in all cases the main product on the return sweep is marked . 
At lower temperatures the first reduction peak becomes more reversible, this re-
oxidation peak either disappeared or was significantly reduced in intensity, see 
Figure 5.8. 





-0.75 	 0 	 0.75 
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Figure 5.8. Cyclic voltammogram for 23 recorded in 0. 1M TBABF4 in DMF (sweep 
from 0 -i -0.75 -p +0.5 -p 0 V, 0.1 Vs') as the temperature is changed from ca. 298 
K to 218 K. At the lower temperature scan the reduction becomes more reversible 
and the EC-product is significantly reduced in intensity. 
160 
Chapter 5: Ruthenium(II) Arene lodido Azo Complexes 
5.3.3.1.2 	Second Electrochemical Reduction. 
This irreversible reduction step is assigned to the electrochemical reduction of the 
azo anion radical to the dianion species, equation (2) 
{-N-N-}+e-- {-N-N-} 2 	(2) 
In polar aprotic solvents such as DMF, the two-electron reduction of the azo group is 
seen as two separate electrochemical reductions. 1301  In cases where it was observable 
it appeared with a reduced intensity compared to the first reduction, presumably due 
to the instability of the mono-reduced species (hence not all is present to be able to 
be reduced to the dianion). 
5.3.4 Reactions with Ascorbate 
Ascorbic acid (pKa 4.2, ascorbate anion at physiological pH) is an important anti-
oxidant and acts as a cell protector in nearly all aerobic organisms. 31 j  It is capable of 
donating two electrons and two protons sequentially to form the ascorbyl radical then 
dehydroxoascorbic acid. 
5.3.4.1 Phenylazopyridine Ligands 
The reaction of phenylazopyridine ligands Azpy-NMe 2 and Azpy-OH with ascorbate 
produced some changes in the UV-Vis spectrum with time (Figure 5.9) but on closer 
inspection it revealed that these changes were due to ascorbate decomposing in the 
solution and not due to reduction of the complex. 
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Figure 5.9. Reaction of (a) Azpy-NMe2 and (b) Azpy-OH (50 iM, 95% H20, 5% 
MeOH) with Ascorbic Acid (250 iiM) in 10 mM phosphate (pH 7.2). Readings were 
taken from 600-200 nm every hour over 24 h (310 K). Inset: The reaction of 
ascorbate alone under the same conditions. 
5.3.4.2 Ruthenium Complexes 
The reactions of 23-26 with ascorbic acid were followed over time using UV-Vis 
spectroscopy. Dramatic changes in the UV-Vis spectra of the ruthenium compounds 
occurred upon addition of ascorbate, notably a decrease in the intensity of the Metal-
to-Ligand - Charge-Transfer (MLCT) band and the emergence of a new broad peak 
at ca. 350 nm (25 and 26) or at ca. 480 nm (23 and 24). Interestingly, on completion 
of the reaction, the UV-Vis spectra still showed the intense it-itt intraligand 
transitions of the phenylazopyridine 1321  indicating that the azo moiety had not been 
reduced. Furthermore, isosbestic points at ca. 430 rim for complexes 25 and 26 
suggested that the reaction was a single step transition from starting material to 
reduced product whereas for complexes 23 and 24 the absence of a true isosbestic 
point suggested that there may be intermediates involved in these cases. 
Representative spectra are shown in Figure 5.10. 
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Figure 5.10. UV-Vis spectra recorded for the reactions of (a) 23, (b) 24, (c) 25 and 
(d) 26 (50 j.tM, 10 mM phosphate buffer, pH 7.3 95% H20, 5% MeOH, 310 K) with 
10 equiv ascorbic acid. Readings were taken every 5 minutes over 3 h (24 and 26) or 
15 minutes over 6 h (23 and 25). Isosbestic points are marked *• 
Kinetic data were derived by following the change in absorbance at selected 
wavelengths with time. For the biphenyl complexes, the change in absorbance 
showed an initial plaieau for compound 24 (for Ca. 140 s independent of ascorbate 
concentration) and an initial quick slight increase in intensity for compound 26 (for 
ca. 200 s, independent of ascorbate concentration) 1331  followed by a rate-determining-
step (RDS) decrease in the intensity of the MLCT which gave good pseudo-first 
order kinetics with excess ascorbate to give the second order rate constants of 0.68 
M's' (24) and 0.45 M_ I 5 ' (26) and corresponding half lives of t112 = 488 s (24) and 
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Figure 5.11. Plots of observed pseudo first order rate constants (k) determined 
with differing concentrations of ascorbate and best fit straight lines for the reduction 
of 24 (50 tM, o) and 26 (50 .tM, o). The second order rate constants were 
determined from the gradients as 0.68 M's' (24) and 0.45 M 1 s 1 (26) with 
corresponding half lives of 488 s (24) and 741 s (26). 
The change in absorbance for the p-cymene complexes 23 and 25, however was 
much slower and showed an initial increase in intensity which was found to follow 
pseudo-first order kinetics with differing ascorbate concentrations to give the second 
order rate constants of 3.4 M 1 s_i (23) and 3.0 M 1 s_i  (25) and corresponding half 
lives of ti/2 = 108 s (23) and 111 s (25), followed by a slow RDS decrease in 
absorbance which was independent of ascorbate concentration (Figure 5.12). The 
rate of reduction by ascorbate were determined to be Ca. 1.4 x 10 
4  for both 
complexes (half life t112 = 1.4 h). 
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Figure 5.12. The change in absorbance at 568 nm for complex 25 (50 PM, 10 
mm 
phosphate buffer, pH 7.35, 95% H 20, 5% MeOD) with 10 equiv ascorbate. There is 
an initial increase in absorbance followed by a RDS decrease, independent of 
ascorbate concentration which gives rate for the reduction to be ca. 1.4 x 10 s' (half 
life t,,z = 1.4 h). 
In order to identify the nature of the reduced species, the same reactions were 
followed by 'H NMR. In all cases, the rate-determining step appeared to correlate 
with loss of bound 1 6-arene from the complex as was evident from the appearance of 
new peaks in the aromatic region at ö 7.90, 7.70, 7.45 ppm assignable to free 
biphenyl, or at ö 7.23 ppm due to free p-cymene. The peaks for the starting complex 
decreased in intensity over time and eventually disappeared and several broad weak 
peaks appeared over the reaction course, suggesting that this reduced species was 
unstable and/or multiple products were forming. Figure 5.13 shows representative 
'H NMR spectra for complexes 25 and 26. 
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Figure 5.13. 'H NMR spectra recorded for (a) complex 25 and (b) complex 26 (50 
1iM) in 95% D20, 5% MeOD, 10 mM phosphate buffer pH 7.2-7.4 during their 
reactions with ascorbate. Peaks marked * indicate free arene (p-cymlbip) in the 
solution. L = ligand 1H resonances. 
5.3.5 Reactions with Glutathione (GSH) 
Glutathione (GSH) is the primary cellular antioxidant and is present in mM 
concentrations inside cells (ca. 2-10 mM). For this reason reactions with glutathione 
were investigated. 
5.3.5.1 Ru-X (X = Cl - , I) Substitution 
The reaction of complex 24 and the corresponding chloride complex [(re-
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Figure 5.14. HPLC Chromatograms (?. = 286 nm) for the reaction of (a) complex 24 
and (b) complex 8 (50 riM) with GSH (5 mM) at pH 7.9 (10 mM phosphate buffer, 
95% H20, 5% MeOH). After 1 h incubation at 310 K the main peak corresponds to 
the GS-bound complex [il  and the peaks 
corresponding to the starting material have disappeared. 
Analysis of the reaction mixtures by HPLC (directly after addition of 8/24 to GSH, 
and after 1 h at 310 K, Figure 5.14), suggested that all the Ru-X was displaced to 
form Ru-SG, since no peaks for starting material were present, and one new peak 
formed at ca. 17 minutes. ESI-MS of this fraction confirmed that in both cases [1 6 W 
(bipheny1)Ru(azpy-NMe2)GSJ was present (mlz observed 788.0, calcd 789.2)). 
For complex 24 the initial reaction mixture just contained one peak corresponding to 
the intact cation and after I h incubation at 310 K this peak completely disappeared 
and there was 100% conversion to the GS-adduct. For complex 8 initially several 
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peaks were present, thought to correspond to a mixture of hydrolysis products 
(phosphate, TFA, water coordinated to Ru) including the GS- adduct peak. 
Isolation of this adduct, and subsequent 'H NMR studies, showed that this species 
was relatively stable over 24 h with ca. 57% remaining intact after 24 h incubation at 
310 K, and several breakdown peaks and arene loss was noted (data not shown). 
The rate of displacement of Ru-X by GS in complexes 8 and 24 was determined by 
UV-Vis spectroscopy by following the change in absorbance at 597 nm (298 K). 
Substitution of the halide by GS substitution occurred with a half life of 1.3 mm 
(kobs =8.73 x 10-3 s1 ) for Ru-Cl and 17.5 min for Ru-I (kobs = 6.58 x 	s'), see 
Figure 5.15. 
Figure 5.15. Change in the absorbance (black) at 597 nm with time for (a) 
[it -
(biphenyl )Ru(azpy-NMe2)11 PF6 (24) and (b) [ q6 (biphenyl)Ru(aZPY-N11e2)Cl1PF6 
(8) (50 iM Ru, 95% H20, 5% MeOH, 10 mM phosphate buffer pH 7) after the 
addition of GSH (5 mM). The change in absorbance was fitted to the appropriate 
equation foe pseudo-first order kinetics (red) to give rate constants and half lives of 
8.76 x 10-3 s_ I , 1.3 minutes (8) and 6.58 x 10 -4 s 1 , 17.5 minutes (24). 
Thus the Ru-I bond is Ca. 14 times more resistant to substitution by GS- than the Ru-
Cl bond. 
5.3.5.2 GSH oxidation 
Interestingly, during the course of the reaction of the complexes [re - 
(biphenyl )Ru(azpy-NMe2)IIPF6. 24 and [q 6-(biphenyl )Ru(azpy-OH)I1 PF 6, 26 with 
glutathione, it became apparent that GSH was being catalytically oxidised to GSSG 
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(as detected by 'H NMR, vide-supra) over the course of the reaction. The overall 
redox process is shown in equation (3). 
2GSH—GSSH +2H + 2e 	(3) 
Several experiments have been performed to try and ascertain the molecular basis of 
this oxidation, which must be facilitated by the ruthenium compound(s). The 
experiments were performed in the absence of dissolved oxygen since oxygen (d0 2 ) 
alone can oxidise GSH according to the following equation (4). 
2GSH + /202 -* GSSG + H20 	(4) 
Thorough degassing of the solutions prior to following the oxidation allowed for the 
assessment of this catalytic oxidation to be made, without the competing effects of 
auto-oxidation of GSH by dO 2 . 
The reaction of [1 6-(biphenyl)Ru(azpy-NMe2)IIPF6, 24 and [ 6-(biphenyl )Ru(azpy-
NMe2)IJPF6,26 with GSH followed by 'H NMR showed that incubation of GSH with 
24 or 26 (10 mM GSH, 100 j.tM Ru, 10 mM phosphate pH 7.2, 85% H20, 10% D20, 
5% acetone-d 6, 310 K, followed over 24 h) caused 3.7 mM and 4.6 mM GSH to be 
oxidised to GSSG steadily (Figure 5.16), as evidenced by the appearance of new 
peaks at 6 3.30 due to the J3-CH 2 peaks of GSSG 1341 (Figure 5.16, inset). The 
presence of GSSG was further confirmed by spiking' the NMR sample with GSSG, 
which resulted in an increase in the intensity of the peaks assigned to GSSG. 
Furthermore, ESI-MS of the solution after 24 h incubation showed two peaks 
corresponding to GS (found 305.2, calcd for GS: 305.1) and GSSG (found 611. 1, 
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Figure 5.16. Amount of GSH (mM) oxidised to GSSG in the presence of 100 PM 
24 (blue) or 100 pM 26 (red) over 24 h at 310 K. Inset 
(a) spectrum of GSH 
recorded after 30 min incubation with ruthenium compound and (b) the same sample 
after 24 h where peaks assignable to GSSG can be identified. 
The results suggested that a catalytic oxidation of GSH to GSSG was being 
facilitated by the ruthenium compound in a mechanism not involving d02. Thus the 
ruthenium complex must be undergoing a redox cycle which must involve reduction 
of the complex (causing oxidation of GSH) followed by a subsequent re-oxidation of 
the ruthenium species to generate a catalytic cycle. In order to obtain information 
about the nature of this reduced intermediate species attempts were made to analyse 
the reaction mixture by LC-MS but this was unsuccessful and suggested that 
intermediates were transient. Figure 5.17 shows the high frequency 
1 H NMR 
spectrum of the reaction of 26 (100 pM) with GSH (10 mlvi) recorded initially and 
after 24 h at 310 K. 
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Figure 5.17. The high frequency region 'H NMR spectrum of the reaction of 
complex 26 and GSH (10 mM GSH, 100 jiM 26, 10 mM phosphate buffer pH 7.2, 
85% H20, 10% D20, 5% acetone-d6, 310 K) recorded (a) ca. 15 mins after mixing 
and (b) after 24 h incubation. The peaks corresponding to complex 26 decrease in 
intensity over time and new peaks corresponding to free biphenyl in aqueous solution 
appear (marked *). L = ligand resonances (2 resonances appear underneath the 
GSH-OH peak). 
The intensity of the peaks corresponding to the starting complex 26 drop to ca. 35% 
(as measured by 'H integration) over the 24 h time period. Arene loss is occurring 
(as evidenced by peaks appearing due to biphenyl) but no new NMR active species 
are being formed. A similar speciation arises for complex 24, with ca. 34% 
remaining after the 24 h time period, and arene loss occurs. 
In order to ascertain the mechanism of GSH oxidation, several experiments were 
confirmed to exclude/try and prove a possible mechanism. 
The catalytic cycle occurred after degassing with either Ar or N 2. This 
proved that N2 was not involved in the redox cycle. 
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The catalytic cycle occurred when the buffer was phosphate, borate or even 
when no buffer was present (pH adjusted to Ca. 7 with dilute NaOHIHC1). 
This suggested that the buffer was not playing a role in the redox cycle. 
The catalytic cycle occurred in the presence of 5% methanol-d4 (instead of 
5% acetone-d6, added to help solubilise the ruthenium compound) which 
suggested that acetone was not involved in the redox cycle. 
The catalytic' cycle also occurred for the corresponding chloride complex 
suggesting that released iodide (from 24 and 26, when GS displaces F) was 
not involved in the redox cycle. This was further confirmed by adding 100 
1iM K! to a solution of GSH, where no oxidation of GSH occurred over a 24 
h time period. 
Under similar conditions neither the free ligands Azpy-NMe 2 nor Azpy-OH caused 
an oxidation of GSH to GSSG above the control/blank value. 
5.3.6 Cytotoxicity 
5.3.6.1 A2780, A549 and W138 Cell Lines 
Complexes 23-28 were tested for cytotoxicity towards the A2780 human ovarian 
cancer, A549 human lung cancer and W138 human fibroblast (non-cancerous) cell 
lines (Table 5.2). The cytotoxicity data for complex [(i 6-bip)Ru(en)C1]PF 6 are also 
added for a comparison. The 'free phenylazopyridines were 'also tested for 
cytotoxicity towards the A2780 and A549 cancer cell lines only (Table 5.2). 
fl 
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Table 5.2. Cytotoxicity data (IC 50 values) for ruthenium complexes 23-28 and Ii (11 6 
bip)Ru(en)Cl]PF6 towards the A2780, A549 and W138 cell lines, phenylazopyridine 
ligands Azpy, Azpy-NMe2 and Azpy-OH towards the A2780 and A549 cell lines 
and cytotoxicity for the CDDP control. nd = not determined. 
Complex / Ligand IC50 A2870 I pM IC50 A549 / pM IC50 W138 I pM 
23 4 3 5 
24 3 2 1 
25 4 4 3 
26 5 6 1 
27 >100 >100 nd 
28 39 51 nd 
[(li 6-bip)Ru(en)C1]PF6 2'' 12 
Azpy >100 14 nd 
Azpy-NMe2 >100 >100 nd 
Azpy-OH >100 >100 nd 
CDDP 5 5 6 
Complexes 23-26, containing phenyl rings substituted with electron donating groups 
on the phenylazopyridine ligand were highly cytotoxic to the A2780 human ovarian 
and the A549 human lung cancer cell lines with IC 5 0 value of 2-6 PM, whereas 
complexes 27 and 28, with an un-substituted phenyl ring on the phenylazopyridine 
ligand are much less cytotoxic (IC50 values ca. 40-50 liM  (28) and >100 pM (27). 
Cytotoxicity data for the free azo ligands are also reported and, with the exception of 
Azpy-NMe2 in the A549 cell line, these ligands were inactive. 
The ruthenium phenlazopyridine iodido complexes were all slightly more cytotoxic 
towards the non-cancerous W138 human lung fibroblast cell line than the cancerous 
A549 human lung, whilst the cisplatin control was comparably cytotoxic in both cell 
lines. The ruthenium complex [(11 6-bip)Ru(en)Cl]PF 6 was less toxic towards the 
non-cancerous cell line. 
5.3.6.2 HCT-116 (Wild Type) and HCT116 (p53 Null) Cell Lines 
The cytotoxicity of Complex 24 in the HCT- 116 Human Colon Cancer cell line (wild 
type) and its p53 null analogue was evaluated. Cell survival was qualitatively 
assessed by fixing and staining the remaining (surviving) cells blue after a 24 h 
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exposure to the ruthenium complex. Figure 5.18 shows the surviving cells for both 
cell lines 
(a) 	
blank DMSO 0.1 iM 
	(b) 	
blank DMSO 0.1 pM 
	
0.5 MM 1 p 2 MM 
	




A 10 pMM 
	
5 11 10 MM 25 MM 
Figure 5.18. Cell survival (biomass stained blue) for (a) HCT-1 16 (WT) cells after 
24 h exposure to ruthenium compound 24 and (b) HCT-116 (p53 null) cells after the 
same exposure. Concentrations were tested in duplicate. 
The complex is very cytotoxic towards both cell lines, with no cells surviving after 
25 and 10 iM exposure to the ruthenium compound. Furthermore the complex 
appears to be slightly more cytotoxic towards the HCT-1 16 (p53  null) cell line since 
no cells survived after 5 pM exposure and less cells after the 2 pM exposure whereas 
for the HCT-1 16 (WT) cells some cells still surviving after these concentration 
exposures. 
5.3.7 Measurement of Oxidative Stress 
5.3.7.1 Detection of Reactive Oxygen species (ROS) 
The generation of ROS was detected inside A549 cancer cells over time using the 
molecular probe dichlorofluorescin-diacetate (DCFH-DA) which crosses the 
membrane of live cells, and is hydrolysed to dichlorofluorescin (DCFH). In the 
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presence of ROS it is oxidised to highly fluorescent dichiorofluorescein (DCF)J 231 
This probe measures general oxidative stress, rather than the detection of any 
particular ROS and different ROS have a different sensitivity for the probe. Figure 
5.19 shows the increase in fluorescence detected over time after A549 cancer cells 
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Figure 5.19. Relative increase in DCF fluorescence detected over time after 
exposure to 25 iM ruthenium compounds (23-26), Ru-A ([(rl 6-bip)Ru(en)C1]PF6), 
Ru-B ([(i 6-tha)Ru(en)C1IPF6) and H202. For all compounds the fluorescence 
detected was averaged over 12 wells for each compound (n=12) and a 'blank' value 
was subtracted. 
Compounds 23, 24, 25 and 26 all cause an increase in the DCF fluorescence detected 
with time, indicating that these compounds do generate ROS inside A549 cancer 
cells. In contrast, neither of the ethylenediamine chelates [(ii 6-bip)Ru(en)Cl]PF6 nor 
[(11 6-tha)Ru(en)Cl]PF6 caused an increase in DCF fluorescence above the blank value 
showing that these two compounds do not generate ROS. The hydrogen peroxide 
control confirmed that hydrogen peroxide can oxidise the probe, where an increase in 
DCF fluorescence was observed over ca. 1 h before plateauing. 
5.3.7.2 Effect of Increasing Intracellular Thiol Levels 
Cell viability was determined in the A549 cancer cells after cells were pre-incubated 
with 5 mM N-acetly-L-cysteine (NAC) to increase intracellular thiol levels. Figure 
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5.20 shows the cell viability for the four ruthenium compounds (23-26) after 24 h 
incubation with the drug and 96 h recovery time at selected concentrations for both 
the untreated cells and cells pre-treated with NAC, as well as for the data for the 









(23) 	(24) 	(25) 	(26) 	COOP 
Figure 5.20. Percentage cell survival after 24 h exposure to ruthenium compounds 
and 96 h recovery at 1 1iM (24), or 5 iM (23, 25, 26, CDDP) for untreated A549 
cancer cells (lighter) and A549 cancer cells pre-treated with 5 mM NAC for 2 h prior 
to drug addition to increase intracellular thiol levels (darker). The error bars are the 
standard deviations from an average of three wells. 
There is a greater cell survival for the cells that have increased thiol levels and have 
been exposed to ruthenium compounds whereas the cisplatin control remained 
unaffected by pre-supplementing the cells with NAC. 
5.3.8 p53 and p21 Status 
5.3.8.1 p53  Levels and phosphorylation of p53 at Ser-15 and Ser-392 
The activation of p53 protein by phosphorylation at sites serine- 15 and serine-392 in 
HCT116 (WT) cells after exposure to different concentrations of complex 24 (0.1-5 
j.iM) for 24 h was determined by immunoblotting. Total p53 levels were also 
determined, to confirm the presence of p53. Figure 5.21 shows the immunoblots 
obtained. 
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Figure 5.21. Western immunoblot analysis for p53 Do-1, p53 serineine-392 and p53 
ser-15 after exposure to ruthenium compound 24 at different (PM) concentrations (5-
0.1), a positive control (X-ray), DMSO (0.05% v/v) control (D) and a blank control 
(B). Equal protein loading was confirmed by blotting for 13-actin. 
The results show that no activation of p53 via phosphorylation at either serine-15 or 
serine-392 occurred after exposure to complex 24. The p53 levels appeared constant 
(neither up nor down-regulated) irrespective of the concentration of ruthenium used. 
5.3.8.2 p21  Levels 
The levels of p21 protein was also determined, see Figure 5.22. 
24 / iM 
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Figure 5.22. Western immunoblot analysis for p21/Wafi after exposure to 
ruthenium compound 24 at different (jiM) concentrations (5-0.1), a positive control 
(X-ray), DMSO (0.05% v/v) control (D) and a blank control (B). Equal protein 
loading was confirmed by blotting for 13-actin. 
177 
Chapter 5. Ruthenium(H) Arene lodido Azo Complexes 
Surprisingly increasing the concentration of complex 24 given to the HCT- 116 
cancer cell line decreased the level of p21 protein present. 
5.4 Discussion 
5.4.1 Complexes 23-26 are cytotoxic, despite the lack of hydrolysis 
The cytotoxic compounds 23-26 are all resistant to hydrolysis over 24 h at 310 K and 
at micromolar (tiM) concentrations and a physiological pH. Previous work has 
shown that the rate of hydrolysis of Ru-Cl in [(q 6-arene)Ru(XY)Cl] complexes can 
be controlled by changing the nature of the bonding of the chelate XY to the 
ruthenium centre [15, 361 and in particular slower hydrolysis can be achieved through 
incorporation of a it-acceptor 1igand)32' 371  In the design of metal-based anticancer 
drugs, however, a 'labile group' was often thought necessary for activity since it 
allowed the complex to be able to bind to DNA, the cellular target for most metal-
based drugs. Examples of cytotoxic ruthenium complexes that do not hydrolyse are 
scarce in the literature and are mainly limited to complexes containing planar 
aromatic ligands that are cytotoxic by DNA intercal&tion. 138401 Other examples of 
ruthenium(II) arene complexes containing carboxylate ligands such as [(Tj 
 (PTA = 1 ,3,5-triaza-7-phosphatricyclo[3.3. 1.1 ]-decane) are 
reportedly inert to hydrolysis in an aqueous solution yet still retain cytotoxicity 
comparable to the chlorido analogues ([(r 6-p-cym)Ru(Cl 2)(PTA)}). The solution 
chemistry, however, was investigated at 293 K at mM concentrations and the time 
period over which the solution chemistry was followed was not specified, and so 
comparisons between the system and the complexes studied in this chapter cannot be 
drawn. Furthermore, upon reaction with ss 14mer (5'-ATACATGGTACATA-3') the 
ruthenium-arene carboxylate complex loses its carboxylate ligand to form similar 
adducts to the chloride analogues. The ruthenium(II) arene thiophenolate complex 
[(
71
6-hmb)Ru(en)(SPh)1 does not undergo hydrolysis in aqueous solution yet is 
cytotoxic towards A2780 cancer cells. 141  Current work into this anomaly suggests 
that the complex may initially be activated by oxidation (and then labilisation) of the 
thiol group. [421 
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Thus this resistance to hydrolysis is interesting since current structure activity 
relationships would predict that, on the basis of inertness towards hydrolysis, these 
complexes would be inactive, and not exhibit good cytotoxicity towards both cell 
lines as the experimental results showed. 
The ruthenium (II) arene complexes containing the un-substituted phenylazopyridine 
ligand azpy (complexes 27 and 28) were not as cytotoxic towards the two cancer cell 
lines. In phosphate-buffered solutions, however, the complexes were unstable and 
formed a new species and so the instability of these two complexes is likely to 
account for the lack of observed cytotoxicity. Phosphate can act as a ligand for 
ruthenium complexes. For example, in the reaction of [(TI  with 5'-
GMP (guanosine monophosphate) in phosphate buffer it was found that phosphate 
can act as a competitive ligand for binding to the ruthenium centre. [431 
5.4.2 Substitution of iodide for chloride dramatically increases the cytotoxicity 
of the ft4 6-arene)Ru(azpy-R)X] complexes and this may be due to the 
extra stability of Ru-I vs. Ru-Cl 
The iodide complexes are much more cytotoxic than the corresponding chloride 
complexes (Chapter 3) and this trend was initially thought to be unusual since it is 
not observed for the [(11 6-arene)Ru(en)X] complexes. IC50 values are of a similar 
magnitude no matter whether the halide is Cl or IT (e.g. [(r1 6-benzene)Ru(en)Cl]PF6, 
IC50 = 17 pM, [(ii 6-benzene)Ru(en)I]PF6, 10 50 = 20 pM) 411 because in the presence 
of a large excess of NaCl (such as the cell medium), Ru-I bonds are substituted to 
Ru-Cl. The reaction of complex 24 with excess NaCl followed by UV-Vis 
spectroscopy showed, however, that exchange of iodide for chloride does not occur 
in the corresponding phenylazopyridine complexes. Furthermore the solution 
chemistry of the corresponding chloride comp1exes 32 ' shows that the complexes are 
less stable in water with slow hydrolysis of Ru-Cl and Ru-arene bonds 4 1 12 9-21 h). 
The extra stability of the cation is obviously desirable for cytotoxicity. 
The extra stability of the iodido complexes is due to iodide being a less 
electronegative ligand than chloride and behaving more like a simple two electron 
donor ligand to form a stronger bond to ruthenium, resulting in increased electron 
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density at the ruthenium centre available for back donation into the arene ring; hence 
a stronger ruthenium arene bond and no observable hydrolysis. 
Reactions of complex [( 6-biphenyl)Ru(azpy-NMe 2)IIPF6, (24) and the 
corresponding chloride complex [(T 6-bipheny1)Ru(azpy-NMe 2)C1]PF6 (8) with GSH 
demonstrated that the chloride ligand is much more rapidly displaced by GS than the 
iodide ligand (rate of substitution ca. 14 times greater for 8 c.f. 24). A major 
protective role of GSH is to act as a detoxifier of electrophilic substances such as 
metals via conjugation to form the thioether GS-X, X = electrophilic substance, [44, 451 
and these conjugates can then be eliminated via an ATP-dependent GSA pump. [461 
GS-conjugation is the major deactivation mechanism for platinum complexes such as 
c isplatin .L 47] The greater resistance of the Ru-I bond to conjugation to and possible 
detoxification by GSH compared with Ru-Cl in the complexes may be a further 
reason why the iodide complexes are much more cytotoxic since this would result in 
an overall greater uptake of ruthenium into the cells. 
5.4.3 The coordination of the phenylazopyridine ligands to the arene-
ruthenium iodido centre generates a redox active site biologically 
accessible to ascorbate 
Phenylazopyri dine ligands are well known potential electron transfer centres and 
each ligand can accept two electrons in one electrochemically accessible LUMO 
which is primarily azo in character. 148J  Coordination of these ligands to the 
ruthenium's positive metal centre should allow for the ligand based reduction to 
occur at a much more positive potential; for example the first electrochemical 
reduction of azpy found it to occur at -1.31 V,L27]L49J  which is shifted significantly 
positive in the ruthenium phenylazopyri dine complexes studied here (422 V (27) 
and -0.18 V (28)). Reactions of Azpy-NMe2 and Azpy-OH with ascorbate showed 
that ascorbate was not capable of reducing the ligands, however reduction of the 
ruthenium complexes by ascorbate occurred fairly rapidly. 
'H NMR studies of the reduction of the complexes by ascorbate showed that the rate-
determining-step corresponded to loss of arene from the complex. Unfortunately, the 
absence of well defined product peaks in the NMR suggested that the reduced 
complex was unstable or paramagnetic, and as a result it could not be characterised 
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by this method. However, the UV-Vis spectrum after the reaction had gone into 
completion, still showed the presence of the intraligand ir ir* transitions indicating 
that the azo N=N moiety had not been reduced. Reduction to the hydrazo NH-NH 
would have resulted in loss of colour. 
A reduction of arene hapticity from q 6 	r 4  of the 1 6-arene in ruthenium-arene 
sandwich complexes can occur upon electrochemical reduction at the metal centre 
due to ring slippage as a consequence of the metal re-attaining its 18 electron 
configuration. 110, Thus addition of electron(s) into the LUMO centred on the azo 
* orbital, followed by the electron 'hopping' on to the ruthenium center causing loss 
of arene due to reduced hapticity coordination as a result of the extra electron(s) at 
the metal centre may be the reaction that is occurring but this needs further 
investigation. 
5.4.4 Ruthenium Complexes 24 and 26 catalytically oxidise GSH to GSSG 
unlike the free ligands Azpy-NMe 2  and Azpy-OH 
Glutathione (GSH) is the primary cellular antioxidant and is present in mM 
concentrations inside cells (ca. 2-10 mM).144' 521 GSH can neutralise ROS via its 
oxidation to GSSG. 1531  Here it is shown that under physiologically relevant 
conditions (100 MM Ru, 310 K, pH 7.5, 10 m GSH) the ruthenium compounds can 
deplete GSH concentrations slowly over 24 h by catalytically oxidising it to the 
corresponding disulfide GSSG. 
A proposed reaction scheme for this oxidation is shown in Figure 5.23. 
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Figure 5.23. Proposed catalytic cycle for the catalytic oxidation of GSH to its 
corresponding disulfide GSSG by ruthenium(II) arene phenylazopyridine complexes. 
This oxidation is proposed to proceed via conjugation across the azo double bond 
and subsequent reduction of the azo group to hydrazo, since this is reported to occur 
for azo ester (C6H 5 N=NCOOCH 3 ) 1541  and diamide ((CH3)2NCON=NCON(CH3)2 )[ 551 
compounds. However for these reactions a stiochiometric amount of complex is 
required i.e. the compounds are not catalytic. Other examples in the literature of azo 
groups facilitating the oxidation of GSH include the hodgkins and non-hodgkins 
lymphoma drug procarbazine (CH3NH-NHCH 2C6H4CONHCH(CH 3) 2 ), which 
contains a hydrazo (reduced form of azo group, NH-NH) which is easily oxidised to 
the corresponding azo compound and re-reduced to hydrazo via GSH oxidation to 
GSSG.t561  The re-oxidation of the hydrazo group is facilitated by the molecular 
oxygen present inside cells, and so this catalytic cycle would require 02 (and upon 
re-oxidation of the hydrazo compound H 202 is produced). Interestingly in this work 
oxidation of GSH to GSSG was not facilitated by molecular oxygen; the catalytic 
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oxidation took place in solutions that were thoroughly degassed with N 2/Ar to 
remove any dissolved oxygen. 
In order for the reaction to be catalytic, a net H 2 (i.e. 2H + 2e) is lost from the 
system (from GSH—GSSG + 2H + 2e). The hydrogen could be lost as either H 2 or 
2H (if it was lost as H and H, hydride (H) would react with water to generate H 2 
and OH so this would be the same as FT 2  loss). The reaction of hydrogen radicals 
with GSH is reported to produce H 2 S as a product, 157J which would be observable by 
'H NMR (singlet at ca. 0.7 ppm). It is clear that nothing in the solution is being 
reduced since the reaction still proceeds in the absence of buffer and acetone-d 6 , 
water is in its most reduced state, the GSH is only present as two species, GSH and 
GSSG. Attempts to detect H 2  production (or otherwise) from the system are 
ongoing. 
This catalytic cycle is of potential therapeutic importance as a mechanism of 
cytotoxic action since it does not require molecular oxygen for activation, because 
tumours are hypoxic environments. 1581 
BSO (Buthionine sulfoximine), is an anticancer drug which inhibits the rate limiting 
enzyme 7-glutamylcysteine synthetase in the synthesis of glutathione thus restoring 
the sensitivity to the oxidative cytotoxic effects of platinum compounds and 
alkylators. 1591  The role of BSO as an anticancer agent is thought to relate to its 
modulation of cytotoxicity via GSH depletion. 1601 
The oxidation of GSH to GSSG was not observed for the free ligands and this is not 
surprising since electron-donating groups (here NMe 2, OH) attached to the azo group 
decrease the ability for it to oxidise GSH; 1301  coordination to the ruthenium centre 
must make the azo nitrogens positive enough for the redox reaction to - occur. 
5.4.5 A build up of Reactive Oxygen Species occurs inside A549 cancer cells 
Reactive Oxygen Species derive and present a higher reactivity than molecular 
oxygen with redox activity. 16t1  The term not only encompasses free radicals such as 
the superoxide radical (02), hydroperoxyl radical (H0 2 ') and the hydroxyl radical 
(HO.) but also non-radicals such at hydrogen peroxide (H 202) and singlet oxygen 
(102). ROS are continuously generated in small quantities in normal cellular 
processes and are involved in several biological functions such as cell growth and 
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signalling. 1611  Metal complexes that are redox active can generate ROS inside cells 
due to undergoing several possible redox reactions including Fenton type reactions, 
Haber-Weiss type reactions and also reactions with biological antioxidants.162' 631 
Excessive ROS generation inside cells is very harmful causing the oxidation of bio-
molecules such as lipids, cell membranes, proteins and DNA, which results in a 
phenomenon called oxidative stress. 16t1 
The detection of DCF fluorescence in A549 cancer cells after exposure to complexes 
23-26 confirmed that these compounds cause an increase in ROS production. 
Fluorescence was detected from the first reading and increased steadily for the 6.5 h 
acquisition period. The greater increase in fluorescence observed for 25 and 26 vs. 
23 and 24 may be due to faster cellular uptake for the former; The pK a of the 
phenolic OH in 25 was determined as 6.50 so that at physiological pH these 
complexes should be neutral in charge and this may facilitate faster uptake into the 
cells 164] compared with 23 and 24 which bear a positive charge. Importantly, no DCF 
fluorescence was detected for ruthenium arene complexes containing the 
ethylenediamine (en) chelating ligands and this result potentially illustrates a 
fundamental difference in the mechanisms of action of these two classes (azpy/en). 
5.4.6 Oxidative Stress is an important factor contributing to cell death 
Oxidative stress occurs due to a serious imbalance between the levels of ROS in a 
cell and its antioxidant defences in favour of the former. 165J In this work we have 
shown that the ruthenium complexes 23-26 cause a build up of ROS over time in 
A549 cancer cells. This could be due to (1) reduction of the complex in vitro which 
will generate ROS directly (vide supra) or (2) by depletion of the cells antioxidant 
capacity, which reduces the ability of the cell to neutralise ROS causing a build up. 
It is likely, on the basis that GSH is the primary cellular antioxidant, that the 
depletion of antioxidants is the primary mechanism by which oxidative stress occurs. 
Evidence for the direct effect of increased ROS levels on cell death is from the cell 
viability comparison of A549 cancer cells with / without pre-incubation with N -
acetylcysteine (NAC). The antioxidant NAC is believed to act by raising 
intracellular concentrations of cysteine (and hence GSH) and also by interacting 
directly to neutralize ROS via its SH group. 166J Several reports thus show that NAC 
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can protect against ROS dependent cell death. 167-70J The results showed that the cells 
with increased thiol levels were more tolerant to exposure to the ruthenium-arene 
phenylazopyridine compounds where an increase in cell survival was noted in all 
cases. So this result provides evidence that oxidative stress, by increasing ROS 
levels, is implicated in cell death. 
The cisplatin control appeared un-affected by pre-incubation of the cells with NAC. 
Cisplatin exerts its cytotoxic action primarilly by binding to DNA to form covalent 
DNA adducts. 711  In addition it is also shown to generate ROS. 172' However, 
experiments studying the effects of cisplatin on GSH concentrations in A549 cancer 
cells have shown that increased thiol levels result due to cisplatin exposure 
anyway [73, 741 and separate in vitro experiments showed NAC only protected against 
cisplatin induced apoptosis when it was present in the cell medium with cisplatin, 
and chempoprotection was lost if it was removed from the cells prior to cisplatin 
treatment. 75 ' This result is in agreement with the results obtained in this Chapter. 
5.4.7 Precedence for anticancer drugs that cause an increase in ROS- 
The relationship between the generation of ROS and the cause-of cancer undoubtedly 
exists, thought to be due to the ability of ROS to damage DNA and alter intracellular 
signalling. 1761 However, the involvement of excessive ROS production in the 
induction of senescence, 1771  the fact that an increase in cell proliferation rate of 
normal cells due to elevated ROS pools was not sufficient to induce malignant 
transformation, [781  and that cancer cells (mainly multi-drug resistant cells) are more 
sensitive to the additional exposure to ROS than normal cell s 1781 has recently led to 
the suggestion of using ROS therapeutically to treat cancer. 111, 781 it is thus, perhaps 
not surprising that several established anticancer drugs have been shown to generate 
ROS or other radicals including adriamycint 791 , cisplatint 721  and arsenic trioxide , 180 to 
name but a few. 
Interestingly the Ru" complex [InH][RuC1 4(In)2 1 (In = indazole) or KP-1019 which 
is active against primary tumours, 1811  is 'activated by reduction' via a metal based 
reduction from Ru" to Ru" and the corresponding Ru" species are supposed to 
coordinate more rapidly to biomolecules due to the labilisation of the Ru"-Cl 
bond. 8  The cytotoxic action of KP1019 is put down to reaction with DNA to 
185 
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various extents, but ROS were detected in colorectal tumour cells suggesting that the 
reduction to Ru" generated ROS and that oxidative stress may be implicated in its 
mechanism of action. 1821 
5.4.8 The role of p53 and p21/Wafi proteins 
The p53 protein is the major tumour suppressor protein in the body. 113 ' The 
importance of p53 for preventing cancer is highlighted by that fact that p53 is 
inactivated in almost 50% of all human tumours. 1831 Wild-type (WT) p53 is of 
fundamental importance in cutaneous defence against genotoxic stress and becomes 
activated in cells damaged by exposure to a wide range of environmental agents, 
including ionising radiation. 1841  In response to DNA damage, post-translational 
modifications and/or accumulation of p53 protein enable specific DNA binding to 
p53 and subsequent control of cell growth arrest, thereby reducing the risk of 
accumulation of genetically aberrant cells. 1141 Post-translational modifications most 
commonly occur via phosphorylation (17 serine and three threonine residues) but 
can also occur by other mechanisms including acetylation and ubiquitination. 183 ' 
In this work, activation of p53 via phosphorylation at the ATM kinase site at serine- 
15 and the CK2/FACT kinase site at serine-392 1851 was investigated. The data 
showed that in the presence of increasing amounts of the highly cytotoxic compound 
[( 6-bipheny1)Ru(azpy-NMe 2)I]PF6, (24) no evidence of p53 phosphorlyation 
(activation) at these two sites had occurred. Furthermore, total p53 levels were 
unaffected by exposure to increasing amounts of complex 24 suggesting no increase 
in p53 accumulation, and this result is in direct contrast to the dose-dependent 
accumulation of p53 detected in this cell line after exposure to increasing amounts 
of [( 6-biphenyl)Ru(en)Cl]PF6 . 1211  The ruthenium complex 24 was found to be more 
cytotoxic towards the p53-null cell line than the WT and again, this is in contrast to 
[(i6-biphenyl)Ru(en)CIIPF6 where p53-null HCT1 16 cells were twofold more 
resistant to 24 h {( 6-biphenyl)Ru(en)Cl]PF6 exposure (IC 50 p53-WT 8 MM, p53-null 
16 MM). These results together suggest that, unlike [(TI 	p53 
is not required to be activated/accumulated for the mechanism of cell kill. 
Interestingly, the action of p53 is reportedly intimately linked with RS (ROS). 1761 
ROS can increase p53 activity but if too many ROS are generated they can inhibit 
n Me 
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p53 action. p53 has ten cysteine residues, some of which are involved in binding a 
zinc ion which is required for activity. Oxidation of these cysteine residues inhibits 
the action of p53 as a transcription factor. 76' Oxidative inactivation of p53 will in 
turn raise ROS levels since the normal low levels of active p53 are involved in 
maintaining the cellular antioxidant defence network.' 16, 861 In this work the 
oxidation of glutathione cysteine residues to their corresponding disulfide was found 
to occur catalytically by ruthenium compound 24 and so it is possible that this 
compound could oxidise the p53 protein which would lead to its inactivation (and 
hence its non-activation by phosphorlyation). 
The p21/Wafi levels were down regulated with exposure to increasing amounts of 
24 which, again is a different cellular response to [(11 6-biphenyl)Ru(en)Cl]pF 6 , which 
caused a dosedependent increase in p21 levels. 121 p21/Wafi belongs to the Cip/Kip 
family of cyclin kinase inhibitors (CKI). p21 expression is usually controlled by 
either the p53-dependent or the p53-independent pathway. 187J  It is not easy to 
describe the exact function of p21 due to its vast array of regulatory pathways and 
interactions, however its main function is as a checkpoint in the cell cycle by 
inhibiting cyclin-dependent kinases at the GuS and G2/M interfaces. 187J  p21 is a 
modifier of apoptosis and it has been shown to both promote and inhibit apoptosis 
although it generally counteracts the apoptotic process. 187 ' An agent which down-
regulates p53 will also down regulate p21' 88' but in these experiments p53 levels 
remained unaffected. 
Overall these results show that not only do the ruthenium-azo complexes have a 
different primary mechanism of cytotoxicity (i.e. not involving simple hydrolysis and 
DNA binding) but the further 'downstream' cellular signalling effects are also 
different. Furthermore, oxidation of p53 and its subsequent deactivation may occur 
since ROS are produced. 
5.5 Summary 
Ruthenium(II) arene complexes show a great scope for the design of potential 
anticancer drugs due to the many modifications that can be made to the structure of 
the complex and the corresponding changes in properties that occur as a result. Here 
we show that the attachment of redox-active (generally) non-cytotoxic 
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phenylazopyridine ligands to the {(rl- 6arene)RuX}ruthenium-arene centre results in 
highly cytotoxic complexes when X = iodide. Oxidative stress (increase in 
production of ROS and/or depletion of antioxidants) is responsible for cell death 
since the complexes not only potentially generate ROS in vitro via ligand based 
reduction but also catalytically oxidise GSH to GSSG thus depleting antioxidant 
concentrations. These complexes are stable in aqueous solution and do not undergo 
hydrolysis, a feature quite unusual for metal based anticancer drugs.' The 
corresponding chloride complexes, which are not as stable in aqueous solution 
(undergo slow reaction via hydrolysis of Ru-arene and Ru-Cl) are not as cytotoxic 
suggesting that increased stability of the Ru-I bond correlates with increased 
cytotoxicity. Overall these complexes have a different mechanism of action 
compared to the ethylenediamine analogues, evidenced from the lack of ROS 
produced for when the chelating ligand is en, and the different 'downstream' 
pathways that are (de)activated. 
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6.1 Introduction 
Undoubtedly; the biggest drawback to using chemotherapy as a treatment for cancer 
is that the systematic drug administration likely results in an even distribution of the 
drug throughout the body leading to a reduced specificity for the desired target site, 
non-specific toxicity and other side effects resulting from the higher doses required. 
An attractive and emerging strategy to enhance the therapeutic index is' to 
specifically deliver these cytotoxic agents to the target cancer cells thus keeping 
them away from the healthy cells, which are also sensitive to the toxic effects of the 
drug.W Currently there are several strategies including polymer-based, liposome-
based and ligand-receptor mediated delivery systems. 21 
Another pathway recently been exploited to deliver complexes specifically to cancer 
cells involves making use of the naturally existing iron-binding protein transferrin 
(If) and the transferrin receptor (TfR) 1361  since these proteins are biodegradable, 
non-toxic and nonimmunogenic. 171  Elliot et al. were the first to demonstrate that 
transferrin could carry cytotoxic agents to the cell, by showing that a cisplatin-
transferrin complex (1-2 Pt bound to the Fe site) still inhibited growth towards feline 
lymphoma and human HeLa cells in vitro and also prevented metastatic spread 
and/or growth of tumors in the lungs of rats carrying the 13672NF mammary 
carcinoma in vivo. 181  Clinical trials of this platinum-conjugate were attempted. 191 
Transferrins are a family of iron binding proteins whose principal biological 
properties are thought to be iron binding and transport." The human transferrin 
protein contains 679 amino acids residues and has a molecular weight of ca. 79 
kDa. 110J  The Tf molecule is divided into two lobes; the N-lobe (336 amino acids) and 
the C-lobe (343 amino acids), which are linked by a short space sequence. Each lobe 
has two domains connected by a hinge, and the domains interact to form a deep 
hydrophilic metal (Fe) ion-binding site. Both binding sites have four conserved 
amino acids (two tyrosines, one aspartic acid and one histidine). When the metal is 
bound it is further stabilised by two oxygen atoms donated from a carbonate anion 
(the synergistic anion) to stabilise the Fe 3 ' binding. 
Iron is an essential metal for life and is involved in DNA synthesis, respiration and 
key metabolic reactions! 11  However, the levels of iron in the cell must be delicately 
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balanced as excess iron can lead to free radical damage through Fenton Reactions.t 12 ' 
131 
Thus transferrin proteins bind circulating Fe and prevent it from travelling 
throughout the body in its toxic form. In human serum, the concentration of 
transferrin is about 2.5 mg/mL with 30% occupied by Fe 171  thus there are vacant sites 
available for coordination with other metals. Transferrins deliver iron into the cell by 
interaction with the transferrin receptor (TfRI) via a mechanism called endocytosis 
whereby the iron is internalised through binding to this receptor and a drop in pH to 
ca. 5 releases the iron from the transferrin and into the cell. 
Interestingly the TfR1 appears to be over-expressed in cancer cells due to the cells 
increased requirement for iron; 10,000 to 100,000 TfRl molecules per cell are 
commonly found on tumour cells or cell lines in culture whilst in non-proliferating 
cells, the expression of TfR1 is low or frequently undetectable.t 11 Thus this over-
expression thus provides a natural selectivity for cancer cells over healthy cells. 
In this Chapter, attempts to attach the highly cytotoxic ruthenium arene complex 
[(13 6-p-cymene)Ru(azpy-OH)IJpF 6 (25) to transferrin by the following two different 
approaches is reported. 
Strategy 1 Ester-Maleimide Linker. In the first approach the complex is derivatised 
at the azo ligand moiety to include an ester and a maleimide group (Figure 6.1). The 
rnaleimide group can react specifically with thiol (SH) groups on transferrin to allow 
for attachment to the protein. The ester group should hydrolyse upon endocytosis by 
acid-catalysed ester hydrolysis 1141  liberating the free complex inside the cell. 
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Hydrolyses at acidic pH to 
liberate ruthenium compound 
Figure 6.1. Derivatisation of ligand Azpy-OH to allow attachment to transferrin (via 
maleimide) and release from transferrin (via acid sensitive ester group). 
A similar approach has previously been reported for conjugation of the anticancer 
drug chiorambucil to transferrin. 61  There are no accessible thiol groups on holo-
transferrin and so the protein would have to be modified by the introduction of SH 
groups in order for the complex to bind. This can easily be achieved by using the 
reagent iminothiolane, which reacts with accessible NH 2  groups on the protein to 
introduce a thiol function."" 
Strategy 2, Ru-Transferrin-Conju gate. In the second approach, the complex is bound 
directly to holo-transferrin in place of the synergistic anion bicarbonate via the 
phenolate group of complex 25. Whilst bicarbonate is the synergistic anion in vivo, 
other anions (such as oxalate, malonate, glycolate) with similar physiochemical 
properties can substitute for carbonate in-vitro.' 16 It should be noted that whilst 
these anions are all bidentate oxygen-donor ligands, the phenolate ligand is 
monodentate. Upon iron release (via endocytosis), the ruthenium complex would 
also be liberated from the binding site. 
6.2 Experimental 
6.2.1 Materials 
The preparation of the starting materials is reported in previous chapters;
biphenyl)Ru12 ] 2  (Chapter 2), Azpy-OH (Chapter 3) and [(1 6-p-cym)Ru(azpy-
OH)I]PF6  (Chapter 4). 3-maleimidopropionic acid, dimethylaminopyridine (DMAP), 
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dicyclohexylcarbodjjmjde (DCC) and Holo-Transferrjn (98%) were purchased from 
Sigma Aldrich. All other reagents used were obtained from commercial suppliers and 




Azpy-OH (330 mg, 1.66 mmol) was dissolved in DCM (40 mL) and MeCN (ca. 10 
mL) was added to fully solubilise the ligand. 3-Maleimidopropionjc acid (93 mg, 
0.55 mmol) and DMAP (53 mg, 0.60 mmol) dissolved in DCM (ca. 10 mL total) 
were sequentially added to the mixture and the mixture was cooled on ice. DCC 
(123 mg, 0.40 mmol) in DCM (10 mL) was added drop-wise and the mixture was 
allowed to warm to room temperature and stirred for Ca. 7 h. The solvent was 
removed and the crude product was purified by column chromatography using silica 
and 98% DCM / 2% MeOH by collecting the first yellow ,  fraction. This precipitate 
was re-dissolved in DCM and filtered through celite to remove dicyclohexylurea and 
repeated until no observable precipitate was present (x 5). The product was left to 
dry overnight in vacuo. Yield 130 mg (67.9 %) 'H NMR (CDC1 3 ): 6 8.75 (d, 11-I), 
8.10 (d, 2H), 7.93 (t, IH), 7.84 (d, .1H), 7.31 (d, IH), 6.75 (s, 2H), 4.00(t, IH), 2.94 
(t, 1H). ESI-MS: Calcd for C18H 14N404  [M] mlz 351.11, found 350.91. 
6.2.2.2 ftt1 6-p-cym)Ru(azpy02ccH2cH2maJejmjje)IJp (29) 
The dimer [0j6-p-cymene)Ru12]2 (106 mg, 0.102 mmol) was dissolved in MeCN (40 
mL. Azpy-02CCJ-12C1-j2-malejmjde (72g, 0.204 mmol) dissolved in MeCN (20 ml) 
was added drop-wise to the red solution and no obvious colour change was noted. 
The solution was stirred at room temperature for 4 h. The mixture was filtered and 
volume of solvent was reduced to about 10 mL by removal of MeCN on a rotary 
evaporator. NH4PF6  (166 mg, 1.06 mmol) was then added and the solution was 
placed in the freezer overnight. No precipitation had occurred so the solvent was 
removed, the solid re-dissolved in DCM, filtered to remove excess NH 4PF6, and the 
solvent removed to leave a sticky solid which was scratched with diethyl-ether to 
give a black crystalline product. Yield 105.3 mg (60.2 %) (Found: C, 39.09; H, 3.72 
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N, 5.79. Cal  for RuC28H 29N4O4 JPF6 : C, 39.19; H, 3.40; N, 6.53 %). 'H NMR 
(CDC1 3 ): 6 9.39 (d, IH), 8.63 (d, 1H), 8.21 (t, IH), 8.17 (d, 2H), 7.78 (t, IH), 7.41 (d, 
2H), 6.79 (s, 2H), 6.29 (d, 1H), 5.95 (d, IH), 5.84 (d, 1H), 5.75 (d, 1H), 4.04 (t, 2H), 
2.98 (t, 1H), 2.72 (septet, 1H), 2.47 (s, 3H), 1.10 (dd, 6H). ESI MS: calcd for 
RuC28H29N404I [Mt] m/z 713.02, found 712.73 [M t]. 
6.2.2.3 [(0 6_p -cymene)Ru(azpy-OH)lj'-Holo-Transferrin (HTf-25) 
To a solution of holo-transferrin (110 mg, Ca. 1.4 Mmol) dissolved in 100 mm 
HEPES 4- (2-hydroxyethyl) -1 piperazineethanesu1foflate) buffer (pH 8.48, Ca. 8 mL), 
[(0 6-p-cymene)Ru(azpy-OH)I]pF 6  (10.5 mg, 15 limol) dissolved in MeCN (lmL) 
was added and the mixture was incubated at 310 K for 45 min then left overnight at 
room temperature. The corresponding mixture was filtered through a molecular-
weight-concentrator (Amicon-30 kDa) three times with HEPES buffer then passed 
down a Sephadex G25 PD1O Column using the HEPES buffer as the elutent. The 
resulting protein fraction was purified by FPLC using 100 mM tris-HCI (pH 7.5) as 
A and 100 mM Tris-HC1 (pH 7.5), 800 mM NaCl as B. The purified mixure was 
concentrated to ca. 15 mL and kept stored in the fridge at 277 K. 
6.2.2.4 [(rj 6-p -cymene)Ru(azpyOH)I]Ferric..Bindingprotejn (Fbp-25) 
This Fbp conjugate was synthesised by Dr Arindam Muhkerjee (The University of 
Warwick) using a similar procedure as for the synthesis of the transferrin conjugate. 
Briefly holo-FbpA was expressed using a modified standard literature procedure 1171 
from a recombinant pTrc99A plasmid DNA transfected into TOPIO E. coli cells 
using the heat shock method. The overexpression was performed in Luria Broth 
overnight using 100 microgram/ml ampicillin. The medium was then centrifuged to 
obtain the cells as pellets and these were left overnight in 100 mM HEPES -2% 
CTAB (cetyltrimethylammonium bromide) solution (pH 8.0) on a rotor at 277 K to 
extract the periplasmic protein. The supernatant (obtained after centrifugation and 
decanting) was left in ice for 6 h to precipitate the CTAB and was then quickly 
filtered (0.2 iiM filter) on to a FRACTOGEL-450 cation exchange resin which binds 
the protein and agitated gently for 3 min on a rotor. The resin was then washed to 
remove any neutral or loosely bound impurities using 100 mM NaCl solution. The 
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protein was then extracted from the supernatant with 300 MM NaCl. The crude 
protein was then extensively dialyzed overnight against 50 mM HEPES buffer (pH 
8.0) at 277 K and subjected to cation exchange chromatography (FPLC) system as a 
final purification step. The column was washed with 10 volumes of 50 mM HEPES 
buffer (pH 8.0) to remove any unbound proteins and eluted with a gradient of 0 to 
1M NaCl. The purified protein was concentrated to 10 mg/ml using a Centricon 10 
micro concentrator and stored in 50 mM HEPES buffer pH8.0. 
The holo-protein in 50 mM HEPES of pH 8.0 was loaded with the Ru-complex in 
1:10 mole ratio in 50 mM HEPES buffer and incubated at 310 K for 2 h, then 
concentrated and passed through a PD-10 column pre equilibrated with ammonium 
acetate for efficient exchange with the same. The resulting solution was further 
concentrated in a molecular-weight-concentrator filter (Amicon- 10k Da) and 
exchanged three times with 10 mM ammonium acetate. The resulting solution was 
kept stored in the fridge at 277 K. 
6.2.3 Methods 
6.2.3.1 FTICR-MS (Fourier Transform Ion Cyclotron Resonance-Mass 
Spectrometry 
FTICR-MS was performed by Dr Arindam Muhkerjee (The University of Warwick) 
on a Bruker 12 Tesla FTICR mass spectrometer using Apex control (at The 
University of Edinburgh). The FbP-25 sample was diluted to effective protein 
concentration of 20 pM (10 mM ammonium acetate-10% isopropanol). An 
electrospray mass spectrum was obtained by accumulating 200 scans and averaging 
the time-domain transient. A 1024 kb data set was used to store the transient. The 
applied capillary voltage was 240 V, the hexapole accumulation was 0.80 s, collision 
voltage was -20 V and the ions were excited with an attenuation of 5.0 dB. 
6.2.3.2 ICP-MS (Inductively Coupled Plasma Mass Spectrometry) 
ICP-MS data was acquired On an Agilent 7500ce ICP-MS machine by Dr Ana 
Pizarro and Dr Lorna Eades. Standards were made up as for ICP-OES. 
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6.3 Results 
6.3.1 Ester-Maleimide Linker (29) 
6.3.1.1 Synthesis and Characterisation of [(q 6-p-cym)Ru(azpy-O 2CCH2CH2-
maleimide)I]PF6  (29), 
The synthesis of Azpy-02CCH2CH 2 -maleimide (29) (Figure 6.2) was based on 
literature syntheses for the esterification of carboxylic acids [181  with alcohols using 
DCC and DMAP activation of the carboxylic acid. 191 Briefly, two carboxylic acids 
add to the DCC to form the activated di-acetic anhydride and di-cicyclohexylurea as 
an insoluble by product. This acetic anhydride reacts with the DMAP's pyridine 
nitrogen to form an N-ketone, with regeneration of a molecule of the acid. The 
ketone carbon is sufficiently positive now (this acylpyridinium ion is stabilised by 
delocalisation onto the pyridine ring and NMe 2 substituent) for nucleophillic attack 








DCM / MeCN 
Figure 6.2. Reaction scheme for the synthesis of Azpy-02CCH 2CH2-maleimide 
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The corresponding ruthenium complex was synthesised in a similar fashion to the 
other ruthenium complexes in this thesis. The complex was characterised by 'H 
NMR, ESI-MS and Cl-IN. 
6.3.1.2 Stability in Water 
The stability of the ester bond with respect to hydrolysis was investigated by 'H 
NMR at pH*  6, 7 and 8 using the following conditions: 0.7 mM Ru, 2.1 % DMF-d 6 , 
97.9 % DO, 0.1 M borate buffer at 310 K. These conditions were chosen to mimic 
the conditions that would be used to couple this molecule to the SH groups on 
transferrin. Hydrolysis could be detected by the appearance of peaks corresponding 
to in aqueous solution and the disappearance of the 
starting material peaks. Figure 63 shows the 'H NMR spectra recorded for 29 at 
pH* 7 initially after dissolution (ca. 15 mm) and after 2 h and 12 h incubation at 310 
K. 
cr0 	 0 	0 	.0 	101 
Time ca. 	 A 12h j ,  
Time ca. 0 0 • 	 00 	
00 	M 
2h 
0 	• 	91 	.1 	0 1 1 
Time Ca. 
15 mm 
10 	 9 	 8 	 7 	 6 61 H/ppm 
Figure 6.3. High frequency 1 H NMR spectra (0.1 M borate buffer (pH*  7.0), 0.7 
mM Ru, 2.1 % DMF-d6, 97.9 % D20, 310 K) recorded for complex [(i 6-p-
cym)Ru(azpy-O 2CCH2CH2-maleimide)I]PF6 (29) after certain time periods in 
solution. Key: dots are proton resonances for 29 (red), 25 (yellow) and for 3-
maleimidopropionic acid (green). 
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Unfortunately at this pH the complex was rapidly hydrolysed with Ca. 50 % 
hydrolysing after 2 h and full hydrolysis of the ester bond after 12 h. The complex 
was also found to be unstable at pH*  8 (50 % hydrolysis after 3 h) and at pH*  6 
(50% hydrolysis after 13 h). 
The stability of the ester linkage towards hydrolysis was also determined by UV-Vis 
spectroscopy under biologically relevant conditions (100 pM Ru, 0.5% DMSO, 310 
K, 24 h) at pH 6.53, pH 7.03 and pH 7.53 (0.1 M borate buffer). Unfortunately, 
however, hydrolysis was also found to occur under these conditions. A 




200 	 400 	 600 	 800 
A / nm 
Figure 6.4. Time dependence UV-Vis spectrum of 29 (100 pM Ru, 0.5% DMSO, 
310 K, pH 7.03, 0.1 M borate buffer) recorded initially (. ca. 20 s after 
dissolution) and after 24 h incubation at 310 K ( ). 
Hydrolysis was readilly confirmed by the change in colour as [(11 
 is liberated (solution changed from pale orange to bright blue/purple). At all 
three pH values, the spectra after 24 h resembled the fully hydrolysed product 
suggesting that in biological tests, the ester bond would not be stable and would 
readily hydrolyse. 
203 
Chapter 6: Targeting Ruthenium(II) Arene lodido Azo Complexes to Cancer Cells 
6.3.2 Ru-Transferrin-Conjugate (HTf-25) 
6.3.2.1 Synthesis 
The conjugate was synthesised by direct reaction of holo-transfemn and complex 25 
at pH 8.5, since at this pH the azpy-OH ligand is in its fully deprotonated (0) form 
(pKa phenolic OH determined as 6.50, Chapter 5), and will be more likely to bind as 
the synergistic anion. Furthermore, at this pH the iron will remain bound since iron 
is usually liberated from transferrin at lower pH values (Ca. <5) only. 
63.2.2 Purification by FPLC 
The protein-ruthenium conjugate HTf-25 was purified by FPLC using a Hi-Trap 
Capto Q column. Figure 6.5 shows the FPLC trace obtained 
0 	20 	40 	60 	80 	100 	120 	140 	160 
Time 1mm 
Figure 6.5. Chromatogram (A. = 280 nm) obtained for the purification of HTf-25 by 
FPLC. 
The complex was eluted at 130 mM NaCl concentration. 
63.2.3 Characterisation by ICP-OES 
ICP-OES and ICP-MS data for the crude product (filtered three times through a 
molecular weight concentrator to remove unbound 25 and passed through a 
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Sephadex G25 PD1O Column, prior to purification by FPLC) suggested that the 
composition of the protein was Fe:S:Ru:I, 2:39.4:3.7: 3.1. 
The transferrin protein 38 sulfur atoms (from methionine and cysteine residues) and 
is iron saturated (two iron atoms per protein). This result thus confirmed that both 
ruthenium and iodide were present in the conjugate and that the Fe:S ratio (2:38) was 
essentially unaffected by the complex being present i.e. that ruthenium was not 
displacing iron in the metal ion binding site. 
ICP-OES results on the purified complex, however, gave a Fe:S:Ru:I ratio of 
2:43:1.8:0.11. Thus there are Ca. two moles of ruthenium bound per mole of 
transferrin. Thus after extensive purification the iodide is not bound to the conjugate 
and the iron:ruthenium are present in approximately equal ratios. These results 
suggested that the iodide may have been present as a counter anion only and was 
exchanged for chloride during the FPLC purification process, in which a salt gradient 
is used to elute the protein. Furthermore the ruthenium: iron ratio decreased from ca. 
3.7:2 to 1.8:2 suggesting that some of the ruthenium was initially present as a loosely 
bound species. 
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6.3.2.4 Characterisation by UV-Vis Spectroscopy 
Figure 6.6 shows the UV-Vis spectrum recorded for holo-transferrin and that of the 
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Figure 6.6. UV-Vis spectra recorded in 100 mM Tns-HCI (pH 7.5) for holo-
Transferrin (hTf) (orange line) and hTf-25 (blue line) at Ca. 16 pM transferrin (as 
determined by E278 nm = 93000 M1 cm 1 )J20 ' 
Both spectra contain an absorption band centred near 280 nm arising from n - it 
transitions of the aromatic residues tyrosine, tryptophan and phenylalanine. [201  In 
both spectra there is also a band centred at Ca. 465 nm which is characteristic for 
iron-containing transferrin 1201 and is assignable to a LMCT between from the 
tyrosinate amino acid residue to the Fe 3 , although in the HTf-25 spectra the 
intensity is slightly greater. There is also broad peak at longer wavelengths in the 
HTf-25 spectrum and this could be due absorption from the ruthenium complex 25, 
since at 30 pM it would have appreciable absorbance in this red region of the UV-
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6.3.2.5 Stability in Aqueous Solution 
The stability of the conjugate was investigated over 24 h at 310 K. Figure 6.7 shows 
the UV-Vis spectra recorded in Tris buffer (pH 7.5) and Figure 6.8 shows a similar 
sample where 100 mM NaC1 was added prior to aquisition. 
1.51 	 0.2 1 	 - 
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Figure 6.7. UV-Vis spectra recorded every hour over 24 h for the 25-HTf conjugate 
over 24 h at 310 K in Tris buffer (pH 7.5). The inset shows the changes in the bands 
corresponding to the 25-HTf conjugate more clearly. There is an initial jump in the 
spectrum (from (1) to (2)) after 1 h incubation followed by a slow decrease in the 
intensity of the bands. No isosbestic points are present. 
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Figure 6.8. UV-Vis spectra recorded every hour over 24 h for the 25-HTf conjugate 
over 24 h at 310 K in Tris buffer (pH 7.5) with 100 mM NaCl. The inset shows the 
changes in the bands corresponding to the 25-HTf conjugate more clearly. There is a 
slow decrease in the intensity of the band at ca. 740 nm and a corresponding increase 
in the intensity at ca. 540 rim. There appears to be an isosbestic point at 613 nm. 
It can thus be seen that the addition of NaCl appears to stabilise the 25-HTf 
conjugate, a phenomenon that is well known for transferrinj 211 Since biological 
media usually contain ca. 100 mM NaCl, the latter stability result is more relevant. 
6.3.2.6 Stability in the presence of Bicarbonate Anion 
The stability in the presence of the natural synergistic anion bicarbonate was also 
investigated under physiologically-relevant conditions (Tns Buffer pH 7.5, 100 mM 
NaCI, 25 mM NaHCO3). UV-Vis spectra were recorded every hour over 24 h but no 
change in the trace with time occurred (data not shown). This result either suggested 
that bicarbonate had not replaced the ruthenium complex as the synergistic anion, or 
that ruthenium is not bound to the Fe through the phenolate of the Azpy-OH ligand 
after all and is bound in some other fashion. 
63.2.7 Characterisation of FbP-25 complex by FTICR-MS 
The analysis of HTf-25 by high resolution mass spectrometry cannot readily be 
achieved since the protein weight is ca. 79 kDa and this is outside the upper limit of 
detection of the machine. In order to gain information on whether the intact cation 
can bind to such an iron binding site, reaction of complex 25 with Fbp-A (ferric 
binding protein), FbP-25, was investigated. The molecular weight of this protein is 
only ca. 34 kDa. Fbp is found in the periplasm of several Gram negative bacteria. [221 
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It is considered as a member of the transferrin family, although it is structurally 
homologous to only a single lobe of transferrin and binds only one iron per molecule 
in a similar binding site. 1231  Figure 6.9 shows the FTICR-mass spectrum obtained 
for FpP-25. 
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Figure 6.9. 	FTICR-MS obtained (12 charge state) for FbP-25 (protein 
concentration 20 IJM in 10 mM ammonium acetate-10% isopropanol). Key, azo = 
azpy-OH, cymene = p-cymene. 
Peaks for several fragments were observed and many of these have been assigned. 
Interestingly there is a peak at m/z = 2839.26 which corresponds to the apo-FpP (i.e. 
iron loss had occurred) and complex 25, without the iodide. This provided some 
evidence that the complex minus the iodide ligand was bound to the Fbp. 
6.4 Discussion 
6.4.1 Ester-Maleimide Linker (29) 
The incorporation of an ester linkage attached to a maleimide linker (which could 
then be attached to transferrin) into the ruthenium complex ftr 6-p-cym)Ru(azpy-
OH)LIPF6 was synthetically possible. However this ester group was susceptible to 
hydrolysis at physiological pH values and was not stable enough for subsequent 
studies, since in vitro cell experiments are performed at pH values of between 7.2- 
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7.4. The concept of attaching cytotoxic compounds through acid-labile groups to 
transferrin is well documented. In general, more stability is observed when acid 
labile hydrazone groups (R2C=NNR 2) are used as linkers instead of ester linkages. [24 
These linkers, unlike ester groups, are stable at a basic pH and tend not to hydrolyse 
as readily. [61 
6.4.2 Ru-Transferrin (HTf-25) 
The cytotoxic ruthenium complex [(il 	has been 
successfully incorporated into holo-transferrin. The ICP-OES results show that the 
iron is not displaced by ruthenium (Fe:S ratio is consistent with two Fe atoms per 
transferrin) but that, upon reaction with the transferrin, iodide is lost from the 
complex. The purified conjugate appears stable over 24 h with physiologically 
relevant concentrations of NaC1 to stabilise the protein. Furthermore, the complex is 
stable to physiological concentrations of bicarbonate (the 'natural' synergistic anion). 
This result is encouraging as it suggests that the ruthenium complex would remain 
bound to transferrin under the in vitro testing conditions. Initial FTICR-MS results 
for FpB-25 suggest that the complex may bind as the intact complex minus the 
iodide since a peak appears corresponding to apo-FbP and the complex after iodide 
loss. 
Initially it was hoped that the complex would bind to the Fe" as the synergistic anion 
instead of bicarbonate. It should be noted, however, that the common features of 
synergistic anions are the jxesence of a carboxylate donor and, one or two carbon 
atoms away, a second (proximal) electron donor group that can act as a potential 
ligand for metal binding. 20 ' It is not known at this stage whether the complex is 
bound as the synergistic anion. However, since iodide is lost from the complex, this 
would generate a 'reactive site' for coordinative bonding. There are no accessible 
thiol (SH) groups on transferrin, but the complex may be binding to other amino-acid 
residues. For example, there are two highly exposed methionine sites on transferrin, 
Met 499 and Met 256 and these sites may be potential binding sites for complex 25. 
Previous work has shown that the reaction of [(1 6-bip)Ru(en)Clf' with L-methionine 
(1:2 ratio) affords the S- bound [(T16-biphenyl)Ru(S-L-MetH)(en)} 2 adduct as a 
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product. t25 ' This reaction was, however, slow with a t112 Ca. 2.3 h, and after 48 h, 
only approximately 27% of the ruthenium complex had reacted with L-methionine. 
There are also several surface histidine residues present could be potential binding 
sites (His 16, 349, 350, 473, 598, 606 and 642 are exposed). The reaction of [(1 6 
bip)Ru(en)C1F and histidine (1:2 ratio) reached equilibrium after approximately 24 
h, but only approximately 22% of the complex had reacted, with hydrolysis (59%) 
being the preferred reaction The ruthenium(III) complex 	indazolium trans- 
tetrachlorobis(1H-indazole)ruthenate(I11) complex, or KP-1019, for example, has 
been shown to bind to transferrin via histidine residues. [261 
Further structural characterisation is, thus, required before in vitro cell tests could be 
performed. 
6.5 Summary 
The transferrin receptor TfR 1 is over-expressed on the surface of cancer cells due to 
increased requirement for iron. For this reason there is currently much research 
aimed at targeting cytotoxic complexes specifically to the TfR1 via attachment to 
transferrin, to try and overcome some of the toxicity problems associated with 
chemotherapy. In this Chapter attempts were made to attach the cytotoxic ruthenium 
complex , [(r1 6-p-cym)Ru(azpy-OH)I] PF 6 to holo-transferrin. The ruthenium complex 
has been successfully attached to transferrin to form a conjugate that is stable under 
physiologically-relevant conditions. Once further characterisation has been 
performed on the conjugate to confirm the binding site, this conjugate may be 
suitable for cellular studies including cellular uptake studies in a cancer cell line 
which forced to over-express the transferrin receptor as well as IC 50 determination. 
Overexpression of this receptor can be achieved by adding an iron chelator to the cell 
medium to sequester iron so that less iron is available to the cells. As a consequence, 
more TfR1 receptors are expressed by cells to try and increase iron levels)"". These 
initial experiments would assess the suitability transferrin as a possible carrier of the 
complex. 
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7.1 Conclusions 
This thesis is concerned with the synthesis and characterisation of potential 
ruthenium(II) arene complexes containing chelating azo ligands and determination of 
their cytotoxicity and the mechanism by which cytotoxicity occurs. Initial work on 
[(116-arene)Ru(azo-ligand)C11 (arene = p-cym, thn, bz, bip, azo-ligand = azpy, azpy-
NMe2, azpy-OH and azpyz-NMe2) showed that these complexes were moderately 
cytotoxic towards both A2780 human ovarian and A549 human lung cancer cell lines 
(10 50  18-88 MM) and that, compared to their en analogues, they were much more 
inert to hydrolysis in an aqueous solution and that arene loss could readily occur. 
Both phenomena can be attributed to due to the incorporation of this azo it-acceptor 
ligand. 
The dinuclear analogues offered no improvement on the biological properties; these 
complexes were generally unstable in an aqueous solution and intriguingly 
decomposed in a reaction likely to involve radicals. Electrochemical and EPR 
measurements showed that the complexes can undergo a one electron reduction near 
to 0 V (406 and -0.14 V in DMF, vs. Ag/AgCl) and that this forms the azo-anion 
radical, providing some evidence that the azo ligand is redox active when attached to 
ruthenium. 
Replacement of the chloride 'leaving group' by iodide (ftrj6-arene)Ru(azpy-R)I] 
(arene = p-cym, bip, R = NMe2, OH)) led to complexes that were inert to hydrolysis 
over 24 h at 310 K. Iodide analogues containing the azpy ligand were unstable in an 
aqueous buffered solution and electrochemical studies showed that complexes 
containing this ligand were reduced at more positive potentials (by Ca. 0.1-0.2 V, e.g. 
for [(16-bip)Ru(azpy)I] E red = -0.18 V, in DMF, whereas for (1 6-bip)Ru(azpy-
NMe2)I] E red = -0.36 V vs. Ag/AgC1) than the stable analogues suggesting that there 
is a balance between hydrolytic stability and electrochemical reduction in an aqueous 
solution. 
Surprisingly, the complexes, which were stable in aqueous solution, were found to be 
highly cytotoxic towards both the A2780 and A549 cancer cell line (IC50 1-6 MM) 
which implied that, unlike analogous en complexes, hydrolysis was not necessary to 
activate these complexes and suggested that these complexes may have a distinct 
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mechanism of action, thought to involve redox chemistry on the basis of the ease of 
electrochemical reduction. The complexes were found to steadily generate reactive 
oxygen species steadily in A549 cancer cells over Ca. 6 h and it was thought that 
ROS may be implicated in their mechanism of action; this was confirmed by pre-
incubating the cells with the anti-oxidant NAG before cell viability determination, 
where more cell survival was .observed in this case. Reactions with ascorbate and 
GSH showed that the phenylazopyridine ligands alone were not redox-active under 
physiological conditions and that attachment to the positive {(i 6-arene)RuI} centre 
was necessary in order to achieve reductions biologically. Reactions with GSH (the 
most abundant non-protein thiol) showed that these complexes can catalyse the 
oxidation of GSH to GSSG, and this reaction is thought to be central to their 
cytotoxicity since GSH is the main cellular redox buffering system. The depletion of 
GSH levels will cause an increase in the production of ROS. The exact mechanism 
by which this catalytic oxidation occurs is still unknown although initial conjugation 
of GSH across the azo group, and subsequent reduction of the azo group to hydrazo 
with oxidation of GSH to GSSG seem plausible initial first and second steps based 
on similar reactions of azo groups and glutathione reported in the literature. 
Initial investigations into possible "down-stream" mechanisms have shown that [(11 
6_  
bip)Ru(azpy-NMe2)I], unlike [(fl  does not activate the tumour 
suppressor protein p53 and that, unusually, it down-regulates p21. This suggests that 
the mechanism of action of these two types of complexes differs not only in their 
primary mechanisms, but probably more fundamentally in the later stages of cell 
death too. 
These complexes were, unfortunately cytotoxic towards W138 non-cancerous lung 
cells suggesting that these cancer cells would not be selective for cancer cells in vivo. 
However, cisplatin was also very cytotoxic towards this cell line. Thus work towards 
targeting complex [( 6-p-cym)Ru(azpy-OH)I] specifically to cancer cells via the 
transferrin mediated endocytotsis uptake pathway was also attempted. The complex 
has been shown to bind to HTf and further work into determining the binding site is 
required before determining is this conjugate is cytotoxic at lower concentrations. 
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7.2 Future Work 
Because the most promising potential anticancer complexes discovered in this thesis 
were the iodide complexes, much of the future work would involve additional 
investigation of this class. The following experiments would gain further insight into 
the cellular mechanism of action and allow for a better evaluation into the potential 
of the use of these complexes as anticancer agents. 
7.2.1 Determination of mechanism of catalytic oxidation of GSH 
This thesis has described the catalytic oxidation of GSH to GSSG by the ruthenium 
complexes [( 6-bip)Ru(azpy-NMe 2)IF and [(ij  The 
mechanism by which this catalytic cycle operates is unknown, although it seems 
probable that it is facilitated by the azo group attached to the ruthenium centre on the 
basis of literature for similar reactions, where the azo -N=N- group is reduced to 
hydrazo -HN-NH- with oxidation of 2GSH to GSSG. This mechanism by which this 
net loss of H2 occurs which would regenerate the catalytic cycle is postulated to 
occur by direct loss of H 2 . In order to prove this hypothesis, H 2 would have to be 
detected in the reaction medium. Unfortunately, H 2 is sparingly soluble in aqueous 
medium 111  and the 'H NMR resonance of its protons appears at Ca. 4.6 ppm 121 which 
would be obscured by the broad water resonance. Attempts to detect H 2 in aqueous 
solution by using linear sweep voltammetry at an ultramicro electrode 
[31 were 
unsuccessful. Gas Chromatography would be the most suitable method to detect 
dissolved H2 since this technique is very sensitive. 
[41 
7.2.2 Measurement of intracellular thiol levels 
Reactions of ruthenium(II) iodide (and chloride) complexes with glutathione in an 
NMR tube show that a catalytic oxidation of GSH to GSSG occurs. However, this 
result does not necessarily mean that this phenomenon will occur in the in-vitro cell 
tests; the cellular amount of GSSG is generally kept to very low levels (5-50 tiM) by 
a highly efficient NADPH-dependent reduction of GSSG by glutathione reductase 
back to GSH. 151  The ratio of GSHIGSSG can be determined intracellularly by 
several methods and these have been thoroughly reviewed. 16, 71 For example, o-
phthalaldehyde (opt) reacts specifically with reduced GSH to form a fluorescent 
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product and so GSH levels can be determined from standard curves by fluorescence 
emission at 420 nm after excitation at 350 nm. 181 Any changes to GSH levels (e.g. by 
oxidation to GSSG) could easily be shown by this method. Total thiol levels can 
also be determined by the 5,5'-dithiobis-(2-nitrobenzoic) acid DTNB assay. 19 ' DTNB 
binds to free SH groups and is reduced to form TNB which can be assayed 
colorimetrically at 412 nm. Addition of NADPH ensures all GSSG is first reduced to 
GSH. 
7.2.3 Role of iodide in the cytotoxicity 
Initial data demonstrated that the iodide complexes were much more inert in aqueous 
solution than the chloride complexes and this was thought to be the main reason why 
they were more cytotoxic. Studies with the biomolecule glutathione showed, 
however, that both F and Cl - in Ru-I and Ru-Cl can be displaced by the sulfur 
nucleophile, essentially forming the same compound in vitro. Interestingly, 
however, in direct contrast to Ru-en analogues (where Ru-I was found to exchange 
for Ru-Cl in a high chloride concentration such as cell medium, e.g. for the complex 
[(i6-hmb)Ru(en)I]), "°' Ru-I in ruthenium(II) arene phenylazopyridine complexes is 
not substituted by chloride, implying that (more) iodide enters the cell. This may 
imply that iodide itself may have some role in the cytotoxicity. 
There are several examples of biological reactions involving iodide; for example the 
oxidation of NADPH catalysed by horseradish peroxidase / H 202 can be mediated by 
iodide and forms iodinated NADP as a product. 11t1 The iodide is first thought to be 
oxidised by H 202 before interacting with the NADPH. Similarly, the oxidation of 
Fe" cytochrome c by hypohalous acids (HOX, X = halide, generated from the 
reaction of HOC! and Br -/1) (1:1 ratio) showed that the efficiency of the oxidation of 
the Fe ll centre to Fe"' decreases in the order HOI/1 2 1121 (z 98%) > HOC! ( 60%) > 
HOBr (3Ø%)h131  The decreased ability of the HOC! and HOBr vs. HOI is thought 
to be due to their increased ability to halogenate amino groups (HOT is not reactive 
towards amino groups) and thus not interacting as specifically with the iron centre. 
The authors note that whilst this one electron oxidation to Fe" would not be serious 
per se (the reduction is reversible), the one-electron transfer would lead to the 
generation of reactive radicals in the vicinity of the heme and these may conceivably 
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damage the protein. 1131  The catalytic role of iodide on the oxidation of Fe" 
cytochrome-c by N-halogenated compounds such as NH 2C1 was also observed and 
the catalytic effect of iodide was explained by redox cycling between 12 and 21 - J' 3 ' 
Bromide, on the other hand, was not found to be capable of catalysing this oxidation, 
probably because the oxidation of iodide is easier to achieve (the standard oxidation 
potentials at 298 K for the oxidation of 2X - X 2 + 2e are -0.54 V (F), -1.09 V (Br) 
and -1.36 V (Cl)). 14' Other work in the same laboratory has shown that iodide can 
also increase the rate of oxidation of NADH by chioroamines and chloroamidesJ' 51 
These examples all show that iodide is capable of reacting with ROS such as HOC1 
or H202 and these reactive species produced can then undergo further reactions. 
Experimental data on the cytotoxicity of KI and KC1 towards an immortalised 
thyroid cell line (TAD-2) showed that not only was KI cytotoxic with an IC 50 of ca. 
20 mM compared with KC1 which had no effect up to 50 mM, but also that KI 
exposure generated ROS (as detected by the DCFH-DA assay) and caused extensive 
lipid peroxidation whereas KC1 exposure did not. 1161  Whilst this cell line contained 
thyroid peroxidase, which oxidises 1 to the very reactive 12,  and the cancer cell lines 
used in anticancer research presumably will not, this example nonetheless 
demonstrates that there is precedence in the literature for a possible biological redox 
role of iodide compared with chloride. 
In future work the DCFH-DA assay should be repeated to include a chloride control 
(e.g. complex [(TI  8), in order to assess if more ROS 
are detected in the iodide vs. chloride case. Cellular distribution of iodide could also 
provide some important information about possible mechanisms of action (vide 
supra). 
7.2.4 Determination of cytotoxicity under hypoxic conditions 
The work in this thesis has shown that ruthenium complexes of the type (TI 6_  
biphenyl)Ru(azpy-R)X] (R = OH, NMe2) can catalytically oxidise GSH to GSSG, a 
reaction that is thought to be a major factor contributing to their mechanism of 
cytotoxic action. Interestingly this mechanism of action does not necessarily require 
02, which is important since the tumour micro environment is considered hypoxic 
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(oxygen deficient),"', 181  and so complexes that have a mechanism of action not 
requiring 02 are of great importance. 
In animals, most cells in vivo are exposed to low 02 concentrations (1-10 mm Hg) 
whereas in the cell culture experimental conditions (95% air, 5% CO2) the cells are 
exposed to Ca. 150 mm Hg 02 exposure.119I  This increased 02 level (and many 
ingredients in the cell medium, e.g. Fe salts, absence of sufficient stable anti-oxidants 
such as ascorbate) causes the production of more ROS than is normal, and cells 
either enter senescence, die, or adapt. 120J  For the cells that manage to survive (adapt), 
the oxidative stress they are under may affect their properties and cellular changes 
could include increasing antioxidant production, down-regulating levels of ROS-
generating enzymes or altering cellular targets of oxidative damage to become more 
resistant to damage by ROS. 1191 For cytotoxic complexes whose mechanism may 
involve ROS, these changes are potentially very important and may lead to a 
mechanism of cytotoxicity that is not mimicked in vivo. 
For future work it would be interesting to determine IC 50 values towards a cell line 
grown and maintained under both normal (ca. 20% 02 (in 95% air), 5% CO 2) and 
under hypoxic conditions (e.g. 0.5% 02, 5% CO2, N2 to balance) 1211  to see if 
cytotoxicity is still observed. If better cytotoxicity towards the hypoxic cell line was 
observed, it would give a good indication that this complex may exhibit good in vivo 
cytotoxicity. 
7.2.5 Ruthenium distribution in the cytoplasm / nucleus and on DNA / RNA I 
protein 
Cellular distribution studies could provide some important information related to the 
mechanism of action of the complex as it could give an indication of the primary 
bimolecular target. 
For example, the distribution of ruthenium on the DNA, RNA and protein can easily 
be determined. This is achieved by first using the reagent Trizol (Invitrogen), 
developed by Chomczynski and Sacchi, 1221 which allows the isolation of total RNA 
from the cell. Following RNA isolation, DNA and protein can also be isolated by 
sequential precipitation. 123J  By counting the number of cells, and by determining the 
concentration of isolated RNA (A 260 nm), DNA (A260 nm) and protein (bicinchoninic 
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acid assay), 124J  and determining the ruthenium concentration by ICP-OES, the 
amount of ruthenium per weight of DNA, RNA or protein can be determined. This 
experiment has previously been performed for [(i 6-biphenyl)Ru(en)Cl] and the 
distribution (A2780 cancer cells, 24 h exposure, 25.2 iM Ru) was determined to be 
ca. 350 ng Ru / mg RNA, 50 rig Ru / mg DNA and 50 ng Ru / mg protein. 1251 
Other cellular distribution experiments include isolation of the cellular nuclei using 
the nuclei EZ prep nuclei isolation kit (Sigma Aldrich). Briefly cells are lysed and 
the nuclei are collected by centrifugation, counted and analysed for ruthenium 
analysis. The supernatant contains the cytoplasmic contents and can also be analysed 
for ruthenium. 	Again this experiment has been performed 1151  for [(it- 
biphenyl)Ru(en)Cl] (A2785 cancer cells, 24 h exposure, 25 PM) and 65.3% of the 
ruthenium was found to be in the nucleus compared with 34.7% in the cytoplasm. 
By performing these experiments, information on whether DNA/RNA/protein is the 
target and whether the complex is concentrated in the nucleus would be gained. This 
may help to elucidate the primary biomolecular target. Iodine analysis could also be 
performed in these experiments and this may give information on its cellular 
distribution snd whether iodide also has a biological target. 
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